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FOREWORD

A ROT IN HEAVEN
A POWERFUL INVESTIGATIVE PARTNERSHIP,
THE OPIOID CRISIS, PILL PROFITS, AND A
PULITZER PRIZE
Becky L. Jacobs*
“Almost Heaven, West Virginia”
Bill Danoff, Taffy Nivert, and John Denver1
“All the host of heaven shall rot away, and the skies roll up like a
scroll.”
Isaiah 34:42

_________________________________
In the spring of 2018, when the Tennessee Journal
of Law and Policy hosted the “Healing Appalachia: The
Role of Professionals in Solving the Opioid Crisis”
symposium, there were more than 400 lawsuits pending
against corporations that manufacture, distribute, and
retail opioids in just one consolidated case in the federal
Waller Lansden Distinguished Professor of Law, The
University of Tennessee College of Law. Email:
jacobs@utk.edu.
1 Bill Danoff, Taffy Nivert & John Denver, Take Me Home,
Country Roads (April 12, 1971).
2 Isaiah 34:4 (English Standard Version).
*
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district court for the Northern District of Ohio.3 This
single, consolidated case initially involved only claims
brought by governmental entities, but the Judicial Panel
on Multidistrict Litigation consolidating the cases
acknowledged that the action potentially could include
claims brought by individuals, consumers, hospitals, and
third party payors, as well as additional categories of
defendants.4
It is not hyperbole to say that we can thank Eric
Eyre of the Charleston Gazette-Mail, of Charleston, West
Virginia, for these lawsuits and for the momentum that
we now are experiencing in support of a response to the
national opioid crisis. The government, the legal
community, and many media outlets seemingly were
willing to ignore the opiate plague that was infecting our
communities, but Eric’s Pulitzer Prize-winning series of
articles5 made it impossible for anyone to profess
ignorance any longer.
As lawyers, we also should take pride in the role
that our colleagues from WVU College of Law, Pat
McGinley and Suzanne Weise, played in supporting
Eric’s efforts to uncover the shocking data that appeared
In re Nat’l Prescription Opiate Litig., MDL No. 1:17-MD-2804
(N.D. Ohio 2017) [hereinafter “MDL Litigation”]; see also Jan
Hoffman, Can This Judge Solve the Opioid Crisis?, N.Y. TIMES
(Mar. 7, 2018), https://www.nytimes.com/2018/03/05/health/
opioid-crisis-judge-lawsuits.html [https://perma.cc/H87X-UYN
W].
4 Transfer Order, In re Nat’l Prescription Opiate Litig., MDL
No. 1:17-MD-2804 (N.D. Ohio Dec. 12, 2017).
5 Eric also won the Scripps Howard First Amendment Award,
was a finalist for the Selden Ring awards, and won a first-place
award for investigative reporting from the Association for
Healthcare Journalists. See Susan Heavey, Reporter’s Work
Pushes Regulators, Legislators to Act on Opioids, ASS’N HEALTH
CARE JOURNALISTS: COVERING HEALTH (May 8, 2017),
https://healthjournalism.org/blog/2017/05/reporters-workpushes-regulators-legislators-to-act-on-opioids/ [https://perma.
cc/MDV6-FF6W].
3
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in his articles. Without their tireless efforts, Eric may not
have been able to prevail against the well-financed
political and industry resistance to accessing the data
that so starkly revealed the appalling opiate prescription
and distribution patterns in West Virginia.
To put the importance of Eric’s contribution, and
that of Pat and Suzanne, in perspective, consider the
odds against which they were fighting - and it is critical
to remember that, at the time Eric, Pat, and Suzanne
were seeking the distribution data, the only litigation
pending against any entity or individual involved in the
opioid distribution chain was the groundbreaking lawsuit
filed by then-West Virginia Attorney General Darrell
McGraw in 2012 against Cardinal Health.6 Eric’s
newspaper, the Gazette-Mail, was a family-owned, daily
newspaper with a print circulation of 37,000, and Pat and
Suzanne were providing their services pro bono.
Thus, the odds were enormous, considering the
Goliath-like financial resources of their opposition.
Opioid painkillers are a nearly $9 billion-a-year market
in the U.S. alone,7 and pharmaceutical companies such
as Purdue Pharma L.P., Johnson & Johnson, Teva,
Allergan PLC, and the Endo Health Solutions unit of
Endo International PLC have all earned billions over the
years from the sale of these drugs.8 Wholesale
distributors like McKesson Corp., Cardinal Health, and
AmerisourceBergen also have profited,9 as have the
See Records: Company Shipped Millions of Pills to West
Virginia, ASSOCIATED PRESS (Oct. 09, 2016), https://
www.apnews.com/20ed75eba921466aba2155f4a846dc75
[https://perm a.cc/P624-LN5W].
7 Haley Sweetland Edwards, The Drug Cascade, TIME (June 22,
2017), http://time.com/4828108/the-drug-cascade/ [https://per
ma.cc/Q9L5-A84S].
8 Stock Review: Two-Bagger Collegium Pharmaceutical Surges
108%, GLOBAL ROUND UP - STOCKS, Mar. 23, 2018.
9 Katie Tabeling, County Files Lawsuit Against Opioid
Manufacturers, CECIL WHIG (Elkton, Md.) (Jan. 9, 2018),
http://www.cecildaily.com/spotlight/county-files-lawsuit6
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physicians, pain clinics, and pharmacies prescribing and
dispensing these medications - some legitimately, some
not.10
These profits, though, have had a very high public
health cost, as Eric’s articles helped to expose. Here is
just a snapshot of the scale of what is being called an
epidemic11 and what President Trump declared, in
August of 2017, to be a “national emergency.”12 According
against-opioid-manufacturers/article_9be21338-13aa-5855b8be-caf98167bf5f.html
[https://perma.cc/Y2PV-RXFU]
(“Among the lawsuit’s 20 manu-facturing defendants, 14 are
subsidiaries of six pharmaceutical giants, including Endo,
Purdue, Johnson & Johnson, Teva, Allegran [sic] and
Mallinckrodt Pharmaceuticals. The remaining defendants are
McKesson, Cardinal Health and AmerisourceBergen characterized in the complaint as ‘the big three’ drug wholesale
distributors.”); see also Joey Garrison, Nashville Sues Opioid
Makers, THE TENNESSEAN, Dec. 23, 2017, at A5,
https://www.tennessean. com/story/news/2017/12/23/nashvillesues-opioid-manufacturers-recoup-costs-fighting-epidemic/
978861001/ [https://perma.cc/3CYT-3L8N] (“Cities like
Nashville and their taxpayers have borne the cost of the opioid
epidemic for far too long while the pharmaceutical
manufacturing industry, consisting of manufacturers and
distributors, has reaped astronomical profits[.]”).
10 Chris McGreal, ‘It was a Conspiracy’: Recovering Addicts
Wage Legal Battle over Prescription Use, GUARDIAN (UK) (Aug.
28, 2016), https://www.theguardian.com/us-news/2016/aug/
28/opioid-addiction-west-virginia-lawsuit [https://perma.cc/Z2
QP-HCJU] (“29 survivors of opioid addiction or relatives of
those who overdosed on painkillers . . . accuse doctors,
pharmacies and distributors in a rural corner of West Virginia
of pushing the powerful and highly addictive drugs, which have
properties similar to heroin.”).
11 U.S. DRUG ENF’T AGENCY, 2015 NATIONAL DRUG THREAT
ASSESSMENT SUMMARY, at iii (2015), https://www.dea.gov/
docs/2015%20NDTA%20Report.pdf [https://perma.cc/5USMJQJS].
12 Joel Achenbach, John Wagner & Lenny Bernstein, Trump
Says Opioid Crisis is a National Emergency, Pledges More
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to the CDC, more than 200,000 people in the U.S. died
from overdoses related to prescription opioids from 1999
to 2016.13 In 2016 alone, more than 46 people died every
day from overdoses involving prescription opioids.14 Also,
in 2016, three of the six states with the highest rates of
death due to drug overdose were located in close
geographic proximity to Tennessee: West Virginia (52.0
per 100,000), Ohio (39.1 per 100,000), and Kentucky (33.5
per 100,000).15 Tennessee’s rate was 24.5.16
These death rates are startling, but perhaps not
as surprising as one might first imagine given that
doctors prescribed enough opioids in 2016 to provide
every man, woman, and child in the U.S. with 36 pills
each.17 The highest prescribing rates, however,
reportedly were concentrated in the more rural states
that year, primarily in the South; in Tennessee, with the
second highest prescribing rate in the nation, every
resident could have had 70 pills each in 2016.18
The West Virginia numbers were even more
alarming. Eric’s research revealed that, “[i]n six years,
Money and Attention, WASH. POST (Aug. 10, 2017),
https://www.washingtonpost.com/politics/trump-declaresopioid-crisis-is-a-national-emergency-pledges-more-moneyand-attention/2017/08/10/5aaaae32-7dfe-11e7-83c7-5bd5460f0
d7e_story.html [https://perma.cc/GTU6-EMRN].
13 CTRS. FOR DISEASE CONTROL & PREVENTION, PRESCRIPTION
OPIOID OVERDOSE DATA, https://www.cdc.gov/drugoverdose/
data/overdose.html [https://perma.cc/6HVX-YYKV].
14 Id.
15 CTRS. FOR DISEASE CONTROL & PREVENTION, Rates, DRUG
OVERDOSE DEATH DATA, https://www.cdc.gov/drugoverdose/
data/statedeaths.html [https://perma.cc/Y7SX-YVZK].
16 Id.
17
PACIRA PHARM., INC., UNITED STATES FOR NONDEPENDENCE: AN ANALYSIS OF THE IMPACT OF OPIOID
OVERPRESCRIBING IN AMERICA 11 (2017), https://www.
pacira.com/sites/default/files/inline-files/USND_Stats_FINAL.
pdf [https://perma.cc/JAS3-WDWP].
18 Id. at Slides 11-12.
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drug wholesalers showered the state with 780 million
hydrocodone and oxycodone pills, while 1,728 West
Virginians fatally overdosed on those two painkillers[.]”19
Proportionately, in terms of geographical distribution
and in terms of population, that “amount[s] to 433 pain
pills for every man, woman and child in West Virginia.”20
In that state, the data that Eric secured uncovered a
dismaying pattern of distribution: small, independent
pharmacies received a disproportionate percentage of the
shipments of prescription opioids, e.g., wholesale
distributors delivered 1.4 million to 4.7 million
hydrocodone pills each year to locally-owned pharmacies
in Mingo and Logan counties when one of the busiest
Wal-Mart’s in West Virginia received only about 5,000
oxycodone and 9,500 hydrocodone pills annually.21
The companies involved in the opioid distribution
chain fought tooth-and-nail to keep these data from being
released, relying upon an impressive array of legal talent
to defend them on this issue22 and on the other claims of,
inter alia, negligence, public nuisance, violations of West
Virginia’s consumer act, etc. that arose in that ground-

Eric Eyre, Drug Firms Poured 780M Painkillers into WV
amid Rise of Overdoses, W.V. GAZETTE-MAIL (Dec. 16, 2016),
https://www.wv gazettemail.com/news/cops_and_courts/drugfirms-poured-m-painkillers-into-wv-amid-rise-of/article_99026
dad-8ed5-5075-90fa-adb906a36214.html [https://perma.cc/R38
M-FFSP].
20 Id.
21 Id.
22 AmerisourceBergen Drug Corp.’s Objection to Hearing Date
and Opposition to Motion on Behalf of the Charleston Gazette
to Intervene for the Limited Purpose of Moving the Circuit
Court to Unseal the Plaintiff’s Second Amended Complaint at
5, State ex rel. Morrissey v. AmerisourceBergen Drug Corp.,
Civil Action No. 12-C-141 (W. Va. Cir. Ct. 2016) (“And if [the
DEA] protect[s] any of that information from the intrusive
journalistic nose of the Gazette, then its confidential nature
must be respected.”).
19

[272]
12

A ROT IN HEAVEN
13 TENN. J.L. & POL’Y 267 (2018)

breaking case filed against them in West Virginia.23
Highly regarded national and West Virginia firms such
as Jones Day; Morgan Lewis; Steptoe & Johnson;
Jackson Kelly; Bowles Rice; and Spilman Thomas &
Battle were involved as defense counsel in the West
Virginia litigation.24
Pat, Suzanne, and Boone County, West Virginia
lawyer Tim Conaway provided essential, legal support to
the Gazette-Mail to force disclosure of the court records
that revealed these staggering distribution figures.25 The
sealed complaint in the State’s lawsuit contained
shipment data supplied by defendants and the U.S. DEA
during discovery in the case, and the West Virginia
Attorney General at that time, Patrick Morrisey,26 and
Complaint, State ex rel. McGraw v. AmerisourceBergen Drug
Corp., Civil Action No. 12-C-141, 2012 WL 2544646 (W. Va. Cir.
Ct. 2012).
24 See, e.g., Docket, West Virginia v. AmerisourceBergen, Civil
Action No. 2:12-CV-03760 (Closed Mar. 27, 2013).
25 See supra note 22. A conversation about these events
between Pat and Eric took place at an event at Washington &
Lee at https://livestream.com/wlu/wv-opioid/videos/165654080.
26 It is not without irony that Morrisey, who is running for the
U.S. Senate as an anti-opioid warrior, see Ken Blackwell, A
Clear Choice in WV Senate Battle: Conservative Patrick
Morrisey,
TOWNHALL:
OPINION
(July
14,
2017),
https://townhall.com/columnists/kenblackwell/ 2017/07/14/aclear-choice-in-wv-senate-battle-conservative-patrickmorrisey-n2354783 [https://perma.cc/9LD5-JD55], lobbied for
the Healthcare Distribution Management Association, a group
that represents drug wholesalers, in Washington, D.C. before
taking office as West Virginia Attorney General in 2013;
Cardinal Health is a member of this group. Louis Jacobson, A
Closer Look at Patrick Morrisey’s Family Ties to ‘Big Pharma’,
POLITIFACT (Mar. 27, 2018), http://www.politifact.com/truth-ometer/article/2018/mar/27/closer-look-patrick-morriseysfamily-ties-big-phar/ [https: //perma.cc/S59G-3MBS]. His wife,
Denise Henry Morrisey, is a partner with a Washington
lobbying firm retained by a number of major pharmaceutical
23
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other plaintiffs apparently agreed with the defendants’
arguments that the data were proprietary.27 Pat et al.
filed a motion on behalf of the Gazette-Mail to unseal the
complaint, and, despite a vigorous and lengthy fight to
maintain the confidentiality of the records, the judge
ordered the first ever public release of these previouslyundisclosed data.28
The import of this legal event cannot be
overstated - these data shifted the public discourse on the
opioid crisis. Opioid abuse was of course on the public
radar, but opinion did not appear to have moved much
beyond the “blame the addict” and “those damn pill mills”
mentality. The data in the lawsuit, however, told stories
of predatory practices and suffering people in pain, and
they inspired a sense of outrage and urgency that
prompted enforcement and reform efforts by regulators
and legislators.29
In West Virginia alone, for example, Cardinal
Health and AmerisourceBergen, two of the nation’s “big
three” drug wholesalers, agreed to pay the State a
combined $36 million to settle their lawsuits, and at least
one county commission has filed suit against all of the
“big three” to recover costs associated with prescription
drug abuse, with other West Virginia counties and cities
declaring their intentions to follow suit.30 Beyond West
clients, including several involved in the opioid industry, such
as Allergan, Johnson & Johnson, Janssen, Purdue Pharma,
and the membership of the Healthcare Leadership Council;
e.g., Cardinal, Sanofi, Johnson & Johnson, and Pfizer. Id.
27 Eric Eyre, Drug Firms Fueled ‘Pill Mills’ in Rural WV, W.V.
GAZETTE-MAIL (May 23, 2016), https://www.wvgazette
mail.com/news/cops_and_courts/drug-firms-fueled-pill-millsin-rural-wv/article_14c8e1a5-19b1-579d-9ed5-770f09589a22.
html [https://perma.cc/2B SG-3TFD].
28 See id.
29 See Heavey, supra note 5.
30 Eric Eyre, 2 Drug Distributors to Pay $36M to Settle WV
Painkiller Lawsuits, W.V. GAZETTE-MAIL (Jan. 9, 2017),
https://www.wvgazettemail.com/news/health/drug-
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Virginia’s borders, nearly every state Attorney General
has either filed a lawsuit against an opioid manufacturer
or distributor or is involved in an investigation and has
issued subpoenas for records.31 The MDL litigation
consolidated in the Northern District of Ohio currently
involves 400 cases filed by cities, counties, and states
against manufacturers and distributors of opiates, but
those involved have publicly acknowledged the
possibility that individuals, consumers, hospitals, and
third party payors might be added as plaintiffs.32 The
distributors-to-pay-m-to-settle-wv-painkiller-lawsuits/article_
b43534bd-b020-5f56-b9f3-f74270a54c07.html [https://perma.
cc/AVK9-TB9E].
31 Jerry Mitchell, Judge: Stop the Legal Fights and Curb the
Opioid Epidemic, CLARION LEDGER (Jan. 26, 2018),
https://www.clarion ledger.com/story/news/2018/01/26/opioidepidemic-litigation-dan-polster/1014046001/ [https://perma.cc/
C7J6-82E9]. Tennessee Attorney General Herbert H. Slatery,
III, for example, filed a 270-page complaint in the Knox County
Circuit Court in May of 2018 alleging that Purdue Pharma,
L.P. violated the Tennessee Consumer Protection Act vis-à-vis
false, deceptive, and/or unsubstantiated claims about its opioid
products or opioids in general including OxyContin; that it
breached a 2007 Agreed Final Judgment with the State
involving the cessation of sales promotions to prescribers
whose practices showed indications of abuse or diversion; and
that it created a public nuisance in Tennessee by significantly
interfering with the commercial marketplace and endangered
the life and health of the State's residents. See Tennessee’s
Motion, Memorandum in Support, and Order Granting Leave
to File Complaint under Seal, State ex rel. Slatery v. Purdue
Pharma, L.P., No. 1-173-18 (Tenn. Knox Co. Cir. Ct. 2018),
https://www.tn.gov/content/dam/tn/attorneygeneral/documents/
foi/purdue/purdue-motion-5-15-2018.pdf
[https://perma.cc/
S8E2-QDQC].
32 See supra note 4. The Tennessee Attorney General was not,
at the time of the publication of this Foreword, a party to the
federal multidistrict litigation pending in Cleveland, Ohio, but
that Office has publicly stated that it is “voluntarily engaging
in settlement discussions” in connection therewith. See Press
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lawsuits involve claims as widely divergent as public
nuisance, negligence, negligent misrepresentation,
fraud, and unjust enrichment as well as violations of
consumer protection laws and the state versions of the
Controlled Substances Act and RICO statute(s).33
The pool of defendants is also expanding. For
example, attributing blame and seeking recovery even
further afield, several cities in West Virginia brought a
class action suit against the Joint Commission on
Accreditation of Health Care Organizations on behalf of
all U.S. cities and towns.34 The Joint Commission is the
entity that certifies U.S. health care organizations and
programs. The suit alleges that the Joint Commission’s
Pain Management Standards “grossly misrepresented
the addictive qualities of opioids and fostered dangerous
pain control practices[.]”35
Outside of the civil context, prosecutors have
begun to bring charges against individuals for crimes
involving opioid abuse and distribution. In 2015, the
Obama-era U.S. Department of Justice issued a memo
directing federal prosecutors to pursue charges against
individual defendants.36 As an example of its use of this
policy, the DOJ charged John Kapoor, former CEO of
Insys Therapeutics, with conspiracy to commit
racketeering and mail and wire fraud in connection with
a bribe and kickback scheme associated with Subsys, the
Release No. 18-10, Tenn. Attorney Gen., No. 18-10: Tennessee
Attorney General Sues Purdue Pharma (May 15, 2018),
https://www.tn.gov/attorneygeneral/news/2018/5/15/pr1810.html [https://perma.cc/R459-5ZP4].
33 Id.
34 Complaint, City of Charleston v. The Joint Commission, No.
2:17-cv-04267 (S.D.W.V. Nov. 2, 2017).
35 Id. at 2.
36 Memorandum from Deputy Att’y Gen. Sally Q. Yates on
Individual Accountability for Corporate Wrongdoing (Sept. 9,
2015), https://www.justice.gov/archives/dag/file/769036/download
[https://perma.cc/8ARN-NPCS].
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company’s powerful synthetic opioid fentanyl in spray
form.37 Closer to home, in early 2017, a Maryville doctor
received a 10-year federal prison sentence for serving as
the supervising and prescribing doctor at a notorious
Maryville pain clinic.38
Legislative activity is also taking place in
response to the momentum generated in the wake of
Eric’s articles. That activity, however, is focused
primarily at the state level. As of April 2018, twentyeight states had enacted legislation that either limited,
offered guidance, or listed requirements related to opioid
prescribing practices.39 Further, every state except
Missouri has enacted monitoring program legislation
“designed to reduce doctor shopping and identify patients
at risk for substance use disorders.”40 In addition to these

Cynthia McFaddin, Billionaire Charged with Bribing
Doctors to Prescribe Opioids, NBC NEWS: HEALTH (Oct. 26,
2017),
https://www.nbcnews.com/storyline/americas-heroinepidemic/billionaire-charged-bribing-doctors-prescribeopioids-n814686
[https://perma.cc/W3D3-L62U]
(“The
corporation is not facing criminal charges and is still selling
Subsys - some $240 million worth of Subsys just last year.”).
38 Jamie Satterfield, Doctor for Maryville Pill Mill Draws 10year Prison Term, KNOXVILLE NEWS SENTINEL (Feb. 22, 2017),
https://www.knoxnews.com/story/news/crime/2017/02/22/doctor
-maryville-pill-mill-draws-10-year-prison-term/98268716/
[https://perma.cc/437L-KJ5V].
39 Prescribing Policies: States Confront Opioid Overdose
Epidemic, NAT’L CONF. ST. LEGISLATURES: STATE ACTION (Apr.
5, 2018), http://www.ncsl.org/research/health/prescribingpolicies-states-confront-opioid-overdose-epidemic.aspx
[https://perma.cc/VR62-LA4U].
40 Chris Elkins, The Opioid Epidemic: What Caused the Heroin
Epidemic?, DRUGREHAB.COM, https://www.drugrehab.com/
opioid-epidemic-causes/ [https://perma.cc/ZX2U-NZ7J]. The
Prescription Safety Act of 2016 is Tennessee’s version legislation that revised or made permanent existing regulation
of controlled substances and enacted several other provisions.
Tennessee Prescription Safety Act of 2016, 2016 Tenn. Pub.
37
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legislative initiatives, states have considered, proposed,
and/or adopted opioid-related legislation in a number of
other categories, including opioid taxes, pain clinic
licensure, training and education plans, and pill “takeback” programs.41
At the federal level, one hears numerous claims
that actions are being taken to “combat the opioid
crisis[,]”42 including President Trump’s plan to use the
death penalty as an option for drug dealers in fatal opioid
overdose cases.43 Not all have been deemed to be a
success. For example, an earlier piece of federal
legislation, the Ensuring Patient Access and Effective
Drug Enforcement Act of 2016, has been subjected to
scathing criticism, with even its title described as
“misleading.”44 According to a report resulting from a
joint investigation by The Washington Post and “60
Minutes,” an ex-DEA lawyer working for a
pharmaceutical company drafted an early version of the
Acts 1002 (codified at TENN. CODE ANN. §§ 53-10-301 to -312
(2016)).
41 Kate Blackman & Amber Widgery, Summer Progress in
Opioid Misuse Prevention Legislation, NAT’L CONF. ST.
LEGISLATURES:
NCSL
BLOG
(Aug.
31,
2017),
http://www.ncsl.org/blog/2017/08/31/summer-progress-inopioid-misuse-prevention-legislation.aspx [https://perma.cc/P
NT2-ZBM4].
42 See, e.g., Combatting the Opioid Crisis, HOUSE COMM. ON
ENERGY & COM.: ISSUE IN FOCUS, https://energycommerce.
house.gov/opioids/ [https://perma.cc/V9DA-VNW9].
43
Louise Radnofsky, Trump’s Opioid Battle Plan Includes
Seeking More Death-Penalty Prosecutions, WALL ST. J. (Mar.
18, 2018), https://www.wsj.com/articles/trumps-opioid-battleplan-includes-seeking-more-death-penalty-prosecutions1521414347 [https://perma.cc/D2JW-N3R6].
44 Scott Higham & Lenny Bernstein, New Drug Law Makes It
‘Harder for Us to Do Our Jobs,’ Former DEA Officials Say,
WASH. POST (Dec. 15, 2017), https://www.washington
post.com/graphics/2017/investigations/dea-law/?utm_term=.6c
c2264b1f35 [https://perma.cc/X 8YA-XEXH].
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law.45 The final version dramatically curtailed the DEA’s
enforcement powers: the agency now must demonstrate
that a company’s actions represent “a substantial
likelihood of an immediate threat” before it can halt drug
shipments, whereas previously it needed only to show
that they posed an “imminent danger” to the
community.46 The law also allows companies to submit
“corrective action plans” before they can be sanctioned by
the DEA,47 which one former DEA investigator called a
“get out of jail free card[.]”48
More recently, the new two-year budget deal
passed in early 2018 promised funding for the epidemic,
the details of which were not specified.49 Additionally, a
bipartisan group of senators introduced a follow-up bill to
2016’s Comprehensive Addiction and Recovery Act,
commonly referred to as CARA 2.0.50 A version of the bill
was introduced in the House of Representatives by
Tennessee Representative Marsha Blackburn.51 If
passed, CARA 2.0 would, among other things, commit
more funding to the fight against the opioid crisis,
restrict access to opioid painkillers, improve access for
medication-assisted treatment, and increase civil and
criminal penalties for opioid manufacturers if they fail to
report suspicious orders or fail to prevent diversion.52
The impact of Eric’s articles and its aftermath can
be seen far beyond the nation’s courtrooms and
Id.
Ensuring Patient Access and Effective Drug Enforcement
Act of 2016, Pub. L. No. 114-145, § 2(a)(1), 130 Stat. 354 (2016)
(codified as amended at 21 U.S.C. § 823 (2017)).
47 Ensuring Patient Access and Effective Drug Enforcement
Act of 2016, Pub. L. No. 114-145, § 2(a)(2), 130 Stat. 354
(codified as amended at 21 U.S.C. § 824 (2016)).
48 See Higham & Bernstein, supra note 44.
49 See, e.g., Bipartisan Budget Act of 2018, H.R. 1892, 115th
Cong. § 50723 (2018).
50 CARA 2.0 Act of 2018, S. 2456, 115th Cong. (2018).
51 CARA 2.0 Act of 2018, H.R. 5311, 115th Cong. (2018).
52 Id.
45
46
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legislatures, with some good results and some not as
positive. Eric discussed some of these results at the
symposium. For example, while he was relieved that
many of the opioid “pill mills” in West Virginia had been
shut down or had voluntarily closed their doors, he
suspected that a number of them had simply changed the
signs on their doors and morphed into “treatment
centers” that use medication to treat the opioid addicts
that they helped to create.
Medication-assisted
treatment
for
opioid
addiction is still very controversial.53 The main criticism
of using medication in this context is that it is just
replacing one drug - whether an opioid painkiller or
heroin - with another, such as methadone,
buprenorphine, and naltrexone.54 Research clearly
demonstrates, however, that medication improves
outcomes for patients with opioid use disorders.55
Along with the success of these treatments,
several tag-along legal issues have arisen which are
worthy of monitoring. One involves claims by the
Attorneys General of 35 states and the District of
Columbia that British pharmaceutical manufacturer
Indivior Inc. and U.S. company MonoSol Rx “product
hopped” in order to delay less expensive generic versions
See, e.g., Sameer Hassamal et al., Overcoming Barriers to
Initiating Medication-Assisted Treatment for Heroin Use
Disorder in a General Medical Hospital: A Case Report and
Narrative Literature Review, J. PSYCHOL. PRAC. 221 (2017).
54 Medication and Counseling Treatment, SUBSTANCE ABUSE &
MENTAL HEALTH ADMIN. (APR. 8, 2018), https://www.
samhsa.gov/medication-assisted-treatment/treatment
[https://perma.cc/5VC4-LULF]. Buprenorphine (Subutex) and
Buprenorphine-naloxone (Suboxone) were approved by the
U.S. FDA in 2002 to treat opiate dependence. Naloxone is the
drug used to revive overdose victims.
55 Mollie Durkin, Primary Care Takes on Opioid Addiction,
ACP INTERNIST: OPIOIDS (Oct. 2017), https://acpinternist.org/
archives/2017/10/primary-care-takes-on-opioid-addiction.htm
[https: //perma.cc/L49U-BM2H].
53
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of Suboxone, Indivior’s opioid addiction treatment drug.56
The defendants in that case are accused of conspiring to
create a sublingual film version of its Suboxone drug
shortly before its license expired in order to extend its
patent; of incrementally increasing the price of its tablets
and engaging in potentially misleading marketing to
encourage patients and doctors to switch to the new film
version; and of then announcing its intent to remove the
tablets from the market entirely.57
Another pharmaceutical manufacturer in the
ever-growing opioid treatment market has drawn fire for
its marketing practices. Alkermes, a Massachusetts
company, makes a monthly injectable treatment
medication called Vivitrol that blocks the effects of
opioids and reduces cravings, and the company has taken
its aggressive marketing pitch directly to drug court
judges, prosecutors, and other officials in the criminal
justice system who appear receptive to the “nonaddictive”
qualities of its product.58 According to medical
professionals, this approach is misleading and
contributes to the “existing stigma on the use of opioid
[methadone or buprenorphine] therapy in the treatment
of opioid addiction, despite a large and robust evidence
base showing [its] effectiveness . . . for opioid addiction.”59
In addition to the potentially predatory practices
of the companies and individuals seeking to exploit the
market for opioid addiction treatment, there are other
See Wisconsin v. Indivior Inc., Civ. No. 16-5073, 2017 WL
3967911 (E.D. Pa. Sept. 8, 2017).
57 Id.
58 See, e.g., Press Release, U.S. Senator Kamala Harris,
Senator Harris Launches Investigation into Pharmaceutical
Manufacturer Alkermes Regarding Opioid Addiction
Treatment Manipulation (Nov. 6, 2017), https://www.
harris.senate.gov/news/press-releases/senator-harrislaunches-investigation-into-pharmaceutical-manufactureralkermes-regarding-opioid-addiction-treatment-manipulation
[https://perma.cc/G5C7-YFKP].
59 Id.
56
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obvious downsides to the successful closure of many of
the unethical pill mills that blighted our rural
communities. Some of the poor souls who are no longer
able to access opioid prescriptions have turned to heroin
or to the very deadly synthetic opioid, fentanyl. According
to the CDC, “illicitly manufactured fentanyl is now a
major cause of opioid overdose deaths in multiple
states.”60 One law enforcement officer compared it to a
community weapon of mass destruction: “[i]t’s
manufactured death.”61
Hopefully, no one will be discouraged from
seeking to combat the opioid crisis in all of its forms,
whether the drug has been produced legally or illegally.
We should look to Eric’s efforts, and those of our
colleagues whose legal work supported him, for courage
and inspiration. The unsealed data that Eric and Pat et
al. secured in West Virginia are still among the only such
data that are publicly-available. The industry, with
support from the U.S. Department of Justice and the U.S.
DEA, is still demanding that its data be protected on the
grounds that disclosure could violate privacy rights,
breach trade secrets, interfere with law enforcement
investigations, and encourage criminal activity.62 This is
Maggie Fox, Synthetic Fentanyl Deaths Rise in Americans
Opioid Epidemic, NBC NEWS: HEALTH (Oct. 27, 2017),
https://www.nbcnews.com/storyline/americas-heroin-epidemic/
synthetic-fentanyl-deaths-rise-americans-opioid-epidemicn814956 [https://perma.cc/S42J-CTEH].
61 Nicole Lewis et al., Fentanyl Linked to Thousands of Urban
Overdose Deaths, WASH. POST: NAT’L (Aug. 17. 2017),
https://www.washingtonpost.com/graphics/2017/national/fent
anyl-overdoses/?utm_term=.d64447b619c9 [https://perma.cc/
ZRV4-N57W].
62 Letter from David A. Sierleja, First Assistant U.S. Attorney,
N. Dist. of Ohio, to Paul T. Ferrell, Jr., Partner, Green,
Ketchum, Farrell, Bailey & Tweel LLP (Feb. 26, 2018),
https://images.law.com/contrib/content/uploads/documents/39
8/11419/Critical-Mass-opioid-DOJ-letter.pdf [https://perma.cc/
EQ9L-FBGV].
60
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despite the Justice Department’s request to participate
in the settlement talks in the large MDL pending in the
Northern District of Ohio.63
This reluctance is understandable. The publiclyavailable raw numbers in Tennessee are sobering. In
Knox County alone, there were 294 suspected drug
overdose deaths in 2017 and 84 so far in 2018. Those are
not just numbers: those are our children, mothers,
fathers, siblings, and friends, and each leaves behind
grieving loved ones, all of whom deserve the best of our
combined professional efforts. As painful as the truth
may be, lawyers and journalists should be working to
uncover it, individually and as partners. Eric and his
legal support may be a tough, if not an impossible, act to
follow, but it is one to which I hope that we all will aspire.

United States’ Motion to Participate in Settlement
Discussions and as Friend of the Court, In re National
Prescription Opiate Litigation, MDL No. 1:17-MD-2804 (N.D.
Ohio April 2, 2018). This apparent cognitive dissonance
appears to be an issue amongst the manufacturing community,
too. OxyContin manufacturer Purdue Pharma recently
announced that it would stop promoting opioids to physicians,
see OxyContin Maker Purdue Pharma Stops Promoting
Opioids, Cuts Sales Staff, WASH. POST: HEALTH SCIENCE (Feb.
10, 2018), https://www.washingtonpost.com/national/healthscience/oxycontin-maker-purdue-pharma-to-stop-promotingthe-drug-to-doctors/2018/02/10/c59be118-0ea7-11e8-95a5c396801049ef_story.html
[https://perma.cc/9FR5-4WSP],
while at the same time “funneling $4.7 million to organizations
and physicians from 2012 through last year” that promoted the
use of opioid painkillers. Associated Press, Opioid Makers Gave
$10 Million to Drug Advocacy Groups Amid Epidemic, NBC
NEWS: NEWS (Feb. 18, 2018), https://www.nbcnews.com/storyline/
americas-heroin-epidemic/opioid-makers-gave-10m-advocacygroups-amid-epidemic-n849211 [https://perma.cc/LW39-63UK].
63
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HEALING APPALACHIA: KEYNOTE
DISCUSSION
Eric Eyre
Patrick C. McGinley
Becky Jacobs, Moderator
INTRODUCTION:
Welcome to "Healing
Appalachia, The Role of Professionals in Solving the
Opioid Crisis." My name is Michael Deel. On behalf of
the Tennessee Journal of Law and Policy and the
University of Tennessee College of Law, thank you for
attending.
Today we have gathered experts who are working
to find legal and political solutions to this public health
crisis while also working with individuals who are
suffering on a day-to-day basis. I invite you to not only
listen to their stories but to learn from them and to
remember their efforts when you make your own
everyday decisions, decisions like how to help a friend,
how to effect policy, how to find hidden information, or
simply how to vote in the next election.
I would like to thank all the panelists and
moderators that are participating today and also thank
everyone who helped put this event together. So many
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people gave their time and energy to make this
symposium possible.
Mr. Eric Eyre and Professor Patrick McGinley will
deliver our keynote address which will be followed by two
panel discussions and a documentary viewing. We will
take a 15-minute break between each session and there
will be a transcript available after we get it published in
the next issue of TJLP.
Mr. Eyre won the Pulitzer Prize for investigative
reporting for his articles regarding the distribution of 750
million prescription pills in West Virginia and the tragic
overdoses that followed those pills. He currently works
as a statehouse reporter for the Charleston GazzetteMail.
Professor McGinley is a Charles H. Hayden II
Professor of Law at West Virginia College of Law.
Professor McGinley teaches administrative law,
environmental law, and appellate advocacy. He also
represented the Charleston Gazzette-Mail in a lawsuit
that resulted in a court order unsealing the documents
that led to Mr. Eyre's articles.
Professor Becky Jacobs from the University of
Tennessee College of Law will moderate this discussion.
Please join me in welcoming them.
MS. JACOBS:
So just to like frame our
discussion this afternoon, I want to give you just a few
facts. So opioid painkillers are a nine-billion-dollar-ayear market in the U.S. alone. In pharmaceutical
companies such as Purdue Pharma, Johnson & Johnson,
Teva, and Allergan have all earned many billions over
the years from the sale of these drugs. Wholesaler
distributors like McKesson, Cardinal Health, and
AmerisourceBergen also have profited, as have the
physicians and pain clinics that prescribe these
medications, some legitimately, some not so legitimately.
These profits, though, have had a very, very high
public health cost as the work of our guests today helped
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to expose. According to the CDC, from 1999 to 2016, more
than 200,000 people have died in the U.S. from overdoses
related to prescription opioids.
That's just the
prescription opioids. In 2016 alone, more than 46 people
every day have died from overdoses involving
prescription opioids. Also in 2016, three of the five states
with the highest rates of death due to drug overdoses
were close to us: West Virginia had 52 per 100,000, Ohio
had 39.1 per 100,000, and Kentucky had 33.5.
Tennessee's rate was 24.5. And our guests today fought
to make these data public. So I want to thank them very
much for being here.
I want to start by asking you, for those who aren't
familiar with kind of what these drugs are, can you
describe the specific painkillers that we're talking about
and which ones are the focus of this investigation?
MR. EYRE:
Sure. The two that we primarily
focused on, because we got the DEA data on were
hydrocodone, which is Lortab and Vicodin, and
oxycodone, which is OxyContin. And there's plenty of
other pills that are distributed, but those were the two
that we focused on primarily.
MS. JACOBS:
Okay. So how you did you get
interested in the topic, and how and when did Pat get
involved?
MR. EYRE:
I kind of wound up in it in a
different way. I covered the legislature for West Virginia,
so I'm based at the Capitol, and we had a new attorney
general elected in our state. There had been a lawsuit
filed about six months prior to his win by our former
attorney general, and that lawsuit was against the drug
wholesalers. When our new attorney general got elected,
I got this phone call that this woman wanted to meet with
me outside the Capitol; she had some information for me.
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She brought this envelope of stuff. She had— I
remember it was crazy because she had a dog with her
named Bernard the Pekinese. So she's literally handing
stuff out and I'm worried I'm going to get bit by this dog,
Bernard the Pekinese. What it was was information
about the new incoming attorney general's ties to these
drug wholesalers. The one company that you mentioned,
Cardinal Health, had paid for his inauguration, and then
when we also looked back at contributions, a lot of these
drug wholesalers after the lawsuit was filed in July of
2012 had given money to the attorney general. And so
we did a story about that and he said over and over that
he had recused himself from the case at the beginning of
when we assume he took office, but we had heard from
staff that that wasn't the case. So we actually filed a
number of Freedom of Information Act requests and that
wound up in court.
This photo here is— the attorney general is on the
right there. This was a photo taken by a New York Times
reporter, Eric Lipton, who actually won the Pulitzer Prize
two or three years ago and he was writing about both the
Republican Attorneys General Association and the
Democratic Attorneys General Association wining and
dining various attorneys general to get them— to try to
persuade them to drop lawsuits or not file lawsuits. And
the woman there is Pam Bondi. I believe she's still the
attorney general in Florida.
And the story was about her being pushed— this
was in the Hotel del Coronado in San Diego, a beautiful
resort there— she was being pushed to drop a lawsuit
against 5-hour ENERGY. And these guys are lobbyists.
I think it was something like three thousand dollars a
night to stay there. I met the reporter at the Pulitzer
ceremony. And eventually when they found out what he
was doing, he got kicked out of course but . . . So the next
step was the FOIA lawsuit, and maybe Pat can talk a
little bit about that. This is back in 2013, 2014.
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MR. MCGINLEY: Yeah. So—
MS. JACOBS:
little bit and—
MR. EYRE:
MS. JACOBS:
McGraw filed.

Before you do that, step back a
The lawsuit—
—the first lawsuit that Darrell

MR. MCGINLEY: So in was it 2012 a long-time
West Virginia attorney general, Darrell McGraw, filed
the first case against drug distributors of opioid drugs,
recognizing the impact of opioids in West Virginia, and,
really, the first public official to take some kind of action.
The lawsuit, the cause of action, was new and it was
suggested that this is a looser, the attorney general's
office is up against Big Pharma, billion-dollar
enterprises, lawyers from New York and Philadelphia
and Cleveland. But that lawsuit was filed. And then in
a very narrow election, Attorney General McGraw lost to
Patrick Morrisey. He's pictured there in blue jeans with
a lobbyist and the attorney general of Florida. And so
within six months of the time that these "pill mill" cases,
that's what they were referred to, were filed in the
summer of 2012, a new attorney general who had
formerly been a lobbyist for trade associations from the
pharmaceutical industry took office.
MR. EYRE:
And what I forgot to mention, his
wife was the lead lobbyist for Cardinal Health in
Washington D.C. and made millions of dollars.
MR. MCGINLEY: Cardinal Health being one of
the three leading opioid drug distributors in the country.
And she continued to be a lobbyist until after our lawsuit.
There was an ethics complaint filed against the attorney
general at some point and said, well, I don't have to do
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this but I won't have my fingers on any of these cases.
But that took a couple of years. In the meantime, Eric
and the Gazzette-Mail are interested in what this new
attorney general was going to do in terms of supervising
these "pill mill" cases, considering his former relationship
with the industry. And Eric filed several FOIA requests
and he was basically stonewalled, the responses didn't
meet the requirements of the West Virginia Freedom of
Information Act. I think the first one, they said, well, if
we had these documents you're requesting that relate to
whether the attorney general is supervising the "pill mill"
cases, if we have them, they would be exempt.
And, you know, at that point the Gazzette asked
me to be of assistance, because I've done a lot of FOIA
stuff, and so I wrote to the attorney general and I said,
well, that's not good enough, you've got to look for it, you
can't just say if you have it. And then there was a series
of back and forth with nonresponsive answers from the
attorney general, and I would say, well, let's read the law,
you know, you must have something.
And then,
ultimately, after about six months, they said— they
called Eric and said, okay, you can come and look at the
documents but they are totally redacted and you can't
take photographs, and they set a time for it. And we
talked and we responded, that's not what the law
requires, no, we're not doing that. And they said, we'll
get back to you.
They didn't get back to us. We filed a FOIA suit.
It went on for almost a year. We did discovery. We found
out they had documents that they hadn't mentioned
before but they claimed were attorney-client privilege,
work product. And we thought we had a really good
paper trail, a good case for joint motions for summary
judgment, cross motions for summary judgment. And the
judge ruled against us and granted summary judgment.
And I was depressed. I thought this is a winner. Eric
and the others at the Gazzette were taken aback. And
then something happened that was interesting.
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MR. EYRE: So after we lost the FOIA case,
somebody— I was not home. This is a recreated—
actually I found this— this is actually the envelope that
it came in but somebody walked up to our house and my
son texted me at work and said some man just came up
to our house and dropped something in the mailbox with
your name on it.
Go to the next slide. You can't see it there but that
was one of the e-mails that was being withheld, and what
it said in the e-mail was that the attorney general has
specific instructions regarding this case. So it was hard
to believe— he had done multiple interviews, not just
with me but with other media, over and over again saying
that he was completely recused from the case, he had had
nothing to do with it since the day he took office. And
this countered his assertions for sure. And then where
do you want—
MR. MCGINLEY: Well, so Eric wanted to write
about this of course—
MR. EYRE:

Oh yeah.

MR. MCGINLEY: —because this is exactly the
opposite of what the attorney general had stated in court
proceedings. And so, Eric, you can tell the story. As
reporters usually would do, you asked him for comment.
MR. EYRE:
Yeah. They required all their
questions to be e-mailed, so I e-mailed a bunch of
questions about when you said that you recused yourself
from the case, it would seem this contradicts what you
are saying. We also found at around the same time there
had been some documents saying that a court hearing
related to this drug distributors lawsuit had to be
canceled because Attorney General Pat Morrisey can't fit
it into his schedule and can't make it. And so if he was
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recused from the case, why would they be saying he
couldn't be there and things like that. So I e-mailed to
their press person these questions about what's going on.
And then the next thing you know, their general counsel
called or e-mailed you, Pat.
MR. MCGINLEY: Their solicitor general.
MR. EYRE:

Became solicitor general.

MR. MCGINLEY: We never had a solicitor
general in West Virginia but it sounds like a good title.
Yeah, he called me, and I was actually here in Knoxville,
at the time I was on my way to the Public Interest
Environmental Law Conference, and I get the call on my
cell phone from Misha—
MR. EYRE:

Misha Tseytlin.

MR. MCGINLEY: —Tseytlin.
MR. EYRE:
Wisconsin.

He's now the solicitor general at

MR. MCGINLEY: —and there were documents
that were in the files of the court in our FOIA case that
were produced by (inaudible) and that were examined by
the court, quashed by the court in camera before it
granted summary judgment against us. And so he called
me and he said you better tell your client not to publish
this story about documents that are under seal in the
court, you're going to be sanctioned, and we're not going
to tolerate this. And, you know, I'm in the rental car
and—
MR. EYRE:

And I'm like am I going to jail or .

..
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MR. MCGINLEY: And I said, Misha, have you
ever heard of the Pentagon Papers case? Misha was a
law clerk to Justice Kennedy, so he knew the story. I said
you do what you want but I can assure you this is going
to go to print. But that wasn't the end of the story. We
had to have conversations with the editor and publisher
and they were concerned with are they going to sue us.
And I said they can sue you, anybody can sue you, but
this is a winner.
And they went ahead and Eric told the story. It
didn't have much impact. He continued to deny and it
just sort of went over people's heads. But we knew about
that, it was clear the relationship there. The overarching
concern was that the attorney general would somehow
dump the "pill mill" cases, that it would settle them cheap
or make errors, who knew, who knows. But he certainly
with the appearance of impropriety with his prior
relationships and the representations made to the Court,
he shouldn't have been involved at all.
MS. JACOBS:
Well, in fact, he wasn't very
aggressive about the data that you guys had to intervene
to get. So tell us about that. Because that's what broke—
MR. EYRE: That was— that was the next thing.
So if we sort of flash forward, I kind of kept following the
story and started seeing stuff in various legal filings. But
in I think it was around March 2016 we got wind that
there had been what was called a second amended
complaint or a revised complaint. When they filed the
original lawsuit back in 2012, the judge in this rural
county that was handling it said we need some specifics
here, we need some examples of, you know, this sending
these larger quantities of drugs, these "pill mill"
pharmacies. So they had filed an updated complaint
called the second amended complaint and it was filed
under seal. So this was the State of West Virginia filing
a complaint outlining its allegations against the drug
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distributors and you couldn't see it.
It was just
completely filed under seal. And I went to Pat and said,
is this possible.
MR. MCGINLEY: Yeah. I said, well, that
certainly violates the West Virginia Constitution,
violates West Virginia Freedom of Information Act, and
the West Virginia Rules of Civil Procedure. So the
general rule is that public documents should be public
when they are filed with the court. And here he had a
complaint on behalf of the State that says on behalf of the
people of West Virginia against these drug companies,
but the people don't know what the allegations are. And
so the State itself had come around to the point where it
wanted the second amended complaint to be unsealed,
but the Court did nothing and they didn't assert that
aggressively. So I talked to Eric, and I got other things
to do at the law school, and I'm thinking well they are
going to act, nothing happened, so we filed a motion to
intervene for the purposes of seeking unsealing of the
second amended complaint, which is in the materials that
you have. And we basically argued that there's no law on
the side of the drug companies.
Their response, which I think is in the material as
well, was that these are essentially trade secrets,
confidential business information about how many pills,
opioids, that we sell to pharmacies, so our competitors
would find out who the pharmacies are and how much.
And, you know, we read that and said, what? And not
only that, it was old data. And we went to Boone County
Circuit Court for a hearing. There were lawyers from
everywhere. The court was filled.
MR. EYRE:

It's a picture from the courtroom.

MR. MCGINLEY: That's our co-counsel from
Boone County, Tim Conaway. And we were totally
outnumbered. There must have been 40 lawyers there
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for the various drug companies and pharmacies. And we
argued the case. And the judge eventually said he was
going to rule to unseal the documents, and then one of
the drug companies filed a motion and wanted to have a
conference call and— what did they say—
MR. EYRE: There was like this 11th hour try to
block the release of this— to unseal this complaint and
what they said was they wanted to redact 18 words. We
had a conference call about it, and I think they filed
something too. And they said— and it was probably 70
pages long. And they said we just want to redact 18
words. They just kept saying if you can keep these 18
words out, we're good with that. Well, it turned out— I'm
making a spoiler alert here, I'm jumping ahead— but it
turned out the 18 words were 18 numbers and it was
numbers of pain pills. They said words.
MR. MCGINLEY: Yeah. And, well, the judge
didn't buy that. He ordered the complaint to be unsealed.
And then that gave Eric insight into the bigger story, the
sheer volume of opioids that were being marketed in the
places they were being marketed. When we saw that first
information, we were stunned. We're talking about a
couple hundred million doses over a five-, six-year period.
But there was more. But Eric wrote a story that was part
of the Pulitzer recognition in May of 2016. You can
describe what—
MR. EYRE: That one was some of these numbers
were— these orders were shipped— you have 20,000
oxycodone to one pharmacy in a little town of a couple
hundred people, and then it would say on the following
week they'd get another 50,000, and then the next week
they'd get another 20,000. So it was just these large
shipments over consecutive days or consecutive weeks.
And what the average hydrocodone I think nationally is
90,000 per pharmacy per year, and oxycodone is probably
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like 50,000 doses per year. So these small-town
pharmacies were getting the equivalent of what they
should have gotten in a year in a matter of a week or two.
But what ultimately happened though, where this really
opened things up, is throughout the complaint that was
unsealed, they kept referring to DEA data shows, DEA
data shows, DEA data shows this, that, and the other. So
I did a FOIA asking the attorney general's office for all
the DEA data that they used to cite all these various
figures. And it turns out that there was a 2015 e-mail
sent from DEA to the attorney general's office outlining
every shipment to every pharmacy in West Virginia of
hydrocodone and oxycodone and also it was broken down
by the name of the company and how many pills they
distributed to each county in West Virginia. And what
we— just to sum it up, after we got this DEA data, there
was a disproportionate number of pills sent to the
southern part of the state, the coalfield region.
And you had these situations where you had
pharmacies with— one town had a pharmacy— 400
people— and got nearly nine million hydrocodone pills in
two years, in just two years. There were cases like this all
over southern West Virginia, Logan County, Boone
County, Mingo County. They had a town of 3,000 in
Mingo County, they got 20 million hydrocodone over
eight years. Just these incredible numbers. And then we
looked at, you know, we did the (unintelligible) maps and
looked at where most of the overdose deaths were, and
they don't line up perfectly, but they match up pretty
closely. And these counties here, not only are they
number one for prescription drug overdose deaths in
West Virginia, but they are I think of the top 10 about six
or seven of them were all in West Virginia in the country
for overdose death rates. So it was an incredible thing.
And, in addition, I don't have a slide to show it, but the
DEA agent who sent the data to the attorney general's
office, he also did a— he mapped out the strength of the
pills of the OxyContin, the milligram levels had
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increased. So you had in 2007 the most popular milligram
level of OxyContin was five milligrams, and then the next
year it was like 10 milligrams. So the strength of the pills
were actually getting stronger too in terms of—
MR. MCGINLEY: How high did they go?
MR. EYRE: They had OxyContin 80, but that was
outlawed I believe.
MR. MCGINLEY: But they went beyond 10, it
went pretty far above it.
MR. EYRE: Yeah, I think it went to like 30.
MS. JACOBS: I know there's a quote from your
article that there were 433 pain pills for every man,
woman, and child in West Virginia.
MR. EYRE: Just those two, right. I mean, we're
not even doing hydromorphone, oxymorphone, Xanax,
and all the others.
MS. JACOBS: That's astounding.
MR. MCGINLEY: There's one parenthetical that
Eric was— when he filed actually a Freedom of
Information Act request with the attorney general
seeking the DEA data in August of 2016. And under West
Virginia law, a FOIA law response is required within five
working days. Well, the attorney general's office kept
delaying, we're looking for the data, we'll get back to you,
we'll get back to you. Meantime, there's an election going
on where the attorney general is running for re-election.
His opponent has a lot of cash and is running— has spent
several million dollars on TV ads trumpeting the
relationship of the attorney general to the drug
companies and the opioid epidemic. And there was an
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infusion of cash into Morrisey's campaign in October of—
what was it— six million dollars from the National— the
Republican Attorneys General Association, more money
that flowed from that association than any other attorney
general race. That money is sort of dark money. The
contributors are the Koch brothers, pharmaceutical
companies. And so the attorney general continued to
delay responding. And what happened then?
MR. EYRE: Pat came up with a good idea that we
should file a FOIA asking them— because they kept
responding that they are searching for the records, they
are searching for the records, and they would just keep
every five days saying we're still searching for the
records— Pat came up with an idea just to do a FOIA
saying any documents that would show you're actually
searching for the records. Of course there were none. And
then about two or three weeks before the election he did,
to his credit, he did release the DEA data.
The backdrop, as Pat was describing, was this
immense pressure in terms of ads from the democratic
opponent. Actually, CBS News had picked up on our story
and came to West Virginia multiple times. And the
attorney general agreed to do an interview with CBS
News, which I can't— I don't know who told him to do
that. But of course they did the things where they are
asking all these happy questions and then they say what
about your wife works for Cardinal Health and you have
this lawsuit and, you know, they zero in on your face and
you start seeing the twitches and all that. Well, the
democratic guy that was running against him just kept
running that interview over and over in his ad. But that
was countered by all the money from the Republican
Attorneys General Association who said that the
democratic opponent was big friends with Hillary Clinton
and Obama and they pounded that over and over and
over, which is a simple effective message that worked.
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MR. MCGINLEY: And Attorney General Morrisey
won the election. It was close but he prevailed. I don't
know that I would give him credit because he knew that
Eric and the Gazzette were going to write stories and we
were considering a lawsuit against him, a FOIA suit, that
would have come out right before the election. So I think
he had some good political counselors in-house that said
you better get this information out there. And it's really
a question whether that information should be— should
not be available to the public because it came from the
DEA. And that's more the problem, all this information
the DEA has but it's not shared, the public doesn't have
access to it. So the public knows because of Eric's
reporting the volume of prescription opioids that were
sold in West Virginia. But we don't know, we don't have
the data at this point, about the sales in Ohio, in New
Jersey, Tennessee, Kentucky, and so forth. And that's a
real flaw in the system. But subsequent to Eric's
reporting there have been numerous lawsuits that have
been filed here in Tennessee, for example, by
Municipalities, Indian tribes, Cities, States, against the
drug
manufacturers
and
distributors
seeking
compensation for the cost of dealing with the opioid
epidemic, which is enormous.
The American Enterprise Institute report just
came out pegging the cost to the gross domestic product
in West Virginia of eight billion dollars. That sounds high
to me but I don't know. And the human cost, you can't
calculate that. And, hopefully, in these cases that are, you
know, following up on what West Virginia did, that
litigation and exposure. But the volume— I was looking
at the audience here, we were talking about how many
oxycodone, OxyContin pills, and the total is 780 million.
And when we saw that, I said oh my God. I think that's
what a jury would do, if you've got a case where you could
get it to the jury. It's a question of creative lawyering,
having statute or common law remedies that will make
these— hold these billion-dollar companies responsible.
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And that's one of the grossest things about this whole
story is the billions of dollars that these companies have
made and there have been very few repercussions,
certainly not to the companies. Three of the top 15
Fortune 500 companies are drug distributors and were
parties in the "pill mill" litigation in West Virginia.
McKesson, Cardinal Health, Amerisource Bergen, not
household names, but they're right up there with WalMart and Apple. And what do they do? I mean, what—
MR. EYRE: They ship drugs from factories to
warehouses to pharmacies and hospitals.
MS. JACOBS: Purdue Pharma who produces
OxyContin—
MR. MCGINLEY: The manufacturer.
MS. JACOBS: —they're the manufacturer,
privately owned by a family, and they are I think the
wealthiest, or maybe behind Bill Gates, in the country.
MR. EYRE: Well, like McKesson is the number
five on the Fortune 500. And that shocked me. I didn't
even figure that all out until we were in the courtroom
and I turned around and introduced myself, and
somebody was telling me they were from D.C. and like
Cardinal Health or the other companies would have three
or four lawyers there. We don't have the rankings but I
think it's Wal-Mart, Apple is number two on the Fortune
500, or Berkshire Hathaway, Exxon, and then McKesson
is number five. And then I'm not going to get these
exactly right but I think AmerisourceBergen is 12 and
Cardinal Health is 15. And they've actually climbed—
since my story has come out, they've actually climbed in
places in the Fortune 500. These are CEOs that are
making— a guy in McKesson— there's been stories in
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Fortune or Forbes— Forbes— making over 60 million
dollars a year in compensation.
MR. MCGINLEY: The McKesson CEO one year
was the highest paid CEO of any corporation in the
United States.
MR. EYRE: And nobody had heard anything.
MS. JACOBS: I've heard another topic you've
done. You were talking about the distribution
outlets, some of the pharmacies. It wasn't Wal-Mart or
Walgreens or— tell us about where these pills were being
distributed in West Virginia.
MR. EYRE: Yeah. That was surprising. Because
before I covered the— as you guys know a lot about the
meth epidemic when they're doing the shake and bake
bottles and making it with Sudafed, and we used to
identify the pharmacies that were selling the most
Sudafed in the state and they were typically the WalMarts and the Rite Aids. But in this case it was these
independent pharmacies, these mom and pop
pharmacies. They were literally drive-thru pharmacies.
They didn't sell Band-Aids, they didn't sell Q-tips. They
literally had names like Meds To Go Express and Larry's
Drive-thru Pharmacy. And you'd see people lined up up
and down the block. People would come from all over. You
know, I've seen recent stories where some of these
pharmacies are defending themselves saying we just
didn't serve the town of 400, people came from all over.
But I think that's more damning than— I mean, they
were literally coming from Tennessee, Kentucky, Ohio,
Pennsylvania to these little small towns in the southern
part of West Virginia. Whitfield, Virginia is another
place.
And you had these— you know, I wasn't there—
but everybody describes these scenes that there's one
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pharmacy in Kermit, which is this little town of 400
people, because there were so many people in line, they
started handing out bags of free popcorn just as a bonus.
They had bags for the people in town where if it was
opioids, you'd get it in one color bag, and if not, like if it
was blood pressure medication, you'd get it in another
color bag, because they didn't want the senior citizens in
town getting robbed. Because if the people would see you
had the color bag that wasn't opioids, then they wouldn't
rob you. They actually set up a hotdog stand with
hamburgers and hotdogs while people were waiting in
line. It was just an unbelievable scene from what's been
described to me.
MR. MCGINLEY: What about the doctors? I refer
to this as a legal cartel. You have the Mexican brown
heroin cartel or Columbian cocaine cartel. You have the
legal cartel, you've got manufacturers, you've got the
distributors, you've got the doctors who were writing the
scripts, you've got the pharmacies who were filling the
prescriptions, they all had to know. With those numbers,
all of them knew. And where was the law enforcement?
Where is the Pharmacy Board? Where was the DEA? And
this was going on for more than a decade. And I think the
numbers, when we finally saw the numbers, the light
went on and the country woke up to realize that this was
all legal and they had— the defense was of the
manufacturers, well, we're just making stuff to help
people with their pain. The distributors, we're just taking
them to the pharmacies. The pharmacies, we're just
filling the doctors' prescriptions. And the doctors saying
we're helping our patients with pain. They are all
pointing fingers, they didn't do anything wrong. The
doctor's office, what was that like?
MR. EYRE: Just last week or this week they
busted what's called The Hope Clinic. I think at one point
they had— yeah, what a name for a "pill mill" pain clinic,
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The Hope Clinic, we're giving people hope— I had
actually written about them. One of the prisms of my
stories is they only focused on the drug wholesalers. My
mom called me the day that story came out, when it first
came out back in December 2016, she said what about the
doctors. And I said I've been writing about the doctors for
years. They had these pain clinics where the doctors
didn't even show up. The one that just got busted that we
wrote about back in 2014, 2015, they had former cops,
retired cops, who were taking people's blood pressure,
doing the weight, doing their charts. They carried guns
holstered at the site. They had these special machines, I
can't remember the exact name of them, but they were
these electronic machines that would crank out
prescriptions by the hundreds. They would have the
doctor’s signature on them, but they were just being
reproduced through the machines. And I would get calls
back in 2014, 2015 from legitimate pharmacists that
would call me up and say come up and let me show you
what they are doing, you know. But they would set up
special relationships with some pharmacies that were
disreputable, and they would fill those prescriptions. And
it was an all cash basis. There was no insurance or
anything like that. It was just a cash only business.
MS. JACOBS: It's astounding that— where was
the Board of Pharmacy? In your third article you talked
about the responsibility to file reports about large
shipments. What happened with all of that?
MR. EYRE: Well, our Board of Pharmacy is
almost exclusively made up of independent mom and pop,
including some that were involved in this "pill mill" stuff.
Their directors are all appointed by the governor and
they are all independent pharmacists. So they had some
rules on the books related to something called "suspicious
orders" and those are orders of large numbers of drugs
over consecutive days or massive quantities over one day.
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MR. MCGINLEY: Those are Federal rules; right?
MR. EYRE: It was a DEA rule that the State had
copied and put into their rules at the Board of Pharmacy.
And I asked our executive director of our Pharmacy
Board, because it was cited in the lawsuit, I said what are
you doing with that. They said that hasn't been on my
radar, we just don't enforce that rule. So there had been
no suspicious order reports filed by any of these drug
wholesalers before 2012. But when the lawsuit was filed
by the former attorney general, a couple of them— two of
them started sending suspicious order reports to the
Board of Pharmacy, sometimes two or three a day. I went
and said can I take a look at them. I thought they would
be cataloged, they'd have a total number or something.
And they just came— I came into the office and they came
in with two big bankers boxes full and they dropped them
on the table and they said here is all our suspicious order
reports. And I said, well, what have you done with them.
And they said we haven't done anything with them, we
just shelve them. And they hadn't cataloged them, so I
literally had to count through each one to figure out how
many had been filed.
MS. JACOBS: Were they included in the lawsuit,
the warrant?
MR. MCGINLEY: Not at that point, no.
MS. JACOBS: That's amazing. So talk a little bit
about the consequences, like the kind of after-effect. Your
work had a significant impact on all the lawsuits that
happened. And what else do you think you have done,
your work has done?
MR. EYRE: Well, the biggest development is there
is a congressional investigation in the House Energy and
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Commerce Committee and what they're doing that we
hadn't been able to do for the most part is linking up exact
numbers from each company to each of these pharmacies,
and many of them were shuttered, a lot of them are still
open actually, and they've been able to sort of dovetail or
expand upon our work. They were originally stonewalled
by the DEA. I think in some respects the Congressional
Committees were still being stonewalled. But they've
come out with some more shocking numbers like
McKesson over a two-year period they figured out of
those nine million pills like five million were from
McKesson alone, 76 percent of the business. They've
gotten some real granular detail. And they've identified
other regional wholesalers. Another name is MiamiLuken, H.D. Smith. They're starting to get more
numbers. But what's frustrating is, we talked a little bit
about this earlier, the DEA, they have all this data. I get
calls from all over the country saying can we replicate
what you did. And I said the DEA in a matter of I can't
imagine it would take more than an hour to do the
spreadsheets that we got, it's a simple sort, but they just
won't do it. They point to there's data available on their
Web site called ARCOS data but it's broken down by
grams and by zip code prefixes. Which I tried to look up
our zip code prefixes in West Virginia and they span
sometimes four or five counties or they dig into half of a
county, and it's very complicated to do it that way. There
are ways to see the overall number of grams by state,
things like that, but nothing like what we got.
MS. JACOBS: Yeah. So what do— I mean, I've
noticed—
MR. MCGINLEY: Can I add something there?
MR. EYRE: Yeah.
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MR. MCGINLEY: With regard to the DEA, some
of you may have saw the story, the DEA had an official
that was in charge of checking on the drug distributors,
you know, for suspicious orders and volumes and was
trying to organize enforcement actions, at least the story
that's been told publicly, and wasn't permitted to go
forward. I think there was pressure from higher up in the
agency or political pressure in the regional offices. But
there were people in the DEA enforcement that wanted
to do something about the enormous volume of opioids
that were being distributed. And the trade associations
for the pharmaceutical industry hired a former member
of the DEA's general counsel's office to draft legislation
that essentially took away the DEA's enforcement power.
That's the old revolving door. You know, anybody that's
been around government knows about that. And that bill
was written in language that was not penetrable by those
who don't really understand the legal terminology and
what the DEA does, and so it was sponsored by a
congressman from northeast Pennsylvania and it was
passed on a voice vote in both the House and the Senate
unanimously. I think the attorney general did raise some
question about it. President Obama signed it and
nobody— clearly, no one read it and knew what was in
there. So here is an effort funded by the industry to talk
about DEA oversight and enforcement power and it just
goes totally under the radar until the Washington Post—
was it—
MS. JACOBS: 60 Minutes.
MR. MCGINLEY: —60 Minutes last fall did this
exposé. At that time the congressman of Pennsylvania
had been nominated by President Trump to be the new
head of the DEA.
MS. JACOBS: Yeah, the drug czar.
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MR. EYRE: The drug czar.
MR. MCGINLEY: Drug czar.
MS. JACOBS: It's very interesting. It's very
Orwellian. The name of the legislation was "Ensuring
Patient Access and Effective Drug Enforcement Act".
That was the name of the legislation. It sounds really
great, so if you didn't read it, you would vote for it
thinking this is great for enforcement. But it basically—
the DEA, to take any kind of enforcement action, they
have to show a substantial likelihood of an immediate
threat. Immediate. So it's a higher bar than they ever
had. And they also cannot sanction any company unless
they allow them first to put in place a corrective action
plan.
MR. MCGINLEY: Which did not exist in the prior
legislative plan.
MS. JACOBS: Yeah. So it's a very different
enforcement regime than they had previously.
MR. MCGINLEY: A little bit of good news is the
congressman's nomination was withdrawn a few days
after the 60 Minutes show ran.
MS. JACOBS: Well, apparently, there's a lot of
outrage about it in the House and Senate, so I think
there's a move to repeal it. So, hopefully, that might
happen. I think there's a lot on the legal side, and
hopefully the next panel will talk about some of the legal
fallout from this, but I think there are over 250 public
lawsuits, you know, Cities, Counties, and State attorneys
general. I think every state either has a lawsuit pending
or they are investigating lawsuits against the opioid
industry, some faction of it. And they consolidated a lot
of those in this multi-district lawsuit in Ohio and— but
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the companies have tried to like get settlement
discussions going and to seal a lot of the data that's been
coming out of that. Interesting development I read about
yesterday, there's some lawsuits in Michigan on RICO,
which I think is a really great kind of cause of action, a
really creative theory. Hospitals have begun to sue,
which is another really interesting— looks like if the
cities can do it, we should be able to do it. Insurance
companies are probably next. And legislatively, I think
people have started— I don't know if it's happened in
West Virginia— they a resetting prescribing limits,
which I think should have been—
MR. EYRE: We have a bill pending that was just
approved by the Senate that's been turned over to the
House for seven-day. Do you guys have three-day or—
MS. JACOBS: I don't know what Tennessee is, if
we have one.
MR. EYRE: Some states have three-day, some
have five-day limits.
MS. JACOBS: And there are other— and just last
week I think, the OxyContin manufacturer, Purdue
Pharma, said they are not going to market to doctors
anymore. I'm not sure at this point that makes any
difference since they're firmly entrenched but . . .
MR. MCGINLEY: Marketing to doctors often
means paying doctors large amounts to give a talk at
some proceeding sometimes in Rome or Paris or resorts,
and it can be very lucrative for doctors and inroads to
doctors prescribing particular drugs. It's not only in the
opioid field but certainly makes a difference. Purdue
Pharma has one of the worst records in terms of they're
really marketing their opioids as not being addictive.
That was the first round. I mean, that's when the opioids
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really started to kick off, you know, doctors prescribing
them, manufacturers saying they are not addictive. Am I
right about that?
MR. EYRE: Yeah, absolutely right.
MS. JACOBS: They said it was something like
ibuprofen.
MR. EYRE: Our public health commissioner is one
of the champions at trying to reduce that the opioid
epidemic— he's really a good guy. He's like— he actually
came from Tennessee and he's like, you know, we just
were fed a bill of goods, and he's regressed and he's like I
was a big prescriber of OxyContin. When I talk about
these "pill mills", I mean, these were guys that had been
like disciplined in other states, that lost their license in
other states, and then show up in southern West
Virginia. These were bad, bad guys.
MR. MCGINLEY: Can I say just one thing about
that?
MR. EYRE: Yeah.
MR. MCGINLEY: The legal actions now that have
multiplied, I mean, they are looking for reliable legal
theory, might be RICO, might be common law, whatever,
but the thing that exists is intent and knowledge. You
can't look at those numbers and believe that this was a
legal operation. And the doctors made millions. The
pharmacies made millions. The distributors and the
manufacturers made billions. So, you know, there's the
intent, there's the knowledge. It's looking for creative
lawyers and law that would at least try to bring some
money back to the communities and try to figure out what
the solutions are. And I know you're going to be talking
about that on panels this afternoon. I mean, this is a long
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road. It's difficult. Money is important and it's just one of
the parts of the puzzle.
MS. JACOBS: So we don't have tons of time left
but do you have questions? Anybody have questions?
UNIDENTIFIED SPEAKER: I missed whether or
not you got that all unsealed or not.
MR. MCGINLEY: Yes.
MR. EYRE: Well, actually, companies that settled
previously were allowed to keep their numbers under
seal, who had settled previously with the State. But we
got most of the larger companies.
MR. MCGINLEY: The complaints in— the second
amended complaint is in the materials and it does say
redacted, that was almost wholly redacted, so we have
some of the ones that settled. The judge let them off the
hook. I think we could still get that through—
MR. EYRE: Miami-Luken was the one— probably
the one— the largest of the ones that were nonexempt.
But a lot of them are real small and didn't have large
distributions in the state. And I could see from the DEA
data that I had later which ones were, you know, larger.
We got Amerisource Bergen, we got Cardinal Health. The
McKesson case is a separate lawsuit that's still pending.
UNIDENTIFIED SPEAKER: Well, the same way
that the states sue tobacco companies, is that going on
yet?
MR. EYRE: Yeah. And one thing we haven't
talked about yet is that there's been some evidence, in
particular with McKesson and Miami-Luken, that there
were concerns brought to higher-ups, to executives, from
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regional managers, and things like that, that these
numbers were extraordinarily high. There was
something with the McKesson, there's a separate action
against McKesson by shareholders in Delaware and
there's allegations that there were actually concerns
brought by certain employees to the Board of Directors
and they didn't do anything, allegations.
MS. JACOBS: And, interestingly, one of the main
tobacco lawyers, Mike Moore, is involved in a lot of these
suits, the pharmaceutical suits, also on the plaintiff's
side. So they're getting that same coalition together to
work on these pharmaceutical cases.
MR. MCGINLEY: One of the problems with those
suits is if the plaintiffs are awarded compensation, will it
go to deal with the problem. That's one of the problems
with the tobacco suits and the lawyers— there's a lot of
good lawyers. Moore is, you know, he's effective but— and
they will make money. That’s what lawyers do. But will
the proceeds go to help solve the problem.
UNIDENTIFIED SPEAKER: I have some family
there, married into family that's from Boone County. So
I guess what I'm thinking is what now. There's all of this.
Obviously your work has exposed a lot of this. But what
is happening in West Virginia to try to help these people?
MR. EYRE: They did take the money from the
settlements and put it towards treatment beds but the
sad thing is—
UNIDENTIFIED SPEAKER: The trouble with
those towns, like when I go to visit my husband's
grandmother who is in Madison, you know, she's lived
there—
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MR. EYRE: That's where all this started, in
Madison.
UNIDENTIFIED SPEAKER: Yeah.
MR. EYRE: Everything started in Madison.
UNIDENTIFIED SPEAKER: Like I know where
Larry's is, you know, I've driven past there. There's no
one hardly left in the town, I mean, they've either moved
away, died.
MR. MCGINLEY: One of the problems is that, you
know, people who are disempowered who have lost their
jobs in the coal industry, you know, they've lived in the
area, their family has been there for generations, what do
you do. And, you know, coalminers that were injured,
they take painkillers, and it just steamrolls. And an
economy that is already going down is plagued by this
epidemic. And it's an enormous problem. I would say— I
mean, there are certainly well-meaning people
throughout West Virginia who are trying to come up with
solutions, but there's a lot of talk too and there are people
who are trying to make a profit off of the solutions.
UNIDENTIFIED SPEAKER: And not enough
money, right—
MR. MCGINLEY: Right.
UNIDENTIFIED SPEAKER: —to actually help
all the people that actually have problems?
MR. MCGINLEY: Right.
UNIDENTIFIED SPEAKER: So unless it's on a
national level—
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MR. EYRE: And the problem is it keeps shifting,
you know, it went to heroin, and then it went to Fentanyl.
And now— I was just a week-and-a-half ago in Madison
talking to Judge Thompson— you probably knew Judge
Thompson— he said now I'm seeing all this crystal meth
and cocaine overdoses. So it keeps shifting when you—
UNIDENTIFIED SPEAKER: What about the
pharmacists and the doctors, any disciplinary action,
anything happening to the people who—
MR. MCGINLEY: A little.
MR. EYRE: The pain clinic, they— but that was
like three years too late— but they finally indicted 12
doctors that were affiliated with The Hope Clinic for
something that occurred back in 2012 to 2015.
UNIDENTIFIED SPEAKER: I'm from Tyler
County. I did my undergraduate at WVU. I just recently
last summer spent the summer working with the drug
court of the Circuit of Marshall, Tyler, and Wetzel, so I've
seen first-hand the experience of the issue. Just kind of
piggybacking off of her question, it seems like the
Suboxone is becoming a replacement for the addiction. I
just wondered if you had looked into or, you know, this
could speak to that issue that we are replacing a drug
dependency with another prescription that has a high
risk of dependency.
MR. EYRE: Well, the Boone County judge has his
drug court too and he is very upset because he's directed
to do the treatment with Suboxone and they are diverting
the Suboxone. Another problem that's cropped up is
many of these "pill mill" doctors that lost their licenses
and went to jail, they are out of jail now and now they are
opening up Suboxone clinics next to legitimate, you know,
the more corporate Suboxone clinics. They're opening up
[313]
53

TENNESSEE JOURNAL OF LAW AND POLICY
VOLUME 13 | SUMMER 2018 | SPECIAL EDITION

and they are not doing any counseling, they're not doing
anything but just handing out the sublingual things that
they take.
MR. MCGINLEY: That's a really important
question. I know that there is some discussion in the
panels this afternoon. I know Suzanne Weise is here and
she's going to talk about it from her experience with the
Child & Family Law Clinic at WVU. I want to give
Suzanne the shoutout too because she was co-counsel in
the FOIA cases and in our intervention in the "pill mill"
cases. But I think that's going to come up in discussion
this afternoon.
MS. JACOBS: That's another interesting legal
consequence though. Suboxone's maker is a British
company, Reckitt Benckiser, and they actually are being
sued by 35 U.S. states for artificially inflating their prices
and for fraudulently trying to delay their patent
expiration so to prevent generics coming in. So the kind
of collateral consequences, again, you know, they are
making all this money off of the crisis and now you have
to address their bad actions because they've got a product
that everybody suddenly needs, so . . .
MR. EYRE: Yeah. The drug money that they
distributed, they did some new grants for treatment,
Suboxone people have a very strong lobby down at the
Legislature, so all faith-based, peer-to-peer type
programs were excluded from funding because they got it
written in that you had to do medication-assisted
treatment in order to qualify for funding into the grants.
You've probably seen that with the drug courts; right?
UNIDENTIFIED SPEAKER: Yeah.
MS. JACOBS: One more. I think we have time for
one more.
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UNIDENTIFIED SPEAKER: Tell us what it's like
the afternoon you get a telephone call and they tell you
you've won the Pulitzer Prize.
MR. EYRE: I was in shock for about three months.
Yeah. We're— unlike the— we're just a little-bitty paper,
30-some thousand in Charleston, West Virginia. I had
always thought when you got the Pulitzer Prize that it
was— if you've ever seen the photos in the New York
Times and Washington Post, they're standing there with
champagne bottles like they get tipped off. And then I
realized later, they didn't really get tipped off but they
just win one every year. Yeah, it was a bit crazy and . . .
I don't know. The sad end of this, and I don't want to end
on a sad note, but the numbers have continued to climb
of the overdose deaths, as yours has as well. I think yours
went up by I think 12 or 15 percent, again, because it's a
moving target. But we at least have good people on the
ground that are trying to work on it.
MS. JACOBS: Thank you for the work you've
done, and Suzanne. Thank you, guys.
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THE OPIOID EPIDEMIC
REGULATION, RESPONSIBILITY, AND REMEDIES
Tricia Herzfeld
Gerald Stranch
Zack Buck
MR. GROVES: My name is Alan Groves. I served
as the Editor in Chief of the Tennessee Journal of Law
and Policy from February 2017 until just a few weeks
ago. My successor Editor in Chief will be moderating our
second panel this afternoon. Our first panel discussion
today is going to focus on some of the questions you all
were asking at the end of the last session about
regulation, responsibilities and remedies. So, our first
two panelists to my immediate right come from the firm
of Branstetter, Stranch and Jennings located in
Nashville, Tennessee. In the past year, their firm has
filed three different lawsuits in Tennessee against
several opioid manufacturers. Tricia Herzfeld is a 2001
graduate of George Washington University Law School
and is now a partner at Branstetter, Stranch and
Jennings. Ms. Herzfeld has previously served as Legal
Director of the American Civil Liberties Union of
Tennessee where she successfully litigated dozens of
high-profile civil rights cases in state and federal courts.
She has also served as a public defender in Miami where
she conducted over 80criminal trials. In 2012, she was
selected as one of the nation’s Super Lawyers, and among
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those with that honor, she attained Rising Star status in
2013.
Her colleague, Gerald Stranch, received his law
degree from Vanderbilt University. He is now the
managing member of Branstetter, Stranch and Jennings
and chairs the firm’s complex litigation team. He
oversees the firm’s securities, class actions, antitrust,
shareholder derivative, mass tort and consumer class
cases. Mr. Stranch also served as an adjunct professor at
Vanderbilt University School of Law. He was named the
top 40 under 40 from the National Trial Lawyers
Association and was named the Mid-South Rising Star by
Super Lawyers.
And finally, Professor Zack Buck at the end of the
table, teaches a variety of health law classes at the
University of Tennessee College of Law, including a
bioethics and public health seminar, torts, health care
finance and organization, health care regulation and
quality, and health care fraud and abuse. His scholarship
examines governmental enforcement of laws affecting
health and health care in the United States. Before
joining UT, Professor Buck taught at Mercer University
School of Law, Seton Hall University School of Law and
the University Pennsylvania School of Law. He also
practiced complex commercial litigation at Sidley Austin
in Chicago.
So, with this distinguished panel now introduced,
let’s just jump right into our first question, and we are
going to start off where the last panel ended talking about
remedies and particularly the search for a cause of action
in some of these lawsuits that have been filed.
So, Ms. Herzfeld, I’ll throw this first question to
you. Can you talk to us a little bit about the suits that
your firm has filed and particularly why you chose to
bring those causes of action that you did, the statutory
and the common law public nuisance claims and then
also a cause of action under Tennessee’s Drug Dealer
Liability Act.
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MS. HERZFELD: Sure. Thanks very much for
having us. We appreciate the opportunity to talk about
our lawsuits. Lawyers always like to talk about their
lawsuits, so we can answer any questions you all have,
and we happily do so. Our lawsuit that we brought− we
have actually brought three different lawsuits
throughout Tennessee. They have been filed in the
Tennessee state courts. So that means our lawsuits are a
little bit different than the vast majority of them across
the country. Those have been filed primarily in federal
court or have been moved to federal court. So, we made a
very, very rational, I think, and determined decision that
we wanted to keep our cases in state court, and there
were some reasons for that. We don’t think that a federal
judge, with all due respect to the federal judiciary in
Cleveland, Tennessee, where the multi−district litigation
is, is going to have the same understanding of the real
day-to-day impact of the opioid crisis. So, we really made
a point to file our cases in Tennessee.
So, the first case that we filed is in Sullivan
County, Tennessee, so up in the very, very top corner in
the Appalachian region where it is really ground zero to
the opioid epidemic here in Tennessee. They have the
number one statistics for births of children that are born
dependent on opioids, and so those children are classified
as having neonatal abstinence syndrome, and that was
the primary reason that we decided to file that first case
there. Our cases are a little bit different than many of the
others, because ours has primarily been filed by District
Attorney Generals, and I think you are going to hear from
one of our clients a little bit later today. We did that
because we have a somewhat unique− I say unique, sort
of− statute in Tennessee called the Drug Dealer Liability
Act. Now, the Drug Dealer Liability Act initially was put
together by an organization called ALEC. Has anybody
heard of ALEC? American Legislative and Exchange
Council.
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So, they put together somewhat conservative
proposed legislation and kind of pushed that legislation
out throughout the country. I think it was 23 states ended
up passing various versions of the Drug Dealer Liability
Act back in the day, and Tennessee was one of them.
Now, initially the Drug Dealer Liability Act was
supposed to− I think the thought process at that point
was, there was a crack cocaine epidemic, and the idea was
to be able to go after the higher−level drug dealer chain,
not just the person you’re buying from or the person at
the drug house, but kind of going up until you get to the
suppliers and the producers, further and further. So, we
took that law and decided, well, it kind of seems like the
same thing for opioids; right? You have the street-level
dealers. You have the people that they are getting them
from. You have the pill mill doctors who are supplying
them, which is often without a legitimate prescription;
that’s mostly how that happens. They get them from
various pharmacies, who get them from distributors, who
ultimately get them from producers. And why is that any
different than a drug cartel? So that’s why we decided to
file under the Drug Dealer Liability Act, because,
truthfully, we think the opioid epidemic and the way that
it’s impacted Tennesseans and most of the state, it really
is illegal drug activity; right? That’s really what we’re
talking about. It may have the veneer of being legal,
because there are legal uses for opioids, but the legal uses
of opioids are not what is causing this epidemic and
causing so many people to die. It’s the illegal uses.
So, we’re really trying to tackle it from that way.
Now, the Drug Dealer Liability Act has a lot of benefits
to it. One of them that we really like is, there’s not that
level of causation. So, the principles of this law are more
actually rooted in antitrust, so it’s market participation.
So, all we have to prove− all we have to prove− is that
someone or a corporation knowingly participated in the
illegal drug market, and as you have heard earlier, with
those numbers, how could you not have known; right? I
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mean, the diversion is clear, the news stories are clear;
we simply have to prove that they knowingly participated
in this illegal drug market. Now, a lot of other causes of
action shave been filed, a bunch of other different
lawsuits across the country. They are more of a
traditional negligent standard, where you would have to
prove in this context that this individual got this pill from
this person, there was a duty, there was a breach, and
you’re going to have to work your way all the up pill by
pill all the way through. That’s not required under the
Drug Dealer Liability Act. So that’s why we chose that
cause of action. The other one that we filed is, we filed
under common law and statutory nuisance, and you will
see nuisance showing up in a lot of the lawsuits
throughout the country. Specifically, for us, our District
Attorneys typically file nuisance lawsuits. They are the
ones who file those. They shut down houses of
prostitution. They shut down crack houses. They do this
stuff all the time. So, it meshed very well with an
additional cause that is typically within their purview
infighting crime. So, the purpose of our lawsuit is to focus
less kind of on consumer protection, more to really focus
on the fact that these drugs are now being used illegally
and everybody knows it.
MR. GROVES: Mr. Stranch, I’ll throw the next
question to you. Ms. Herzfeld just talked about the state
law claims that your firm has brought, the Tennessee
Drug Dealer Liability Act and then the common law and
statutory public nuisance claims. Some attorneys for the
opioid manufacturers have argued that federal
regulations actually preempt any state law claims. So,
what is your response to that argument?
MR. STRANCH: Those defense lawyers are
saying anything and everything they can to try to shut
this litigation down. They are absolutely shameless. They
are even attacking whether cities and counties have the
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authority to bring the lawsuit or to hire outside counsel
to do it. Their entire strategy right now is delay, delay,
delay as long as possible. I don’t think the federal
regulations preempt anything in our litigation in
particular, because we have specific state statutory
claims that don’t talk, reference or have anything to do
with federal regulations. One thing that’s clear is, this is
not a complete preemption area like an ERISA where any
claim at all would be preempted− field preemption is
what it’s called. They have not really raised federal
preemption in our case in the motion to dismiss that we
already argued. They did throw in the rest of the kitchen
sink, though. Some of the other cases that are out there
might have more of a federal preemption issue,
particularly with the distributors; the McKessons, the
Cardinals, the AmerisourceBergens, those entities,
because those claims are often based on− you have this
federal duty that you have to report when certain key
things occur, you didn’t report, so now I’ve got a cause of
action against you, and so you might run into some
preemption issues on that. We have chosen not to file the
distributor cases yet until we can get the discovery so we
can point to exactly what they knew and when they knew
it so that we can plead around and avoid any possible
problems with preemption. But, again, it’s not really as
much of an issue for our case, because we are not trying
to prove you knew about this through federal regulation.
We are saying, hey, look, you not only participated in the
illegal drug market because you continued to ship pills to
known diversion sources. So, it’s completely outside of
that realm. And so, we’re a little bit different in what we
do. But, yes, they are raising any and all defenses that
they can to delay this as long as possible.
MR. GROVES: Thank you. Ms. Herzfeld, you
mentioned the remedies that are available for some of
these causes of action. Can you talk about what kind of
damages that you are hoping to obtain for the clients that
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you represent, and are there any procedural or legal
obstacles that you face in obtaining those damages?
MS. HERZFELD: So, we are hoping to obtain
really big damages for our clients, huge, huge, and there’s
a lot of reasons for that, not because anybody is trying to
get rich; right? When you look at these towns and you
look at− Sullivan County, Tennessee, is a great example.
I think someone in the audience said earlier that the
towns are emptier. They are full of people that can’t get
jobs, because nobody can pass a drug test, and that’s
nobody’s fault; right? I mean, it’s not because you decided
that you were going to become a drug addict and that’s
how you wanted your world to end up. Nobody intends to
become a drug addict. But you did have a workplace
injury because you worked in the coal mines or you
worked wherever it is, and your doctor gave you these
drugs. Nobody intends to get addicted. Nobody intends to
become a drug addict. And the consequences of that are
just devastating, especially in a small town. We know
that there are employers that have jobs they can’t fill
because they cannot find sufficient people to pass a drug
test. So, our case not only includes damages for the town,
which I’ll talk about more specifically in a minute, but
also claims for babies. So I think our case is the only
casein the country, at least the last time I checked, where
we have included claims on behalf of particular infants,
and these are individual children whose identities are
sealed; I know who they are, but their identities are
sealed, and they were babies that were born dependent
on these drugs, so their birth mothers took the drugs
during pregnancy and at some point gave birth to these
children who suffered enormously.
So, I would like to talk about their damages first.
What we know about the children that are born with
neonatal abstinence syndrome is actually, pardon the
pun, in its infancy. It’s not something that has been
studied for an extraordinary amount of time, but this
[323]
63

TENNESSEE JOURNAL OF LAW AND POLICY
VOLUME 13 | SUMMER 2018 | SPECIAL EDITION

phenomenon, neonatal abstinence syndrome and opioids,
hasn’t been around that long. Here’s what we know:
When these babies are born, they shake, they cry
uncontrollably, you cannot sooth them. That is the one
thing you will hear everyone say. They scream and
scream and scream to the point where their volunteers
whose only job is to cuddle the babies. They just walk and
cuddle and rock and walk and cuddle and rock. And why
is it? Because the children have had a constant supply of
these highly-addictive medications in utero, and once
they are born, it’s discontinued. Do you know how they
treat those babies? Morphine. They have to give those
babies morphine. In the first days of their life, they are
given a bit and then they wean them down and they wean
them down and they wean them down, and so they end
up in the neonatal intensive unit and they are being
given controlled doses of morphine to wean them down.
So that’s the first few weeks, which is crying and shaking
and rocking and horrible. But then what comes next? You
have a lifetime of learning disabilities: oppositional
defiant issues, inability to concentrate, emotional
outbursts that they don’t understand why that is
happening; the parents, the grandparents, foster
parents, no one understands why this child is just not
behaving in a way that makes sense, and what we’re
finding, through the studies, is that most of that can be
taken back to this exposure in utero. Babies are
developing; there’s stuff that happens there. So, we are
trying desperately to get damages for those babies. We
know that they will have a lifetime of medical needs, a
lifetime of special needs. They need early intervention.
The educational costs, imagine the educational costs of
taking a child with needs. We don’t quite understand
through essentially 20 years. We don’t know what that is
going to look like. And Tennessee has the highest number
of babies born with neonatal abstinence syndrome due to
opioid addiction.
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MR. STRANCH: It’s a baby born every other day
dependent on opioids.
MS. HERZFELD: It’s so bad that the Children’s
Hospital up there had to open up its own wing, its own
wing with its own beds just for these babies. So, I don’t
want to lose sight of that. Of course, we’re filing through
District Attorneys who are seeking truth and justice and
going to get the bad guys and drug dealers out of their
districts; right, and that’s true and important and
amazing, but also, it’s the babies; right? It’s the people
who are raising the babies. It’s the families that are
broken and destroyed by the fact that now the
grandmother or the auntie or the cousin that’s raising
these babies. And when you take that, and you multiply
that not just from a one-family perspective, but from an
entire community, the devastation is extraordinary. So
what kind of damages are you hoping to get? Well, let’s
see, prosecutors have to spend more time prosecuting,
cops have to spend more time arresting, more Narcan,
more ambulance costs, more emergency room costs, more
overdose costs, more educational costs. Court system
costs go up; right? Everything exponentially goes up.
Those resources might have been used for other things,
positive things, but instead they are all being diverted to
deal with this completely overwhelming crisis.
So, what are the damages? Good question. They
are enormous. The other thing we have asked for, in
addition to damages to fix all the stuff that’s happened in
the past, is, we have asked for injunctive relief going
forward, and that sounds crazy; right? How do you get
injunctive relief on a pill epidemic, an illegal pill
epidemic? But that’s what we want. We want the drug
manufacturers to stop. That’s just the answer, stop, stop
doing it. You know what you are doing, you know what
the harms are, stop putting profits over people, stop. And
if that means that they have to pay for remediation in
order to make these things happen, in order to not only
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make the communities whole for the past damages, but
to pay for rehab beds, education, different drug courts,
these types of things going forward to kind of help fix that
damage, special ed students, all these things, they all
need to pay that going forward. So, the damages are
huge, and I think it will probably be a bit challenging to
figure out exactly how big, because there’s a lot of zeros
there.
MR. STRANCH: One of the things you need to
know about that, like in Hawkins County, the sheriff did
an analysis at the jail. Eighty-eight percent of the jail
population, which was full, was there because of pills,
either DUI while high on pills, stealing to buy pills,
domestic violence while high on pills. It’s all pills. It’s 88
percent of the jail in Hawkins County. And so, we really
can’t emphasize enough how bad this is in the
communities. It’s easy when you’re in a city like
Knoxville to miss exactly what’s going on in some of these
smaller communities.
MS. HERZFELD: We missed it. We didn’t know;
right, until we knew? I mean, we didn’t know until we
knew. It’s devastating.
MR. GROVES: Professor Buck, we have heard a
little bit about the suits against these drug
manufacturers. Just from a broader public health
perspective, what are the similarities in this type of
litigation against the drug manufacturers to the
litigation that occurred against Big Tobacco in the 1990s,
and are there any differences?
MR. BUCK: Sure. So, focused on manufacturers
for a minute and talking federal regulations. I think
there’s one kind of major similarity, and that is, in many
of these claims that are the federal claims, there is a core
to them that focuses on some kind of fraudulent
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advertising. So the drug companies are actually
advertising these drugs either direct to consumer or in
doctors’ offices in some way that can be alleged to be
fraudulent, and in that way we have a similarity with Big
Tobacco in the 1990s. You know, they’re burying bad
science, they’re minimizing poor results from clinical
trials, and they may be actually misbranding these drugs
through their misleading advertising. But beyond that,
there are a lot of differences, and in particular there are
three that I was able to kind of come up with in thinking.
First, opioids have a lot of regulation around them to
begin with. They actually are FDA approved to treat
chronic pain, and we have been talking a lot about misuse
of opioids and illegal use of opioids, but I think it’s
important to also recognize that through the last
generation of health law and policy, there’s been a lot of
discussions about how chronic pain in this country is
undertreated and how individuals have a stigma
attached to them who are facing chronic pain, as well as
the individuals who prescribe those drugs, and that’s
complicating the regulation of these drugs in a way that
never complicated the regulation of tobacco. Tobacco was
not subject to FDA approval until 2009 in this country.
Drugs that are sold in this country are approved by the
FDA, and so we have a regulatory structure in place from
the federal perspective that is different than tobacco in
that regard. The second I guess you could say a way that
these are very different is that these drugs are subject to
a number of antifraud tools at the federal level when
we’re talking about manufacturers. So, the most potent,
you can talk about the False Claims Act.
The federal government is able to go after
manufacturers who misbrand their drugs, who advertise
their drugs to doctors in ways that are untrue, because
the federal government pays for these drugs through
Medicare and Medicaid, and these programs allow the
federal government to empower the Department of
Justice to go after manufacturing companies who make
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untrue statements in their advertisement. The problem,
of course, with this way or this pathway is that there’s
often a desire to settle these cases, particularly of course
from the drug companies’ perspective, but also from the
Department of Justice. There’s been a reliance on
Corporate Integrity Agreements over the last couple of
years that are put in place to try to govern drug
companies’ behaviors going forward and check in every
quarter on pricing or advertising. And I think the biggest
challenge here is that misbranding is really profitable for
these manufacturing companies. So if you’re a
manufacturing company and you have gotten your drug
approved for a narrow segment of the population, but you
can go into a doctor’s office and allegedly talk about an
off−label use that the FDA has not approved your drug
for, which is the case in the Purdue case around
Oxycontin, they were minimizing the addictive effects of
the drugs to the doctors; that’s the allegation. There’s a
huge market out there for which you do not have to go
through the FDA to seek approval. You can get doctors to
prescribe your drug off label, and often doctors will do so.
It’s a very profitable thing, if you are a private company
and you owe a duty to your shareholders to maximize
profits and you see that you can open up the market by
eight, nine, ten billion dollars and the statutory penalties
might only amount to a two or three-billion-dollar
settlement, that’s a calculation that many drug
manufacturing companies make. And so, I guess the
thing that I would say about this is that our enforcement
and regulatory system here is not potent enough and that
we settle too much with drug companies in this respect.
Of course, there’s also a challenge that if you take
a drug company to trial for one of these cases, what faces
them, in the event of a bad verdict from their perspective,
is exclusion from Medicare or Medicaid, and that means
they can’t basically do any business with anybody related
to the American healthcare system, to which they make
the argument to the Department of Justice this is
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something that will hurt a lot of people. Like the Pfizers
of the world going to court and saying we do a lot of good,
so you can’t exclude us because think about all the
patient harm that will come. And I know I’m blowing that
out of the perspective there, but that’s the heart of the
argument from the pharmaceutical company. The final
thing, the third I think big difference is going back to a
point that I had made earlier, which is a lot of these
drugs− and this is what makes this problem so
complicated and much more complicated than the tobacco
problem− is that, again, these drugs, some of them are
indicated, some of them are legitimate. We can’t
categorize them all in one way or the other. And we built
the system, at least in this country, around prescription
drugs that values professional autonomy, and it
complicates the regulation of prescription. We trust our
doctors and we give them a lot of authority and discretion
to make determinations about our drugs. And so, the best
way I think we can try to go about this problem is to go
after the manufacturers using the tools I mentioned. I
think those are the things that complicate the analysis
when we’re comparing it to tobacco.
MR. GROVES: Mr. Stranch, Professor Buck just
talked a little bit about the federal government’s
involvement from a regulatory perspective, but let’s talk
about what the Justice Department has done just in the
past year. In August of 2017, the Justice Department
announced the formation of the Opioid Fraud and Abuse
Detection Unit, which will temporarily provide financial
resources to 12 of the 94 U.S. Attorney’s Offices for the
purposes of prosecuting health care fraud and abuse, and
the Eastern District of Tennessee U.S. Attorney’s Office
was selected to participate. So how significant of a
development is this in your mind, and in general what
should the role of the federal government be in
combatting this crisis?
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MR. STRANCH: I mean, they’re putting drapes on
a burning house. You’re not going to arrest your way out
of this problem. It’s way too big. The time to do that was
25 years ago. And the federal government, there’s been a
complete failure of the regulatory system to do anything
about this, both at the state and at the federal level. I can
tell you, from representing District Attorney Generals,
that they are absolutely underwater with pill problems. I
mean, it’s the number one thing they deal with. We have
even got one DA that we’ve talked with who says, look, if
I dig hard enough on any case that comes into my office,
there’s going to be pills in there somewhere, I’ve just got
to dig deep enough to find it, and I take a little slightly
view, I say maybe in 99 percent of the cases, but he’s
adamant it’s a hundred percent. That’s how bad the
problem is. So, some funding to help find opioid fraud and
abuse and maybe shutdown a pill mill here or there, it
will be nice, it will help, but it’s− I mean, you’re standing
at a breaking dam and you’re sticking your finger in a
crack. It’s going to take the full weight of the federal
government, the state government, the court system
through private litigation and the legislature in changing
laws if we’re actually going to try to get ahead of this
problem, because right now we have not even hit the crest
of the tidal wave. It is still coming. It is still getting
worse. Every year there’s more babies born dependent on
opioids. Every year there is a rise in the number of deaths
due to overdoses. And even in places where we have seen
the overdose deaths start to level out, what we are seeing
is a number of overdoses have continued to rise anyway,
and what it is a reflection of is, now they have Narcan in
the cop cars, now they have Narcan in the ambulances,
so they can deploy immediately when something
happens.
We have got districts that we’re working with
where they’re putting it in schools because kids are
overdosing at school on opioids. So, a couple of million
bucks from the Department of Justice to put five or six
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people looking at pill mills is not going to change
anything. I mean, it’s a window dressing so that someone
can stand up and say, look, we’re doing something, but
they are not really doing anything at all. I will speak
briefly about Purdue for a second. They pled guilty to
misbranding back in 2006, and they admitted to what I
call the Holy Trinity of Lies. They said we told people that
if you have true chronic pain, you will not become
addicted to our pills. We told doctors and people if you
have true chronic pain, you won’t develop a tolerance to
our pills. And we told people if you have true chronic pain,
you won’t go through withdrawal when the pills are
taken away. They admitted in their criminal guilty plea
that those statements were all false and they knew they
were false at the time they made them, and these are
statements that they were training their people to go out
and detail doctors and tell them this over and over and
over again, and it went on for over a decade before the
federal government got involved on it. And during that
time, Oxycontin use went from a mid-eight figure drug to
a billion dollar drug every single year and created an
entire generation of doctors that believe these scientific
facts that are not facts that are in fact false, and it
created an entire generation of addicts, and despite that
guilty plea, despite paying $600 million that they paid as
part of that and agreeing that they’re not going to do that
and submitting to all these monitoring programs with
states and the federal government where they’re
supposed to submit, here’s the list of doctors that are
prescribing our pills at certain levels, there’s been no
enforcement action on that at all, and they have
continued to do the exact same thing. At the time we filed
our first complaint, they were still pushing OxyContin for
use in chronic pain, for people that have a history of
substance abuse and saying they probably would not get
addicted or less likely to get addicted. This is on web sites
that they run that they host with their name on them
that are designed for doctors to answer their questions
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about the drugs. The regulatory world failed, and they
have done nothing about it. And having a couple more
people in the U.S. Attorney’s Office who are focused on
pill detection and finding street−level drug dealers, it’s
going to do nothing.
MR. GROVES: In the second half of the discussion
I want to talk about some legislative policy proposals that
are percolating in the Tennessee General Assembly, but
before we get to that, Professor Buck, I’m going to throw
the ethics question at you. Rule 1.6(c)(1) of the Tennessee
Rules of Professional Conduct requires lawyers to review
information relating to the representation of a client to
the extent the lawyer reasonably believes disclosure is
necessary to prevent reasonably certain deaths or
substantial bodily harm. So, what are the implications of
this rule for attorneys that are representing the
pharmaceutical companies?
MR. BUCK: Well, I think that the reasonably
certain deaths or substantial body harm in 1.6(c)(1)
probably is not as applicable as you might think when
you take a look at it, because the individual that 1.6
contemplates is identifiable, and it’s hard to make that
causal link if you’re representing a pharmaceutical
company. I think that the ethical question that is perhaps
more interesting is, what if you find yourself
representing a pharmaceutical company that wants to
engage in some kind of activity that you think is
fraudulent. This happens a lot in the health care world
when I talk to people who practice, and it’s one of the
things that keeps them up at night. If our client
determines that they have gotten overpaid by Medicare
or if they find that some of their scientific statements
aren’t defensible, what is my role as the attorney?
Tennessee’s rules are permissive in that instance,
so you, as the attorney, have the ability to disclose, it’s
not required, but it is available to you if you think that
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you need to in order to prevent an ongoing crime or fraud.
And withdrawal also is permissible, and so in the event
that you might find yourself advising a client that’s
unwilling to reconsider a course of action, the withdrawal
would be permissive. There are cases in which
withdrawal is required, and that is when you know that
your client is using your services to perpetrate a crime,
so the line between those two standards is pretty blurry,
but usually there’s a lot of discretion given to the attorney
to decide what he or she needs to do in that instance, but
it is not an easy place to be in, and it happens I think
fairly regularly, so it’s worth thinking about when you’re
talking about the topic.
MR. GROVES: Now we will make that transition
and we’re going to talk more about legislative policy
proposals. As many of you might know, Governor Haslam
recently announced his Tennessee Together Plan, which
proposes a host of legislative and regulatory efforts to
fight this epidemic, and the plan emphasizes three
different strategies: prevention, treatment and law
enforcement. So, I want to spend the rest of our time
talking about this, and then at about 2:00, 2:05 we will
open it up to audience questions; you can be writing those
down. So, Ms. Herzfeld, some lawmakers in the General
Assembly have suggested that one way to prevent future
opioid addiction is to limit the supply and dosage of opioid
prescription such as what was mentioned earlier,
limiting new patients to a five−day supply. Others are
calling for prevention education in public schools. What
is your reaction to some of these preventative policy
proposals?
MS. HERZFELD: I think they are all really good
ideas, and they are very, very well intentioned, but I
think as Gerald has made it clear, we are really just kind
of nipping around the edges at this point. Legislation
alone isn’t going to fix the problem. I like the
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three−or−five−day limit on the ability to get those pills.
That is something that we have noticed is a really big
deal. The stuff that we have reviewed, I mean, just the
sheer number of pills that are given to folks, it’s crazy. I
mean, it’s a crazy amount, when you’re getting a
30−daysupply and five pills a day and four refills and
doctors don’t even worry about it; sure, you want another
refill, no problem. I had my tonsils out a couple years ago
and they had given me hydrocodone, I think, and of
course I had taken it for two days. I had my tonsils out;
right, in my 30s, and it was painful, but after the second
day, I was like my God, get me off of this stuff, like please.
When I went for my follow−up a week after, the
doctor is like do you want more hydrocodone? And I’m
like oh, my God, no. They just hand it out to you so easily.
And, again, I don’t think they mean anything by it. I
think they’re trying to be helpful, at least in some
circumstances. So, limiting that and limiting who can
prescribe I think is really another important thing. You
have a lot of nurse practitioners− and this is not to get
down on nurse practitioners− but you have a lot of nurse
practitioners who don’t have sufficient supervision who
are running things kind of on their own and you are
seeing an extraordinary number of these pills getting into
the system that aren’t necessary, they are not medically
necessary, it’s too much, it’s overkill, and a lot of that is
coming through nurse practitioners. So, there’s a lot of
things. There needs to be accountability; what is the
enforcement mechanism if somebody is violating. There
needs to be monitoring. There needs to be limitations on
all that. I don’t think it can just kind of be one thing and
here’s a little bit of education and we’re going to take the
pills and make it for five days. It has to be a more
omnibus kind of gigantic regulatory scheme to even begin
to make a dent.
MR. GROVES: Mr. Stranch, I was going to ask
you if you thought $25 million was enough to fund
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treatment and recovery services, but I think I know your
answer to that.
MR. STRANCH: Twenty-five million bucks won’t
even run a quality facility in one area of the state for a
year. Again, window dressing is all it is. What you need
to know about addiction when you’re dealing with opioids
such as this, you actually have multiple levels of addition
you have to break. You have to break the chemical
dependency. For many people in Tennessee, that is
actually broken while they are in jail, because they lose
the opioids, they go through withdrawal in jail.
Oftentimes they receive little to no medical care or
therapy as part of that process. They just literally detox,
go through the shakes, horrible diarrhea, headaches,
nausea, throwing up in the jailcell. That’s how it
normally goes. Once you break the chemical dependency,
you still have a behavioral dependency that has to be
broken as well, and your brain won’t go back to the way
it was before you started taking opioids for 12 to 18
months after you have broken the chemical dependency,
and so that’s why you have so many people that relapse
in that first year, because their brain is still not back to
normal and they’re feeling depressed, the hormones and
things inside your brain and the way it works and the
receptors are not working right again. They’re still not
back to normal, so it’s easy to slide back to the addiction,
because that feels good at that point. And so, if you really
wanted to do this correctly, I mean, you can look at
programs like the Tennessee Medical Association; they
have an assistance program for doctors that become
addicted.
It’s a multi-year program once you enter it, and
you lose your medical license if you don’t complete it.
They have an 85-percent cure rate, but it’s a multi−year
program. You have to go inpatient depending on the level
of your addiction. You have regular meetings with people.
You have regular drug tests. You have therapy on a
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regular basis, not like 12−step−type stuff, but like sit
down and talk about what’s going on in your life, what
are your triggers, help to identify your triggers so you can
deal with them, and $25 million is not going to let you do
that for a couple hundred thousand Tennesseans that are
currently addicted right now. Twenty-five million is not
going to let you do it for 400 or 500 Tennesseans in one
small area, and it’s certainly not going to provide the
aftercare once you break those addictions and you’re
trying to re-enter society as− as my father would always
say for me, I just want you to be a taxpayer− try to
become a taxpayer again. There’s no support services for
that. Twenty-five million dollars is nothing.
MR. GROVES: Professor Buck, part of the
Tennessee Together Plan also involves law enforcement,
and so the question that I have is, how do we enforce
criminal laws that are already on the books with respect
to users and distributors while also not re−enforcing the
negative stigma that is associated with addiction or
prescribing?
MR. BUCK: I think it’s a very hard question to
answer, so I’m just going to take up a couple minutes and
then we can go to the audience. But going back on what
was previously said, I mean, we don’t think about this as
a holistic problem, you think about physicians or dentists
prescribing these drugs and you ask yourself, well, why
would they? Well, first of all, they are seeking to treat
some symptom that you might have, but also, they are
incentivized to do that. We pay them to prescribe in this
country. Medicare pays more for drugs that are more
expensive to those doctors. They get a higher cut of the
cost. And so, until we actually look at our own laws that
actually create some of this problem in the first place and
reverse them, we’re not really going to make any dent in
the problem. In talking about the criminal aspect, I
mean, these issues that are so interesting find
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themselves on the line between public health and
criminal law, and I think part of the challenge is to
adequately calibrate the response.
Is it a public health problem or is it a criminal law
problem? I’m somebody who approaches these issues
from kind of a health policy perspective, and so I’m much
more likely to treat them at least on the addict side as a
public health problem. It reminds me of the case where
the students, common law students in here or others who
recently graduated, Ferguson versus the City of
Charleston that you might do in common law. It becomes
a Fourth Amendment case, but in that case the issue is a
hospital is testing the blood of pregnant women who
comes to the hospital against their consent, and then for
women who test positive, they are given the option of
either entering a drug counseling program or going to
jail. Now, if you think about that and apply a public
health lens, that’s a terrible program, because not only
does it penalize people who might need medical
assistance, but it deters people who need prenatal care
from coming to the hospital in the first place. So, the first
thing I would say to the governor is, do no harm, don’t
have a system in place that deters people from seeking
help that they need. And so, in that perspective, a public
health perspective, would say let’s put more money on
drug rehabilitation centers, let’s expand Medicaid in this
state, let’s provide care for people who need it who don’t
have access to these services, but I don’t think that’s the
total answer. I think the other part of it is, you have got
to calibrate the penalties for those that have the ability
to change their behavior, and that’s the manufacturers,
it’s the drug companies, it’s the distributors, and maybe
it’s the doctors; maybe we need to change the way we pay
physicians in this country, and also think about what we
can do to the regulatory mechanism. Is it really doing
enough to deter the pharmaceutical companies in this
country to think twice about advertising their drug in a
way that they can alleged to be fraudulent, even if it’s the
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case that they stand to make a lot more money if they do
so. So, I think we need to think about it from more of a
holistic perspective. I think you have to be really careful
that you don’t harm providing care for people who need it
by leaning too far toward criminality for those who are
struggling from addiction.
MR. GROVES: We will open it up to questions
now. I believe we have a couple of microphones that are
going to be walking around, so if you will just raise your
hand and I’ll call on you. I think right here in the front.
UNIDENTIFIED SPEAKER: Thank you. As an
attorney, if I’m working with the DPR and I’m being
accused of knowingly lying three times with regard to
relevant facts, even if I’m cooperating and remorseful, I’m
going to lose my license for some period of time at least,
and why do the manufacturers not lose their license for
some period of time at least when they knowingly mislead
and fraudulently tell things like that?
MR. STRANCH: Because our government is not in
the business of shutting down big business. They cut a
deal with them, they take some money, they let them
move on. I’ll give you an example of how bad it is. In our
lawsuit, we sent requests for admissions. Each one of the
facts that they admitted in that criminal guilty plea, we
asked them just to admit it in our lawsuit, and they
refused. They denied each one of them, said they are not
true facts.
UNIDENTIFIED SPEAKER: I was just
wondering, you had mentioned that there are kids
overdosing in schools now and I was wondering are those
primary, middle or high schools? What’s the frequency
that you all are seeing this now and where in the state,
which schools, what area is that happening?
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MR. STRANCH: It’s actually happening across
the country. It’s showing up in high schools. So, one of the
big things that’s going on is, school boards are now
discussing whether they want to deploy Narcan in the
high schools, because there’s been about a dozen or more
overdoses that have occurred in high schools where kids
would go to school, take a couple pills to help float their
math class and OD. It’s particularly becoming a problem
with the introduction of fentanyl and carfentanyl, which
is dangerously potent, and you don’t really know how
strong it is, because they’re pressing out pills to make it
look like something, sticking a little fentanyl in it, and
sometimes you’re getting a dose that’s ten times what you
think you’re getting. They had an outbreak down in
Florida recently where I think it was 12 students
0D’dand died where they were all taking the same pills
that were supposed to be one strength but were actually
about 10, 12 times that strength. And so, yeah, it’s
happening in high schools all over the country. I know
there’s been a couple of deaths in Ohio. There were the
deaths in Florida. We have talked to a couple people here
in Tennessee that are looking into it for their high schools
as well, as to whether they ought to be deploying Narcan
for suspected overdoses in the school. It’s a real problem.
MR. GROVES: We have another question down
here.
UNIDENTIFIED SPEAKER: This might be more
of a rhetorical statement or rhetorical question. I’m
thinking somewhat of an analogy to what’s happened
with the groundswell against the NRA for what
happened I guess a week and a day ago in Florida where
at least the kid seemed to be −− there seems to be some
friction, some impetus to fix. So, here’s my analogy, and
I’m not sure it works, and I’m wondering what you think
about it. So if I’m a doctor in Sullivan County, or a
dentist, and I’m figuring I’ve got, off the top of my head,
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a hundred colleagues, maybe 50, and I’m going to the
local county club once a month to meet with them just to
−− I don’t understand how the doctors in a smaller
community like that, why there can’t be some
groundswell from them that would be effective in
preventing this or something.
MS. HERZFELD: I think with a lot them, there
actually is. We have talked to an extraordinary number
of doctors who actually have an incredible amount of
remorse, who have unwittingly participated in this and
not realized. We were just talking about −−Gerald and
our other law partner, Jim, were telling the same story
about doctors who have said I have prescribed so much
opioids, I have given all these things, and now I’m looking
back going, oh, my goodness, how many people did I hook,
how many people did I harm, and they were talking about
two different doctors and two completely difference
conversations, which is wild; right? But it’s not. There’s
been a million articles− you can Google it− of doctors
sitting down and saying did I contribute to this, how did
I do this, and how do I get out of it, because now you have
patients coming to these doctors, and I’m talking about
the legitimate ones, I’m not talking about the Fentanyl
pill mills; that’s a drive−through business. It’s different.
It’s criminal. But for legitimate doctors, I mean, they are
now trained to ask what is your pain level; right? When I
was growing up, nobody asked that. It was how are you
feeling, what’s your blood pressure, looked at your heart
rate, blah, blah, blah.
But now it’s please rate your pain. So, we as a
society now expect the doctors to keep us out of pain, and
if you go to your doctor and say I’m in pain and I have got
this root canal, you haven’t given me enough medication,
you’re mad at your doctor for keeping you in pain, and
the truth of the matter is, he’s actually good; right? I
mean, not all the time and not an extraordinary amount,
but it is natural. There is a thing about pain. Sometimes
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you’re going to be in pain. That root canal is going to hurt.
So, I think that friction between the doctors and the
patients of I’m expecting you to make me feel better and
the doctor doesn’t want to give you something but yet
needs to give you a little something and there’s a dance
there. There have been some extraordinary things
written that you can find online where doctors talk about
that struggle.
MR. STRANCH: By the way, the whole focus on
pain and how we should never have pain, there’s all these
groups, Americans Against Pain, the American Society
for the Prevention of Unnecessary Pain, I mean, they are
all front organizations that have been funded by the
opioid manufacturers, and that’s what started this fifth
vital sign of your pain, because they want to be able to −−
they have something that they can justify, but it’s
completely subjective. My grandmother, for example,
every time she goes to the doctor −−she’s on her fifth bout
with cancer −− doctor says what’s your pain on a level of
one to ten. It’s ten. Every time it’s ten. The doctor finally
says to her, well, it’s always ten. She says, well, yeah,
either it hurts or it doesn’t. That’s what it is. That’s the
way she views it. And so, what this pain thing is, it gave
the doctors the ability to write down in the chart pain of
eight, oxycodone and give support for it, when it’s just a
completely subjective measure. There’s nothing objective
about it. It’s not like your blood pressure or your white
blood cell count or your temperature. It’s just a complete
subjective thing that is used to justify prescribing pills.
And they use these front groups to go in and train and to
talk to doctors that people should not be feeling pain on
a day−to−day basis. You should not ever feel pain, pain
is bad. Well, that was an actual sea change in the way
doctors view things.
I blew my knee out playing rugby in the ’90s and
had to have a knee surgery. When the surgery was done,
the doctor said to me afterwards, look, I’m going to give
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you this five-day prescription for pills, but I only want
you to take them when the pain gets to be too bad. The
pain is supposed to be your guide. It tells you what you
can and can’t do with your knee. If it hurts, stop doing
what you’re doing, because you’re going to over-extend
and reinjure yourself. That’s what the purpose of the pain
is. It’s a warning sign to you to don’t do that. And they
have completely changed that. And the doctor told me you
should probably only be taking these pills at night,
because you’re going to be worn out, your knee is going to
be hurting and it will help you fall asleep. That was it. A
friend had a very similar surgery last year. He got a 30day supply of Oxycontin and the doctor said, "And if you
feel any pain at all, you call me, and I’ll get you something
stronger." That’s the change, and it’s this emphasis on
pain that is not created through the medical community
by doctors doing largescale studies, blind studies, double
blind studies, observational studies, longitudinal studies,
it was created by a bunch of front groups that the opioid
manufacturers supported, because that’s how they can
push their pills.
UNIDENTIFIED SPEAKER: The first ten years
after law school, I did plaintiffs’ asbestos work and so I
know what’s in front of you and I wish you well. I’m
interested in causation and damages. Addicted children,
they don’t all have these horrible effects later in life. Now,
I’m in family law and I know that. So the test that we
were stuck with is, if you’re going to say− we were faced
with this: Okay, yeah, this guy has had all this asbestos
exposure, he has a much, much higher risk of contracting
cancer later on, but you have got to prove it’s more likely
than not that this guy is going to have cancer, so how are
you going to, A, prove that this baby is going to have
learning disabilities and obstructive disorder eight, nine,
ten years from now and there are kids that have learning
disabilities and obstructive disorder who never were
exposed to opioids? So, you have got to get over that too,
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that it’s this and he wouldn’t have just already had it, and
I can’t imagine how you’re going to do that. So how are
you going to do that?
MR. STRANCH: For starters, the Drug Dealer
Liability Act has a specific section that deals with
assigning claims to babies that are exposed in utero. So,
they have a specific test already for what you can do, and
we know for the kids that we filed, they already have
those problems now. They already have impulse control
problems now.
UNIDENTIFIED SPEAKER: How old are they?
MR. STRANCH: They range in ages. Most of them
are close to school age or in school.
UNIDENTIFIED SPEAKER: Some of them will
graduate from college before you’re through.
MR. STRANCH: More than likely, more than
likely. But one of the things that what we believe the
current state of medicine to be on this is, look, if you’re
exposed to significant amounts of opioids in utero, you’re
going to have impulse control problems later in life,
period, full stop, that’s going to happen. The question
becomes, are you able to deal with it, control it or not,
which is kind of ironic for someone with impulse control
problems, but the way it works is, you have to do early
childhood intervention and you have to work with the
children from day one and you have to provide them with
a stable environment so that they cannot have external
stressors. One of the problems of the opioid epidemic is,
of these babies that are born with NAS, like 25 percent of
them end up in foster care within a year. Many of them
end up bouncing in and out of foster care.
So, they don’t have a stable environment to start
with, which only causes to exacerbate the impulse control
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problems. Now, if a kid gets adopted straight out of
coming out of the NICU, goes to a stable, loving family
and they take care of him and they provide all of the early
childhood intervention, you may see a child that is going
to graduate and, as my dad said, become a taxpayer.
Greatest thing you could ever want for your kid is to
become a taxpayer. But that doesn’t mean that there’s
not going to be problems and struggles and the
behavioral therapy and other stuff that’s going to have to
be done along the way. We also know from another child
we represented that it can be much more than just
impulse control problems. It can literally be a question of
will this child ever be able to be a functioning member of
society without having to have an adult doing things for
them and overseeing them.
UNIDENTIFIED SPEAKER: The corporate boys
are going to say prove that this kid doesn’t need $1,000
worth of treatment rather than the$500,000 worth of
treatment that you say he needs ten, 15 years from now.
MR. STRANCH: We’re still struggling to get them
to admit they’re selling opioids. They’re not admitting
anything. But we’re going to have our experts that are
going to go through and that are going to talk about
what’s facing these kids, what’s going to happen, what
money is going to have to be spent on them, the problems
they’re going to have, and they’re going to have their
experts, like in all cases where you have medical experts,
who are going to say this kid was never harmed, and if
there was any harm, it was because the dad had bad
genetics or the mom had bad genetics and they all
preexisted and had nothing to do with this, and by the
way, would you like some opioids?
I mean, that’s what they’re going to do. And I just
think our experts are going to be more believable than
theirs, because we’re going to be putting them in front of
a jury that is going to be living in a community where
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they’re seeing this on a day−to−day basis, where they’re
seeing the disruption in the classroom through their kids
and their neighbors’ kids. Our first hearing that we went
to in our case, there was three divorces on the docket, and
two of them was because the spouse ran off because she
was addicted to pills. These communities know this, and
they are not going to be very impressed with a medical
doctor that comes in and says there’s no long−term harm
damage from shooting up opioids during pregnancy and
that these kids are not going to have any problems, and
if they do, it’s because they didn’t have a stable home life
beforehand and they’ve got bad genetics.
UNIDENTIFIED SPEAKER: Baby Doe is a very
sympathetic plaintiff.
MR. GROVES: That’s about all the time that we
have for this panel of discussion. Join me in thanking our
panelists for joining us.
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RESPONDING TO THE IMPACTS OF
THE OPIOID EPIDEMIC ON
FAMILIES
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Barry Staubus
MR. ANDREW SCHRACK: Good afternoon,
everybody, and welcome to our second panel today here
at “Healing Appalachia.” My name is Andrew Schrack.
I'm the current Editor in Chief of the Tennessee Journal
of Law and Policy. It’s my privilege to introduce our next
panel. On our left here is Professor Wendy Bach, she's an
Associate Professor of Law here at the University of
Tennessee’s College of Law. She received her Bachelor's
and Master’s from the University of Pennsylvania and
her JD from New York University Law School. She's
currently involved in research regarding the opioid crisis.
Sitting next to her is Professor Suzanne Weise.
She's the Director of the Child and Family Advocacy Law
Clinic at West Virginia University College of Law. She
received her Bachelor's from Boston University and her
JD from West Virginia University College of Law.
Professor Weise has encountered a lot of the effects of the
opioid crisis in her Child and Family Advocacy Clinic.
Finally, on her right is General Barry Staubus. He
is the District Attorney General of Sullivan County,
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Tennessee. He received his Bachelor's from East
Tennessee State University and received his JD from
Memphis State University Law School. He was appointed
as Assistant District Attorney in May 1994 and
appointed to District Attorney General by Governor
Haslam on July 1st, 2011. He was elected as DA in
August 2012 and re-elected in August 2014. He is also a
plaintiff in the lawsuit that was discussed in the previous
panel. The format for our panel is going to be that each
one will have an opportunity to talk for about fifteen
minutes, and then we'll open it up for questions and
answers at the very end. To start us off, we have
Professor Bach.
PROFESSOR WENDY BACH: Thank you. I want
to thank the organizers of this wonderful Symposium and
everyone that is presenting with me today. It's obviously
an extremely important topic. As you just heard, I'm here
today because I’ve been conducting a study, and that
study is actually about something I'm not going to talk
about which was the prosecution of women in Tennessee
for fetal assault. I’m happy to take questions on that. I
know General Staubus knows a lot about that and would
be happy to take questions. But what I wanted to do
today instead is share some information that I've learned
in the course of doing research. First, I want to talk to
you about the profound medical complexity in the
medical and treatment literature about NAS and
maternal drug use.
I want to talk to you a little bit about history
because we've been here in some ways before. And then
finally, I want to talk to you about the relationship
between treatment and the courts. One of the things that
I've done as I’ve conducted this study is, I've read a
tremendous amount of medical literature, and I've
spoken and interviewed medical experts about the use of
opiates during pregnancy which you heard a lot about
during the video. We're spoken about the effect on
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children in the short and long-term and the best practices
in the field for treating both moms and kids. And as I
mentioned, at the same time that I've looked at history,
and the last time we focused as a culture on the use of
drugs during pregnancy during the late '80s and '90s
during the crack epidemic. So going to today, beginning
with NAS, I think it’s important that we know precisely
what the condition is. And you've already heard about
some of that today. How an infant gets it and what we
know and don't know right now about the facts. And I just
wanted you to know that I’m going to respectfully be
slightly more moderate in what I have to say about the
effects of NAS on children than you’ve already heard
today. And that may be me just me not being a litigant or
in this moment but me being a professor. But I wanted to
share at least what I've learned. As you've heard, NAS is
a diagnosis given to infants when they exhibit a defined
set of symptoms associated with drug withdrawal after
birth.
Generally, NAS in particular is generally
understood in the medical literature to be a short-term
and treatable condition, the NAS infant. The infants you
saw on the video were infants who were suffering some of
the more extreme variations of NAS. But infants who are
diagnosed with NAS have symptoms that vary
significantly. So you saw some of the more severe sets of
symptoms that we do see. On the less severe end, things
like NAS can be treated without using drugs given to the
infants, they can be treated with things like swaddling,
right, comforting the infant, rooming in with their moms,
if they’re still with their moms, and breastfeeding. And
the literature says that for those earlier cases, those
kinds of treatments are appropriate. So I think it's just
important to know that this is on a spectrum and that
some of the kids look like that but not all of the kids look
like that. And this is— my job is to tell you that this is
complicated. We know, as you heard, that an infant is at
risk for developing NAS if the mother took opiates during
the pregnancy. But what I want you to know about this,
[349]
89

TENNESSEE JOURNAL OF LAW AND POLICY
VOLUME 13 | SUMMER 2018 | SPECIAL EDITION

and this has been referenced a little bit today, is that in
Tennessee in 2016 over half the cases, 52.5 percent,
result from the use of opiates that were prescribed and
lawfully used. So this is a condition that is coming from
lawful conduct by moms being prescribed. And the reason
of that, the majority of those 52.5 percent, 86.1 percent of
that group results from something called medication
assisted treatment which you've also heard referenced.
Medication assisted treatment, or MAT, is the use of
substances, methadone, suboxone, things like that, given
in this case to pregnant women to treat their addiction.
Now, this may sound like a strange choice, and it may
sound counter-intuitive that a doctor would give opiates
to a pregnant woman knowing that NAS might result.
But what you should know is that the American College
of Obstetricians and Gynecologists has long
recommended MAT as the best practice treatment for
women who are addicted to opiates. I’ll talk a little bit
more about that. Some of it is— and some of it is, in fact,
illegally used. But if 52 percent result from prescription
drugs, most of that is MAT.
The others result from an illegal use or a
combination of legal and illegal use. Illegal use is— and
you're not going to be surprised by this, because what
you've seen today is almost entirely the result of
prescription drug diversion. Something we've already
heard a lot about, right? So that other big chunk is mostly
prescription drug diversion or a combination of getting a
legal prescription and then using drugs illegally that
you're obtaining from some other source. Only 3.8 percent
of NAS cases in 2016 were reported to be coming from
heroin. So this really is what we've been talking about
today, having to do with the prescription drugs. I already
said that not all infants who are exposed to opiates are
going to get NAS. And looking at the medical literature,
at this point, I can say that we actually don't know a
whole lot about why some babies get it and some babies
don't. We do seem to know that MAT as opposed to
[350]
90

RESPONDING TO THE IMPACTS
13 TENN. J.L. & POL’Y 347 (2018)

occasional use, take a couple of pills after knee surgery,
you're going to be less likely to give birth to an infant
than if you're on medication assisted treatment or longterm opiates throughout your pregnancy, that can make
it a little more likely. We also know, and this is
important, that exposure to multiple substances not only
makes it more likely, it appears to make it more likely,
they could give birth to an infant with NAS, but that the
NAS is more severe if you take different things as
opposed to the same thing. That actually leads to an issue
that a lot of people are talking about, because although I
told you that the American College of Obstetricians and
Gynecologists has always— has since the heroin
epidemics, really, in the '70s, have said that methadone
is the right thing to do, it might have been later than
that, actually, but for a long time. There are some early
research, some of it going on at UT, that says you can
safely detox moms. And that if you detox moms during
pregnancy, you will reduce the chance that you give birth
to an infant with NAS. But this is difficult; right? It's
difficult to do well.
And if that mom relapses, as people often do when
they detox, and then she goes and starts to use street
drugs, then she's taking multiple substances. So, it's a
very difficult set of decisions. And, you know, the more I
got into this literature, the more complexity of this
problem of what a mom should do when she's pregnant if
she's an addict, of what she should do in terms of what
medication she should take or not take, how the infant
should be treated, are really difficult decisions, and they
are very specific to that mom and to that baby. And the
more I thought about this, the more I thought, these are
decisions that we have to leave between, hopefully
competent medical professionals— now we've heard a lot
about not so competent medical professionals today— but
hopefully good docs and their patients who are helping to
understand this very complicated field and helping moms
make the best choices they can make in those
circumstances. Another thing I've learned a lot about is
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this data research on the longer-term effects of NAS, and
this is where I might differ just a tad. It's a very
complicated question to answer; right? We know what it
looks like at first, right, we know what it looks like in the
infants.
We don’t know who's going to look like that, but
we do know what it looks like. There are some studies
that show some developmental delays correlating with
exposure. There’s lots and lots of stories; right? There's
lots and lots of anecdotal evidence that the kids are
suffering. But the studies aren't there yet, and I don't
know if they're going to get there. And what's interesting
is, when you look carefully at the medical literature,
several researchers have suggested that once you account
for things like socioeconomic status, exposure to violence,
inadequate nutrition, prenatal and postnatal psychiatric
stress, alcohol use, maternal education, lots of which we
call the social determinants of health, it's really unclear,
right, whether the issues we are seeing are as a result
just of the opiate exposure or a combination of factors or
something else. It is true, and this was said before, that
infants with NAS or with any of those negative social
determinants of health, are going to do better in stable
environments with support.
I promised you I would turn to history. I think it's
important to look at history and know that we have been
here as a society before. In the late '80s and early '90s,
we've labeled a generation of mothers and children crack
moms and crack babies. At the time— and it’s interesting
because I've gone back to read the science. And at the
time, scientists and doctors sounded a lot like the
scientists and doctors today. They were conducting
careful studies, they were seeing some early correlations,
but the majority of those folks were appropriately
cautious about what their findings meant, not so though
the press, the public and the courts. The media building
on the stereotypes of what were then majority poor black
moms, predicted a generation of destroyed children who
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would grow up with a whole host of behavioral problems.
There were crack kids, and the assumption was that this
would be a lost generation. But here's the thing, that
turned out not to be true. After following those kids for
over two decades, we’ve learned a good deal. There are
effects smaller than predicted in development and
cognition that are far less severe.
And one long-term study I think is tremendously
important. Dr. Hallam Hurt and her team conducted at
twenty-five year longitudinal study comparing the
development of infants exposed to crack cocaine to
similarly situated infants who were not exposed. The
study was launched in Philadelphia in 1989. Dr. Hurt
and her team followed two hundred and twenty-four
babies born between '89 and '92, half had been exposed to
cocaine in utero and the other half had not been, and they
were demographically incredibly similar. All the infants
were born near full-term and were from low income,
predominantly African American families. And at the
time Philadelphia— and this is going to sound really
familiar— was experiencing a drug epidemic similar to
the opiate epidemic of today, nearly one in six born at the
time at city hospitals had mothers that tested positive for
cocaine. What her and her team found after twenty-five
years were that there were "no significant differences
between the cocaine exposed children and the controls."
What they did find, however, was that both groups
of children, poor kids, predominantly African Americans,
those who had been exposed to cocaine and those who had
not, lacked developmental and intellectual measures
compared to their non-socioeconomically non-racially
similar compatriots. So, Dr. Hurt started to look at what
else may be harming those children. They looked at
environmental factors and found that while being raised
in a nurturing home led to better outcomes, significant
proportions of the children by age seven who had been
exposed to violence, gunshots, witnessing a shooting and
seeing a dead body, that exposure correlated with
depression and anxiety and delays. Ultimately, her and
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her team turned their focus to the effects of the condition
of poverty on developmental growth and since has gone
on to focus her research on these issues. I tell you this
story not because I didn't know whether history is
repeating itself but as a cautionary tale.
Those kids and the kids today absolutely need
enormous support and services. I hope General Staubus
and his fellow plaintiffs win lots and lots and lots of
money to put into communities to support kids and
families. But I think we need to be really cautious about
labeling these kids and labeling these moms, and
knowing, right, and be very cautious about the science of
it, because the last time we did this, we labeled a whole
generation of kids and we turned out to be wrong largely.
This leads me to my final point, and that’s about the
relationship between child welfare cases, family courts,
criminal courts and treatment. A lot of the focus in the
conversation has been on turning courts into hubs for
accessing treatment. Drug courts and other problemsolving courts explicitly embrace this model, and other
courts use other staff, probation officers, drug treatment
coordinators and the like, that helps folks in the system
access treatment.
Similarly, the Department of Children’s Services,
DCS, has a duty to avoid placement, and as part of that
work, they will often provide folks access to treatment. I
just want to be clear, I think this is all wonderful and
really, really important. There's no question that folks in
those systems need access to treatment. But I do wonder
if we're going too far, and I’ll tell you why. During my
study I have talked to lots of folks in the criminal justice
system across East Tennessee. General Staubus is one of
them. And during one of the interviews, I interviewed a
drug treatment coordinator at a rural northeast
Tennessee court about how she gets folks access to
treatment. It was clear from the interview done in this
very small community she was it, she was the one who
could access treatment. What became clear in the
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conversation is that it took criminal charges to access her
services. She explained that if a mom called her and said
that she wanted to get help for her son or daughter, or
whoever was needing treatment resources, the first thing
she would ask is, can you catch him on a little charge,
because then I can help him. She also explained that she
had three grants available to her to pay for what is pretty
much short-term detox treatment, and two of them
required judicial signoff. So you had to have an open
criminal case in order to get access to those treatment
resources in their community. And then I started asking,
I actually had been asking all along, and every actor in
the criminal justice system that I have asked this
question to so far agreed with me when I asked, is it true
that it's easier to get treatment once you're in court. And
everybody says, yes, that is how it works, right. That's
where the caseworkers are, that's where the ones are that
know how to work with the system. And I think courts
should have access to treatment resources. But I get
worried about the zero-sum game. I think if we are
constantly thinking— and this is what Professor Buck
was talking about, our public health systems to our child
welfare and criminal justice systems, we might be
drawing people into those courts that could be seeking
help outside of those courts. So I'm going to stop for now.
I'm happy to take questions. And I'll turn it over to my
co-panel.
PROFESSOR
SUZANNE
WEISE:
Good
afternoon. I should never have Power Points, so hopefully
I will be able to do this correctly. So, I'm coming at this
from a different angle, because, obviously, I think
everyone would agree that fighting the opioid epidemic in
Appalachia must occur on several fronts. So, the primary
focus of my presentation is the role of family law clinics
in cases where opioid addiction is the cause of child
custody disputes in family court. In those cases, our clinic
has been called upon to16address substance abuse issues
and the need for the players in custody cases to obtain
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treatment for opioid addiction. As you heard earlier from
Eric Eyre and Pat McGinley, in 2016, West Virginia had
the highest death rate from opioid overdose. And
according to the American enterprises, West Virginia's
economic burden from the opioid crisis amounts to four
thousand seven hundred and ninety-three dollars per
resident. Children in foster care, according to the West
Virginia Department of Health and Human Resources,
eighty-four percent of the children in foster care in West
Virginia are in there because of the opioid problems of
their parents. These children's adverse experiences raise
their risk of substance abuse as adults. The 2016 report
of the Surgeon General has recognized that the
experiences a person has in early childhood and in
adolescence sets the stage for future substance use and
sometimes escalation to a substance abuse disorder or
addiction. Early life stressors, such as the ones that I see
that the children experience in the cases in which I’m
involved, involve parents who may have an opioid
addiction. Maybe it's another family member. They have
a parent or family member who may be incarcerated on
drug related charges. There's several factors, but those
are a lot of what we're seeing happen.
Research suggests that the stress caused by these
risk factors may act on the same stress circuits in the
brain as addictive substances which may explain why
they increase the addiction rate. And as you've heard
today, people who are affected by the opioid epidemic
enter the legal system in many different ways. It may be
because of drug charges, it may be because of abuse and
neglect or it may be in family court and child custody
cases. You usually have counsel appointed in criminal
cases, at least in West Virginia, and in abuse and neglect
cases in West Virginia where the party cannot afford
counsel. However, under the current system, many
affected by the opioid epidemic cannot afford counsel in
family court proceedings. These families typically seek
pro bono representation from Legal Aid and often they
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will come to law clinics. We only have one law school in
West Virginia in Morgantown, so we only have one
university child and family law clinic. So, the WV Child
and Family Advocacy Clinic that I direct represents
children and families in custody and education matters
but also other family related matters. Family courts in
Monongalia and Preston Counties in West Virginia often
appoint me and my students to serve as guardian ad
litem to represent minor children in family custody cases.
And importantly— and I'll talk about this in a few
minutes— our clinic partners with Chestnut Ridge
Center at the West Virginia University psychiatric
facility and also with WVU Medicine/Pediatrics. And
what we have is a medical-legal partnership with them,
which I'll discuss in a minute. So, in the majority of cases
that my clinic students and I litigate, at least one family
member of someone involved in the case is suffering from
some form of abuse, whether it's prescription painkillers,
heroin. We’re seeing a lot more heroin and meth.
Also, many of the children we see, they have a
family member, parent, member of the household— we
have a lot of mixed households in West Virginia, where
not everybody is biologically related, they just come
together because they all need a place to live, so they
experience that some member of that household may be
incarcerated. A lot of these children bounce from
household to household, maybe because a parent can't
provide shelter, a parent can't keep a job, so these kids
are shuffled around. And these are the adverse childhood
experiences that increase the likelihood that the children
in these situations will also become addicts as a result.
And I want to give you an example of a couple of cases
that we're currently working on now as we serve as
guardian ad litem for the children. In one case, all parties
have tested positive for drugs at some point in the past
two years. The biological mother tested positive for
painkillers at the birth of her child. The biological father
tested positive for marijuana at the initial court hearing.
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And I have to tell you, in family court, testing
positive for marijuana these days is not that big of a deal.
The judges aren't as concerned about that because of the
problems with these other substances. A biological
parent actually raised this child up until this point, and
that biological father, along with the fiancée, tested
positive in court for opiates. There are also allegations
that the psychological father sells and/or makes meth,
and all parties have been arrested at some point, but are
not currently in prison, and the parties have also called
the police on each other as part of the dispute over child
custody. So, our role in this case is to try to figure out the
best interest of the child in every respect. In another case
where we serve as GAL for the child, the mother
tragically overdosed and died in 2012. The father claims
he is recovering from his heroin addiction and wants to
regain custody. There are allegations that his sister, who
is the aunt, is selling heroin, and the child is currently
living with the grandparents.
So as guardian ad litem in both of these cases, I
mean we can look at the facts, interview the people, talk
to their teachers, talk to the healthcare providers, and
then we can figure out where is the safest place for this
child to be. At this particular time, what's going to be the
best nurturing environment, what the options are. But
resolving that is not going to resolve the drug addiction
that is the root cause of the family problems, nor does the
resolution of these issues address the children’s exposure
to drug addiction and the effect it may have on them. And
these children need healthy parents.
When we are representing a client in a custody
case, and we have some of those right now where the
other party is struggling with addiction, we have asked
the family court to make treatment a part of the relief
given in the case. For example, encouraging the other
party if you seek treatment for your addiction, this will
help you with your visitation with your child, we can
move from supervised visitation to unsupervised, maybe
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we can move to overnight visits, maybe we can move to a
weekend, maybe you can regain every other week and if
you can regain custody. And we’ve asked the court to do
this. And surprisingly, we've had very mixed results. The
court, and one judge in particular, has seemed reluctant
to make that part of the relief granted. In one case, said
that we were somehow trying to gain an advantage.
There's no advantage to be gained in these cases. Nobody
wins. The win would be for the parent who is suffering to
get the help he or she needs and for the best interest of
the child. So this has prompted my clinic students and I
to talk about what is our role. I mean, obviously, we'll be
in a role as a lawyer. But do we have more of a role, a
more important role in addition to just helping with—
you know, with the legal issues that the parties have. So,
I'm citing the West Virginia Rules for Professional
Conduct, but ours are based on the Model Rules, and
they're exactly like the Model Rules. So, under Rule 2.1
of the Model Rules, "In rendering advice, a lawyer may
refer not only to the law but to other considerations such
as moral, economic, social and political factor that may
be relevant to the child's situation"— or to the "client"—
sorry. And then the comments to that Rule recognizes
that family matters can involve problems within the
professional competence of psychiatry, clinical
psychology or social work, and with consultation with a
professional in another field is something that a
competent lawyer would recommend, the lawyer should
make such recommendations.
And finally, the Rule also provides that the lawyer
ordinarily has no duty to initiate an investigation of the
client's affairs Orto give advice that the client has
indicated is unwanted. The lawyer may initiate advice to
a client, but in doing so, appears to be in the client's best
interest. So how do we help our clinic clients or parties
involved in the clinic cases get the help that they need?
And this is where we believe our medical/legal
partnership comes in to help with the treatment side of
the opioid epidemic. According to key findings in the
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Surgeon-general’s 2016 report on addiction, only one in
ten people suffering from a drug use disorder get
specialty treatment. And really, the low grade is really
because of the resources— the lack of resources and
what's available. And what happens is, because the
limited resources are so limited, there can be waiting
periods of weeks or even months just to get help. So
medical/legal partnerships like the one WVU law has
with, especially with Chestnut Ridge Center, which is a
psychiatric facility, may be one way where we can work
together to help these folks get the treatment that they
need. And for those of you who don't know what a
medical/legal partnership is, these are basically doctors
and lawyers, and we have a memorandum of
understanding that we’ve entered into, and doctors and
lawyers are working together to address the
communities' health-related social needs. Professor Val
Vojdik established our first MLP at WVU Pediatrics in
2010, and then she was stolen from us by the University
of Tennessee. And she is now here. So, when she was
taken away, I assumed her role as director in 2011. And
I established our second MLP with Chestnut Ridge
psychiatric facility in 2016.
How does it work? The way it initially started
with these medical/legal partnerships is the healthcare
providers were referring their patients to us. And so it
was really basically a one-way street. They were sending
us their client, their patients to us and we were helping
with their issues. And also, with the client’s consent, the
healthcare providers were allowed to be involved with the
client. And usually, we got the formal consent, but they
were confiding in them anyway. But to get the formal
consent for them to do that. And so what our goal is now
is to now have it a two-way street, so that we’re able to
consult with healthcare providers through the MLP to
refer clients either to the Chestnut Ridge programs or to
the other programs that they feel are more appropriate.
And the reality is that simply referring the client to a
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treatment program is not going to solve all the addiction
issues. They've got to want to be helped. They’ve got to go
through— most of them through a long process of
recovering. Unlike drug court where you have the
incentive, okay, you either go to jail or you're going to
complete this drug treatment program. So you have the
incentive, yeah, I don't want to go to jail, I'll complete the
program. Or in family treatment courts where they say,
you’re going to lose your kids, we're going to
terminateyour parental rights if you don't go through the
treatment program. Those are incentives. You don't have
that in family court, because the worst thing that can
happen in family court is that they're no longer the
primary custodian, maybe they have just now supervised
visitation or limited visitation or just visitation based on
what the other parent will allow. And sometimes that
incentive is not going to be enough. And so we have to
help encourage them to want to get help for the sake of
their children and to work with healthcare providers to
make that happen. So I believe working together that we
might be able to accomplish this.
We were talking earlier, what does this long-term
treatment involve. There are many stages to it, it’s not
something that you just do in a couple of weeks. The one
with Chestnut Ridge goes on for at least two years under
this program. I mean it has stages where they taper off
and then if they get through, then they can just go to
meetings, have their follow-ups, and they are also treated
with suboxone usually. And a law student— I don't think
he’s here now, but he raised it earlier, and I think he
raised a really important issue that's a subject for
another whole another session, is the use of suboxone in
treatment. Because what we've done, we've replaced, you
know, the opioid with another drug. And so a lot of folks
are on this for life.
Originally, suboxone was used just to taper— the
original use of it, at least my understanding is, it was just
to taper a person off of the opioids, and now it's become
the long-term solution. And I'm not a doctor, and I’m not
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going to— I know there are cases where they try to take
them off and other cases where they say it's not possible.
But I think that's something that we really need to
examine in the future as well. So a combination of this, I
think that working together we can do this. But then the
big question is, who is going to pay for this, which is
always the question. In West Virginia, Medicaid will
cover the cost of inpatient or detox partial
hospitalization, care coordination and case management
and they'll have prescription drugs like suboxone. We are
still working in my clinic to try to figure out other
resources that are available to help pay for these services,
what services are available. Because just going to a
suboxone clinic is not going to help you, they need
counseling. They need somebody working with them to
find out— you know, people don't just wake up one
morning and say, oh, I'm going to become an opioid
addict. There’s something underlying, and it could be
something as simple as a car accident. We had a client
that came in addicted as a result of pain resulting from a
car accident, or some really underlying serious problems.
We have another case where a woman who had a
perfectly normal life, hooked up with her old high school
boyfriend who happened to be a drug dealer and her life
is a mess now. So there's all these reasons that you have
to help the person and not just get the suboxone
treatment but really needs counseling. Another tool to
combat the opioid addiction in family court is— and I
think we need to call upon the Bar for a better
representation by lawyers. Rule 1.6, "Every lawyer has a
professional responsibility to provide legal services to
those unable to pay." And this is really an ethical
commitment that has to be made by every lawyer. So I
think that we need to call upon members of the Bar to
step up. I think the family courts need to come up with a
list of lawyers who are willing to provide pro bono legal
assistance in family courts to help these folks with their
custody cases. And finally, as part of the seminar
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component of our family law clinics, I think we've got to
start educating our law students about substance abuse
and its origins so that they may counsel their clients
where such a role is appropriate. Thank you very much.
GENERAL BARRY STAUBUS: Thank you for
inviting me. This is my second time here. Actually, I was
here— The Federalist Society invited me in this very
room to talk about legalization of drugs. Which we do
have legalized drugs. All these opioids almost are legally
given, and we can see what kind of disaster it is. But
that’s for another day, another topic with another group.
You all have been here a long time. I'm going to try to be
short. So I'm going to start off with a clip of a video, and
it's my appearance on the Today Show. It’s not an—
making an attempt at self-promotion, but I thought it
was a well-done video of the clip, segment that the Today
Show had been doing on opioids. And it's done by Ronan
Farrow. You may know him. He's the guy who broke the
Harvey Weinstein story. Also, you may know him as the
stepson of Woody Allen.
And secondly, I would say, if I knew he was going
to say Appalachia, I would have taught him to say it the
right way. So be forewarned, he says it wrong. And third,
I never had any physical contact with Matt Lauer during
the filming and the presentation. So with that, I'm going
to let them play the video. So I don't want to plow the
same ground. You've heard from my lawyers who filed
the lawsuits. I hope I don't repeat what they said. But
how did I get involved in this thing? Well, the State of
Tennessee passed a law years ago, Drug Dealers Liability
Act. I've been a lawyer since 1985. I had never been a
party to a lawsuit. I had filed some lawsuits for other
people, and I signed my name on indictments, but I had
to think long and hard, did I want to do this lawsuit.
And I got to thinking, it's a good thing that they
gave the jurisdiction to DAs to file this lawsuit, because I
feel like as a prosecutor, I have a unique perspective.
There are a lot of perspectives out here. I see the families
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of the people that die of the overdoses. I've been to the
NIC units, and I've seen the babies, I've talked to the
nurses, I've talked to the doctors, I've talked to the rehab
people. I've talked to the mothers who gave birth to those
babies. I have met with the victims of many, many
crimes. Probably ninety percent of all crimes in Sullivan
County result in drug abuse. You know, if there's a
burglary, somebody breaks into a car or a house, a
building because they're looking for drugs. When they
break in, they take stuff from people that's not theirs.
When they shoplift— we have robberies where they don’t
even ask for the money out of the pharmacy, they just
want the pills. We have many, many impaired drivers,
not on alcohol anymore, I see them pilled up, and they
kill people. They wreck, they harm people, they kill
people that are minding their own business in a car. I see
people that are under the influence of drugs when there's
a domestic violence event. Elder abuse, when older people
are abused. There’s a number of ways.
It's sometimes a family member is pilled up and
they take their money, they take their drugs, they take
their credit cards, or they neglect them, let them starve,
put them in perilous condition. I've got one where one
died. And the mother sat there and watched it happen. I
attribute that to drug abuse because she was more
concerned about getting out and getting pilled up every
day. Almost every identity theft I see, worthless check,
under the criminal— other crimes like that. Almost all of
them relate back to people that are addicted to drugs. So
I see that. Then I saw the pain pills. I don't know if this
statistic was given, we have a number of pain pill clinics
in our jurisdiction, and we have thirty-five suboxone
providers in one single county. And one of the pain clinics
was prescribing fifty thousand pills per week, fifty
thousand, and a hundred and fifty thousand
prescriptions a month in a county that has a hundred and
fifty-eight thousand people. So I saw that, and I would
see the people driving from West Virginia down to my
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county and from southwest Virginia and other parts of
East Tennessee and getting off the interstates, sitting in
the parking lot with their kids having fights, eating
chicken and pizza, playing cards, standing in line on New
Year's Eve. You know that’s a legitimate doctor. All
medical providers have people sitting in their parking
lots from multi states on New Year’s Eve. So I see that, I
saw that. And I see people going in there and getting
their suboxone and getting their opioids. I talked to one
mother who gave birth to a baby. She got opioids because
she had hepatitis. She got morphine for hepatitis. Now,
tell me that's a legitimate medical practice. That's the
kind of things as a prosecutor I’m seeing across the board
day-in and day-out. And Sullivan County leads the state
in drug dependent babies. Tennessee is one of the top
opioid users and abusers. One of the other statistics you
may have heard, in Sullivan County, forever man,
woman, and child, there's prescribed 5.5 opioids. Think
about that. Three Tennesseans die per day by overdose.
It exceeds the murder rate and car wrecks. And now we're
flooded with fentanyl and heroin. So a lot of these addicts
have gone beyond that. I talked to the health department.
They said, we're on the cusp of a hepatitis C, HIV
epidemic. Our prison population— our population since
the '90s, in some cases, I think increased two percent, but
our jail population seventy percent, almost seventy
percent.
You crowd that— you put seven hundred people
in a five-hundred-person facility filled with drug
addiction and intravenous drug users and hepatitis and
you're having another health crisis. So those are the
things that I see, that I saw, and they're not getting any
better. I'm seeing it become worse. For the first two
months, according to March, we’ve had about three
overdose deaths a week, and almost everyone of them are
fentanyl and heroin, where we used to see oxycodone and
a mixture of drugs. And a good book that— I don’t know
if you've heard about it, but a book that I read several
years ago that was also a catalyst for me getting involved
[365]
105

TENNESSEE JOURNAL OF LAW AND POLICY
VOLUME 13 | SUMMER 2018 | SPECIAL EDITION

in this lawsuit was a book called Dreamland by a guy by
the name of Sam Quinones, and it tells how the first pill
mills got established in Portsmouth, Ohio. And he
tracked how everywhere these pill mills come, there's
heroin right behind it. And when I read the book, we
weren’t seeing heroin, we weren't seeing fentanyl. We are
now. And people are dying. We had one provider— you
may not know this, but nurse practitioners can prescribe
opioids for pain clinics. We had one nurse practitioner
who prescribed to at least seven people who have died
from drug overdose. When I talked to the family of one of
those people that died, she went personally into the pain
clinic and said, don't give any more drugs to my daughter,
please do not. And she says, as long as the law allows me
to do it, I'll do it. And the mother was right, she predicted
she would die, and she did. So I hear these stories and I
see these facts and I see these events, and so I had to
make a decision, do I want to file this lawsuit or not, do I
want to stick my neck out. And I was lucky to bring in my
DA buddies from next door, Tony Clark and Dan
Armstrong, and we sat down and we had a meeting, and
I told them I was onboard. And they said, why are you
doing it?
And I said, look, I woke up in the middle of the
night and it just seemed like it was the right thing to do.
What have I got to lose? And I hope we win, because I
want a hair transplant. No, I hope we win, and I hope we
win big, because it has been devastating to our county.
It's been devastating to our area and outstate. I read that
there's been a five hundred and forty percent increase in
the prescribing of opiates. Do you think there's been a five
hundred and forty percent increase in pain that people
have? I don't think so. When you see the devastation and
the death and the babies— and another story I'll tell
about, and we touched on it, NAS babies. And I'm not
here for that today, I don't want to really get into that.
But I know a lady in a place called Stoney Creek, and she
walked the walk. She adopted one of these babies. And
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not only did she adopt these babies, but she set up a clinic
for the women that I met that had drug addiction. And
she tries to get those women the resources that they need.
She's a model for what we ought to be doing in West
Virginia and Tennessee and across the country. But she
went a step further, she adopted one of those babies. She
already had raised her kids, had grandkids, she adopted
one of these babies. So, then she decided, right next door
to the clinic where I treat the moms, where are they going
to drop the kids off, next door. So, she has made a facility
just for these babies for their unique problems that they
have developmentally. She's designed a little— she's near
Stoney Creek, which Professor White knows, is next to
Elizabethton. So, she had a man who volunteered, and
he’s built a little town, looks like a little speck there. And
they’ve got a little place where if they get sensory
overload, they can go. And one of the things— and a lot
of these kids are freaked out by doctors because they go a
lot, and stethoscopes and rubber gloves are a big problem.
So, they have a veterinarian place, so they get to play
veterinarian, the kids do. When they play veterinarian,
they want to treat the little Teddy Bears and the dogs.
They let them wear gloves and stethoscopes, just small
things like that. They have a restaurant and they have a
grocery store, so they handle food, because they have a
lot of weird things about food.
Those are the kinds of things that need to be done.
If I win this lawsuit, she's a model for the kind of things
that need to be done. There are a lot people that could
help. There’s a lot of people that are helping. There's a lot
to be done. But these companies, in my opinion, my
humble opinion, is they created this problem. Now, they
didn't make anybody take the drugs, I know that. When
people say, everybody needs treatment. Well, no, if
somebody is doped up and they run into the back of a car
with your mom or your wife and your two kids and kill
them, I'm sorry, I'm not in the mood for rehabilitation
right then. But there are many, many that do need
rehabilitation, either in the facility— but they need help,
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and they need money. And we've seen the devastation. So
that's what I hope the lawsuit will provide is a statement
that you push these drugs— and you heard, I'm sure,
from Mr. Stranch and Ms. Herzfeld, they pushed these
drugs, miracle drugs that had no side effects. And they
make lots and lots of money. And I'm not against making
lots of money, but I am when you're lying to people and
you're destroying people's lives, and then you claim
you’re not doing it when you are. So that's why I filed the
lawsuit. And I guess that's why I'm here today. So, I
guess I've taken up my fifteen minutes, right. So, in the
words of Kurt Monagan, thank you for your sweetly faked
attention. Thank you.
MR. SCHRACK: Thank you. We'll now open it up
for questions from the audience. We do have two
microphones available if anyone has any questions.
UNIDENTIFIED SPEAKER: I actually have a
question for Wendy Bach about one of the things you said
very early on in your speech. You said that one of the NAS
treatments that you had run into was breastfeeding,
which I found very interesting given that we have a
judicial system that tends to take the children away from
the mother as soon as they are tested positive for any
kind of drugs. So, I guess my question would be, is the
justice system worsening the effects that they have by
our reaction?
PROFESSOR WENDY BACH: I don't have any
data. I know what you're saying. I think we have to be—
I mean one of the points I'm trying to make is, every baby,
every mom is unique, right? And when you have a policy
like you just said— and DCS's policy is not every time an
infant is affected, you take the baby away immediately.
They do go in and they assess the situation. That's a little
bit of an overstatement. But I think when we blame the
moms, we maybe won’t see something like rooming in or
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breastfeeding as something good if we're worried that the
mom is the source of the problem or can't do that. And
that mom may need a lot of support to support that baby.
But there are good programs where moms and babies can
be together, and both get the support they need. But I
think we have to look at this through a public health and
medical care lens for that circumstance and look at every
mom and kid and figure out what’s most appropriate and
just be very mindful about the science of what works and
what doesn't.
UNIDENTIFIED SPEAKER: Barry, before you
got here, your lawyers were describing (inaudible) in a
way I found particularly unflattering and were talking
about issues such as the doctors all going down to
Ridgefield County Club and continuing to perpetuate this
problem. So, my question is, you know, you and I both
know that area, so how has the community reacted to
your activism and what, if anything, has the medical
profession in Sullivan and Washington and Carter
County done to help you?
GENERAL BARRY STAUBUS: One, I want to say
that I think the vast majority of doctors are legitimate
doctors and don't want any part of this. Doctors were put
in a bad spot in 2001 when the pharmaceutical companies
pushed for a thing called for "The Retractable Pain Act."
And it said you've got to do one of two things. If somebody
comes to you and says, I want a narcotic, you've either got
to give it to them or send them to somebody else. So, the
legit doctor said look, I think you're a drug seeker, maybe
you need rehab, maybe you need to just wait, maybe you
need an anti-inflammatory. They’re, no, I want it. So
that's how the drug— most of the pill mills are, to me,
they're an outlier in the medical community. The medical
community that I— the people that I’ve talked to,
particularly the ones that are serving these babies, you
know, they're as involved as you could be. And I have
talked to a lot of doctors, and what's the general reaction
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been? Sullivan County, it's my home, my family has been
here for generations, and the people there are generous
and have been generous. And I get a lot of atta-boys for
doing this. The response has been positive, except for—
when after the Today Show a guy from Iowa called me
and said, because of you, I can't get my pills. And I said,
well, move to Tennessee. He said he was reporting me to
the Board. But my experience with— there are a lot of
doctors that are in the rehabilitative business and that
are supportive of what I'm doing, and they've told me
that. And many of the medical providers said, part of the
problem was we had this fifth vital sign that you heard
about that the juvenile judge was talking about. And
basically, the other thing is, doctors are judged by patient
satisfaction. Imagine if you were a professor and you
were graded— your pay increase and your promotions
were just totally the result of how well the teacher liked
you. So, what would that do? That would incentivize
passing everybody, not giving out homework, not being
critical. So that's what’s happened in the medical
profession is that— I've talked to ER doctors that said, if
I don't give them, they fill this out, they'll complain on
me.
So, if I'm looking for a promotion or I'm looking for
a pay raise, and they’re saying, your patient satisfaction
is low. Well, who’s giving the grade? The dope head, the
pill heads, the drug seekers, the addicts. So I find that
the vast majority of the community has been supportive
of the lawsuit, they want to fight this problem. I think the
biggest problem I have is that people don't realize the
magnitude of the problem. I think some people are still
doubters. And it's easy to understand. It's just like when
people come and sit in the grand jury thinking, my gosh,
I didn't know we had this much crime. The only thing
that gets reported in the paper if you’re in Knoxville, it's
going to be the murder cases, the sexy cases, I guess you
would say, high publicity cases. Well, nobody goes to
sessions court or juvenile court and sees twenty, thirty,
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forty, fifty thousand cases, depending on the size of the
municipality. So, my biggest challenge has been people
who work at Eastman, work at school, they go home, they
go to ballgames and they go to movies, soccer, church,
civic groups, and they don't see a lot of it. But that’s
changing because more and more people are saying, you
know what, I've got a relative, I've got a friend that had
a car wreck or— I think of the example you gave, a jobrelated injury. We're seeing more and more people get
addicted because the access is so huge. And doctors have
over-prescribed. Classic example, I had meniscus
surgery. When I went in— it's one of those things you go
in and go out the same day. They gave me a prescription
for ten Percocets. I took one and it hurt my stomach, I
threw them away. So, I came back for my ten-day
checkup, what did they give me, thirty-day supply of
Percocet. And the new studies that have come out and say
that if someone takes Percocet drugs for a thirty-day
period or more, there's almost like a thirty percent chance
a year later they're going to be taking that drug, which is
the sign of addiction. So those are the kinds of things
that— I think that the denial or the misunderstanding or
the lack of understanding is changing because there's so
many people across the board. It's not just your
traditional drug culture people, but now we're seeing
professionals and nurses diverting, doctors diverting, so
we're seeing it across the board professionals, middle
class and lower-class. I hope I answered your question.
UNIDENTIFIED SPEAKER: Can other DAs join
in, like Bradley County—
GENERAL BARRY STAUBUS: Yes. Sixteen DAs
have now joined. We started with three, we've gone to
sixteen—
UNIDENTIFIED SPEAKER: I have to say it was
an unintended consequence that I'm the sponsor of
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Senate Bill that set up the Drug Dealer Liability Act in
the State of Tennessee.
GENERAL BARRY STAUBUS: Congratulations.
Thank you.
UNIDENTIFIED SPEAKER: Thank you. I have a
question. I have a question just about your lawsuit. You
have targeted as defendants the manufacturers. Is that
because of the Tennessee statute, and why not the
distributors?
GENERAL BARRY STAUBUS: Well, I think my
lawyers could be of much more—
UNIDENTIFIED SPEAKER: I don't want you to
breach your attorney/client privilege.
GENERAL BARRY STAUBUS: Well, we've done
the manufacturers, but we've also done a pain clinic,
we've also filed against individuals as well. And the
reason we feltlike— the center point of our theory right
now is the manufacturers and the unregistered
distributors. And that’s why, that we had to focus, we had
to stick with our theory. And what also makes our lawsuit
unique, and I’m sure they told you this, but we filed on
behalf of a drug dependent baby. Nobody else has done
that, so now other people will. A lot of people have asked
for copies of our Complaint. But that's one thing that may
bind me in, it’s not just the DAs, but that baby stands in
for all the babies that got addicted, for me. It stands there
as a representative for all these babies that you heard
about. It’s been estimated that a third or fourth of the
babies in Sullivan County are born addicted to drugs.
And I understand what Dr. Bach is saying, we
don't have the studies in. But common sense will tell you
this much, that if a woman gives birth to a baby and the
drugs normally dissipate within forty-eight hours at
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birth, that tells you that many of these women within two
to three days of giving birth, on the cusp of a birth, they're
still taking serious drugs. And you just know that if that
happens— and usually in bad circumstances where the
women are under anxiety, they're addicted to drugs,
they're afraid of crimes, they're afraid of being picked up,
they're afraid of losing the kids, from pillar to post. They
may be in an abusive relationship— and I'm sure you see
a lot of that. You know that's not the ideal circumstances
to have a baby. So that's why it's so important, I think,
for that baby to stand in as a plaintiff, because it
represents the hell that they may have to endure, that
they did endure just being— the first sensation out of the
womb is either I'm addicted— either been addicted, high
or withdrawn, and that's not a good place to be. So, I
think we have a very strong claim for the baby and all
babies that it stands for.
MR. SCHRACK: We'll do one more question over
here.
UNIDENTIFIED SPEAKER: My question is for
the General too. You talked about suboxone earlier and I
know you probably have a lot to talk about it. There are
a lot of people who believe that is the key to fixing this
problem. And do you know of any known cases of overdose
that are exclusively to suboxone and no other drugs
involved?
GENERAL
exclusively.

BARRY

STAUBUS:

No,

not

UNIDENTIFIED SPEAKER: And what are the
negative effects that you believe suboxone has, and are
they included in your lawsuit?
GENERAL BARRY STAUBUS: No, suboxone
dealers are not, the pain clinic is. I'm not a big believer,
I'll be honest, in suboxone in the way I've seen it used in
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Sullivan County. I'm not saying it's not a tool, it's not an
aid. But many of our suboxone clinics, you go in and you
get your twenty-eight-day supply of suboxone. You come
back in twenty-eight days and get it. There's no
individual therapy, there's no counseling, there's no
really effective drug screening or for risks, there's no
penalties. You know, if you end up having other drugs in
your system. There’s no end game. Most of the suboxone
providers will say, we don't have a game plan to try to get
this person back to being productive. See, I think the goal
ought to be— and it may not always happen. But, you
know, if you’re on suboxone for ten years, there's
something wrong. I mean you’re either on the same
amount or you're going higher, and you're having dirty
drug screens but you're still getting it. And that's not
right. To me, the goal ought to be, we want to make you
a productive citizen. Our highest goal is to get you
completely off of dope of every kind so you can live
productively. But if we can't, we need to get it to a level
where you can get a job and you can raise your family and
you can stay out of trouble.
I’ll give you another example. Suboxone is a lot
like methadone except methadone is more highly
regulated. I had a guy who was committed. He had a
sentence, and he was on methadone. He had court
approval to go to Asheville, which is the closest facility to
get methadone. Of course, if they put him on suboxone,
he’s going to give it to somebody. This guy comes back,
he’s been on methadone ten years, and he's still getting
that substance for his addiction. And he goes to a party,
and he puts that thing in a glass of Kool-Aid, and his
buddy drinks it, and he's not used to the power of that,
methadone, and he had another drug in his system, and
he lays down on the couch and he goes to sleep, and he
never wakes up. To me, no one should do that. I guess the
moral of the story is, nobody should be on methadone for
ten years. I mean it seems to me— I mean if it's a stepoff drug to productivity, that's the problem. That's what I
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have the problem with. Suboxone is given out— as
someone said, it's just another substitute— I'm not
doing— you know, I’m not on opioids and I'm on
suboxone. What we find out— and I've talked to the
toxicologists over at the ETSU Medical Center, and what
they tell me is, that suboxone is really a bartering drug
for many people. What that means is, is that you take the
drug of your choice, and when you need another drug, you
trade suboxone. When you're jonesing, you know, you're
coming off of it, you take that as a temporary bridge until
you can go find a man and get what you need. And the
man often is, you know, I'm waiting my twenty-eight days
out, or I'm going to go to heroin. And people say, why
would anybody go to heroin when you've got these legally,
you know, regulated drugs of certain purity, because
they're after the high. And that's why it's so hard to
combat with just another pill because they're not
rationally thinking. I mean people will take drugs that
are fifty to a hundred times more potent, like fentanyl,
which is so powerful that if a drug dog smells it, it kills
them. If you touch it and an officer touches it in a wrong
way, exposed to it, they can overdose from it.
And you say, well, why would anybody do that
when they can get it? Because they want more. And I
think suboxone is the same thing. It's like a temporary
magic bullet, but it's not a long-term solution, it's not to
their benefit in the long run. They're not getting off
drugs, they're just getting a respite from the addiction.
Now, there are clinics, there are legit clinics that treat
with suboxone and other methods, there are. But there
are a lot of them that are just making lots of money. As a
matter of fact, we convicted one pill mill in Morristown.
You all probably— Morristown is just a little further east,
if you don't know where that's at. He pled guilty and he
paid a fine, he agreed to pay a fine, seven hundred and
fifty thousand dollars as part of his plea deal. Now, when
you can crank out— voluntarily pay seven hundred and
fifty thousand dollars, does that not tell you that it's a
lucrative business for them? So that's why a lot of people
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in the suboxone and pain pill business is in it, for money.
It's a legalized drug dealer.
MR. SCHRACK: Let's thank our panelists for
coming today. At this time, I would also like to thank our
Symposium Director, Mr. Michael Deel, for putting this
together. If you all are interested in this topic, the Baker
Center across the street will be hosting Mr. Eric Eyre
tomorrow for another presentation on this. Thank you all
for coming.
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Introduction

Opioid addiction fractures entire families and
leaves children orphaned by overdoses.1 There is no
stereotypical family of an opioid addict.2 The abuse of
prescription opioids over the last two decades has grown
to epidemic proportions reaching every corner of society
while crossing gender, racial, ethnic, class, and
geographical lines. As a distraught mother who lost her
daughter to a prescribed opioid overdose observed,
“Could be you, could be me.”3 Opioid addiction is a chronic
Opioid Crisis Strains Foster System as Kids Pried from
Homes, NBC NEWS (Dec. 12, 2017, 4:53 PM),
https://www.nbcnews.com/storyline/americas-heroin-epidem
ic/opioid-crisis-strains-foster-system-kids-pried-homes-n828
831 [https://perma.cc/7ANS-P7HQ].
2 Stephano Dipietrantonio, Exclusive Interview Part I: Parents
Talk About Daughter’s Drug Overdose Death, WCHS
EYEWITNESS NEWS (Charleston, W. Va.) (Mar. 31, 2016),
http://wchstv.com/news/local/exclusive-tv-interview-part-1parents-talk-about-daughters-overdose-death
[https://per
ma.cc/FY8R-VW6M].
3 Id. (quoting Kate Grubb discussing her daughter’s tragic
overdose death). Jessie Grubb, daughter of Kate and David
Grubb, died of an overdose of Oxycodone prescribed following
surgery by a physician who failed to read her medical chart
carefully and did not realize that she was a recovering opioid
1
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disease requiring long-term treatment. Medical
specialists in addiction have observed, “Without
treatment or engagement in recovery activities, addiction
is progressive and can result in disability or premature
death.”4
Nowhere has the impact of the opioid epidemic
been clearer than in West Virginia.5 According to the
Center for Disease Control and Prevention, West
Virginia had the highest percentage of drug overdose
deaths in 2016.6 Adults aged twenty-five to fifty-four had
the highest percentage of drug overdose deaths,7 which
in many cases likely left children deprived of a parent.
According to the Secretary of the West Virginia
Department of Health and Human Resources, eightythree percent of the children in foster care placed in West
addict. Her parents were instrumental in the introduction of a
bill entitled “Jessie’s Law,” which would require prominent
display of opioid addiction history in a patient’s medical
records. Id.; see also Jessie’s Law, S. 581, 115th Cong. (2017)
(as passed by Senate and referred to H. Subcomm. on Health,
Aug. 11, 2017).
4 Am. Soc’y of Addiction Med., Treating Opioid Addiction as a
Chronic Disease, https://www.asam.org/docs/default-source/
advocacy/cmm-fact-sheet---11-07-14.pdf [https://perma.cc/Z82
6-6F5K].
5 Eric Eyre, an investigative reporter for The Charleston
Gazette-Mail, was awarded a Pulitzer Prize for investigative
journalism. The 2017 Pulitzer Prize Winner in Investigative
Reporting: Eric Eyre, of Charleston Gazette-Mail, Charleston,
WV, THE PULITZER PRIZES, http://www.pulitzer.org/winners/
eric-eyre [https://perma.cc/ CS49-AQ9R]. Eyre exposed to the
public for the first time the enormous flood of hundreds of
millions of doses of prescription opioids flowing into small
towns in rural West Virginia.
6 Holly Hedegaard et al., Drug Overdose Deaths in the United
States, 1999–2016, NCHS DATA BRIEF, No. 294 (Dec. 2017),
https://www.cdc.gov/nchs/data/databriefs/db294.pdf
[https://
perma.cc/Q2WD-ECQH].
7 Id.
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Virginia are there because of drug problems within the
family.8 These adverse experiences increase the
children’s risks of substance abuse and have an enormous
impact on their development.9 In addition to exposure to
Eric Eyre, Opioid Epidemic Costs WV $8.8 Billion Annually,
Study Says, The Charleston Gazette-Mail (Feb. 6, 2018),
https:// www.wvgazettemail.com/news/health/opioid-epidemiccosts-wv-billion-annually-study-says/article_1cd8aaa5-78eb5fd5-8619-3a0a1c086e66.html [https://perma.cc/5AHF-RY3E].
West Virginia is not the only state where children whose
parents suffer from opioid addiction have flooded foster care.
An eight percent increase in foster children occurred in the
United States from 2011 to 2015:
In 14 states, from New Hampshire to North
Dakota, the number of foster kids rose by more
than a quarter between 2011 and 2015,
according to data amassed by the Annie E.
Casey Foundation. In Texas, Florida, Oregon,
and elsewhere, kids have been forced to sleep
in state buildings because there were no foster
homes available, says advocacy group
Children’s Rights. Federal child welfare money
has been dwindling for years, leaving state and
local funding to fill in the gaps.
Julia Lurie, Children of the Opioid Epidemic Are Flooding
Foster Homes. America Is Turning a Blind Eye, MOTHER JONES
(July/Aug.
2017),
https://www.motherjones.com/politics/
2017/07/children-ohio-opioid-epidemic/ [https://perma.cc/QW
J5-7EL4]. Some children are more fortunate than others to
have grandparents who are willing and able to step in. See, e.g.,
Brenda Breslauer & Hannah Rappleye, Opioid Crisis Forces
Grandparents to Raise Their Kids, NBC NEWS (Oct. 20, 2017,
5:01
AM),
https://www.nbcnews.com/storyline/americasheroin-epidemic/opioid-crisis-forces-grand parents-raise-theirgrandkids-n808991 [https://perma.cc/G9TB-PGV8].
9 The 2016 Report of the Surgeon General has recognized,
The experiences a person has early in
childhood and in adolescence can set the stage
for future substance use and, sometimes,
escalation to a substance use disorder or
addiction. Early life stressors can include
8
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substance abuse, the Center for Disease Control
recognizes other childhood experiences that may
adversely impact child and adolescent development: (1)
emotional abuse, (2) physical abuse, (3) incarceration of
a household member, (4) emotional neglect, (5) physical
neglect, (6) divorced or separated parents, (7) domestic
violence, (8) depression or mental illness of a family
household member, and (9) sexual abuse.10
Because of the risks associated with adverse
childhood experiences (“ACEs”), some states have
enacted statutes acknowledging the impact such
experiences have on “the development of the brain and
other major body systems.”11 Recent legislation proposed
physical, emotional, and sexual abuse; neglect;
household instability (such as parental
substance use and conflict, mental illness, or
incarceration of household members); and
poverty. Research suggests that the stress
caused by these risk factors may act on the
same stress circuits in the brain as addictive
substances, which may explain why they
increase addiction risk.
U.S. DEP’T OF HEALTH & HUMAN SERVS., FACING ADDICTION IN
AMERICA: THE SURGEON GENERAL’S REPORT ON ALCOHOL,
DRUGS,
AND
HEALTH,
at
2-21
(2016),
https://
addiction.surgeongeneral.gov/sites/default/files/surgeon-gen
erals-report.pdf [https://perma.cc/7S2C-VUH2].
10 About the CDC-Kaiser ACE Study, CTRS. FOR DISEASE
CONTROL & PREVENTION (June 14, 2016) https://www.cdc.gov/
violenceprevention/acestudy/about.html
[https://perma.cc/4NNF-2SSJ].
11 WASH. REV. CODE § 70.305.010(1) (2014). “Adverse Childhood
Experiences” are statutorily defined in Washington as follows:
(1) “Adverse childhood experiences” means the
following indicators of severe childhood
stressors and family dysfunction that, when
experienced in the first eighteen years of life
and taken together, are proven by public health
research to be powerful determinants of
physical, mental, social, and behavioral health
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in the United States House of Representatives recognized
that adverse childhood experiences can lead to opioid
abuse.12 Legislation proposed in Tennessee sought to
address “the adequacy of resources to assist children and
youth impacted by the opioid epidemic and adverse
childhood experiences.”13 An early version of a bill
recently passed by the Vermont Legislature found that
“[w]hile much is yet to be learned about the specific
across the lifespan: Child physical abuse; child
sexual abuse; child emotional abuse; child
emotional or physical neglect; alcohol or other
substance abuse in the home; mental illness,
depression, or suicidal behaviors in the home;
incarceration of a family member; witnessing
intimate partner violence; and parental divorce
or separation. Adverse childhood experiences
have been demonstrated to affect the
development of the brain and other major body
systems.
Id; see also Act of May 22, 2017, 2017 Vt. Acts & Resolves 43 §
1(1) (“Adversity in childhood has a direct impact on an
individual’s health outcomes and social functioning. The
cumulative effects of multiple adverse childhood experiences
(ACEs) have even more profound public health and societal
implications. ACEs include physical, emotional, and sexual
abuse; neglect; food and financial insecurity; living with a
person experiencing mental illness or substance use disorder, or
both; experiencing or witnessing domestic violence; and having
divorced parents or an incarcerated parent.” (emphasis
added)).
12 H.R. 3291, 115th Cong. § 2(3) (2017) (“As the number of
adverse childhood experiences increases so does the risk for . . .
opioid abuse . . . ”).
13 H.R. 2580, 110th Gen. Assemb., 2d Reg. Sess. (Tenn. 2017)
(“On or before January 15, 2019, the commissioner of mental
health and substance abuse services shall report to the health
committee of the house of representatives and the senate
health and welfare committee on the adequacy of resources to
assist children and youth impacted by the opioid epidemic and
adverse childhood experiences.”).
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developmental pathways and predictor variables of
opioid addiction, programs that reflect the needs of
people who have suffered from traumatic experiences
must be part of any comprehensive strategy to attack the
opioid epidemic.”14 A hearing of the Health, Education,
Labor, and Pensions Committee of the United States
Senate recently focused on the opioid epidemic’s impact
on children. Hearing testimony addressed infants
experiencing neonatal abstinence syndrome and children
of opioid-afflicted families now in foster care, as well as
the remedial actions that need to be taken on the federal,
state, and local levels.15
Going forward, efforts to address the opioid
epidemic must necessarily occur on numerous fronts.16
S. 261, 2017—2018 Leg. Sess. (Vt. 2017) (as introduced in
Vermont Senate, Findings deleted by amendment).
15 The Senate hearing was held in February 2018 and televised
on C-Span. The Opioid Crisis Impact on Children and
Families: Hearing Before the S. Comm. On Health, Educ.,
Labor & Pensions, 115th Cong. (2018), https://www.cspan.org/video/?440882-1/senate-hear ing-impact-opioid-crisischildren [https://perma.cc/7C9U-4GNW].
16 Courts burdened by an increased caseload as a result of the
opioid epidemic have implemented new programs. For
example, in Florida, trial courts have established “Early
Childhood Courts” in response to the increased number of
dependency court cases:
This epidemic has influenced Florida’s child
welfare system and has resulted in an
increased number of dependency court cases
throughout the state. Many trial courts have
established Early Childhood Courts for
families affected by the opioid epidemic by
offering a continuum of evidence-based
services,
including
Child–Parent
Psychotherapy—an intervention aimed at
healing trauma. According to the Florida
Department of Law Enforcement, Florida
Medical Examiners Report, in 2016, six of the
seven Florida counties with the most opioid14
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For example, family treatment drug courts have been
established throughout the United States to ensure that
parents immersed in the child welfare system because of
substance abuse issues receive treatment and are
reunified with their children.17 The responsibility of
family drug treatment courts is to address abuse and
neglect issues by treating underlying drug addictions in
collaboration with child welfare and substance abuse
professionals.18
related deaths have an Early Childhood Court
in place.
In re Certification of Need for Additional Judges, 230 So. 3d
1164, 1165 (Fla. 2017) (footnotes omitted).
On the federal level, in September of 2017, the United
States Department of Justice (“DOJ”) awarded “$58.8 million
to strengthen drug court programs and address the opioid
epidemic nationwide.” Press Release, U.S. Dep’t of Justice,
Department of Justice Awards Nearly $59 Million to Combat
Opioid Epidemic, Fund Drug Courts (Sept. 22, 2017),
https://www.justice.gov/opa/pr/department-justice-awardsnearly-59-million-combat-opioid-epidemic-fund-drug-courts
[https://perma.cc/S2PR-594F]. DOJ awarded grants to the
Supreme Court of Ohio, the Colorado Judicial Department, the
Judiciary Courts for the State of Iowa, and the New York State
Unified Court System as part of the Family Drug Court
Statewide System Reform Implementation Program with the
goal of helping these states improve the outcomes for families
in the child welfare system who are affected by the opioid
epidemic. Press Release, Dep’t of Justice, OJJDP FY 2017
Family Drug Court Statewide System Reform Implementation
(Sept. 21, 2017), https://ojp.gov/newsroom/ pressreleases/2017/
ojp-news-09212017.pdf [https://perma.cc/ A4CQ-PLJ3].
17 See generally Family Treatment Drug Courts, NAT’L CTR. ON
SUBSTANCE ABUSE & CHILD WELFARE, https://ncsacw.samhsa.
gov/resources/resources-drugcourts.aspx [https://perma.cc/7Q
MX-946M] (information on family treatment courts).
18 Elizabeth Joanne Gifford, How Does Family Treatment Court
Participation Affect Child Welfare Outcomes?, 38 CHILD ABUSE
& NEGLECT 1659 (2014) (citing BUREAU OF JUSTICE
ASSISTANCE, U.S. DEP’T OF JUSTICE, FAMILY DEPENDENCY
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However, in many states, family courts possess
limited jurisdiction,19 and collaborations with substance
abuse professionals are rare. Indeed, a family court may
have authority to order drug testing of parents where
there is credible evidence of substance abuse and also
may order a parent to undergo and complete a drug
treatment program as a condition precedent to being
allowed to regain custody of her children or to have (or
increase) visitation with her children. But, typically the
parent ordered to undergo drug treatment is left to her
own devices in seeking a treatment program and finding
TREATMENT COURTS: ADDRESSING CHILD ABUSE AND NEGLECT
CASES USING THE DRUG COURT
MODEL
(2004),
https://www.ncjrs.gov/pdffiles1/bja/206809.pdf [https://perma.
cc/P396-X838]), https://www.ncbi.nlm.nih.gov/pmc/articles/P
MC4194264/ [https://perma.cc/YN9J-ZTB4].
19 For example, the Supreme Court of Appeals of West Virginia
has recognized the limited jurisdiction of family courts in the
state:
The power of family courts to exercise
jurisdiction over various matters is narrowly
prescribed by the Legislature. “The jurisdiction
of family courts is limited to only those matters
specifically authorized by the Legislature,
while circuit courts have original and general
jurisdiction and other powers as set forth in
Article VIII, § 6 of the Constitution of West
Virginia.” Syl. pt. 5, in part, Lindsie D.L. v.
Richard W.S., 214 W.Va. 750, 591 S.E.2d 308
(2003). Accord Syl. Pt. 2, State ex rel. Silver v.
Wilkes, 213 W.Va. 692, 584 S.E.2d 548 (2003)
(“‘A family court is a court of limited
jurisdiction. A family court is a court of record
only for the purpose of exercising jurisdiction
in the matters for which the jurisdiction of the
family court is specifically authorized in this
section and in chapter forty-eight [§§ 48-1-101
et seq.] of this code.’ W. Va. Code § 51-2A-2(d)
(2001), in part.”).
Deitz v. Deitz, 659 S.E.2d 331, 339 (W. Va. 2008).
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the means to pay for it. Given these challenges, this
article focuses primarily on the evolving roles of family
law school clinics, medical-legal partnerships, and the
availability of pro bono lawyers where opioid-affected
families are entangled in cases litigated in a family court
system.
II.

Treating Opioid Addiction to Resolve
Custody Issues in Family Court Cases.
A.

Family Law School Clinics

Family law clinics are a staple of the curricula of
many American law schools, including states with the
highest rates of opioid overdose fatalities.20
For example, the West Virginia University
College of Law Child and Family Advocacy Clinic
(“CFAC”) has represented children and families in cases
involving custody, guardianship, education, and domestic
violence that are litigated in the state’s family courts. In
addition, family court judges appoint the CFAC to serve
pro bono as guardian ad litem (“GAL”) in child custody
cases.
According to the CDC, the five states with the highest rates
of death due to drug overdose in 2016 “were West Virginia (52.0
per 100,000), Ohio (39.1 per 100,000), New Hampshire (39.0
per 100,000), Pennsylvania (37.9 per 100,000) and []Kentucky
(33.5 per 100,000).” Drug Overdose Death Data, CTRS. FOR
DISEASE CONTROL & PREVENTION (Dec. 19, 2017)
https://www.cdc.gov/drugoverdose/data/statedeaths.html
[https://perma.cc/695M-V3UC]. All five of these states have law
schools that are legal partners in a medical-legal partnership:
University of Louisville Brandeis School of Law, ClevelandMarshall College of Law, Case Western Reserve University
School of Law, University of New Hampshire Law School,
University of Pittsburgh School of Law, and University of
Pennsylvania Law School. The Partnerships, NAT’L CTR. FOR
MEDICAL-LEGAL
P’SHIP,
http://medical-legalpartnership.
org/partnerships/ [https://perma.cc/8UWL-LGXC].
20
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The West Virginia Constitution was amended to
create “a unified family court system . . . to rule on family
law and related matters.”21 In addition to many other
family-related actions, family courts in West Virginia
have jurisdiction over “actions for the establishment of a
parenting plan or other allocation of custodial
responsibility or decision-making responsibility for a
child[.]”22
Article 8, section 16 of the West Virginia Constitution
provides:
There is hereby created under the general
supervisory control of the supreme court of
appeals a unified family court system in the
state of West Virginia to rule on family law and
related matters. Family courts shall have
original jurisdiction in the areas of family law
and related matters as may hereafter be
established by law. Family courts may also
have such further jurisdiction as established by
law.
W. VA. CONST. art. VIII, § 16; see also W. VA. CODE ANN. § 512A-2.
22 W. VA. CODE ANN. § 51-2A-2(a)(6). The West Virginia Code
enumerates the actions over which family courts have
jurisdiction:
(a) The family court shall exercise jurisdiction
over the following matters:
(1) All actions for divorce, annulment or
separate maintenance brought under the
provisions of article three, four or five, chapter
forty-eight of this code except as provided in
subsections (b) and (c) of this section;
(2) All actions to obtain orders of child support
brought under the provisions of articles eleven,
twelve and fourteen, chapter forty-eight of this
code;
(3) All actions to establish paternity brought
under the provisions of article twenty-four,
chapter forty-eight of this code and any
dependent claims related to such actions
regarding child support, parenting plans or
21
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other allocation of custodial responsibility or
decision-making responsibility for a child;
(4) All actions for grandparent visitation
brought under the provisions of article ten,
chapter forty-eight of this code;
(5) All actions for the interstate enforcement of
family support brought under article sixteen,
chapter forty-eight of this code and for the
interstate enforcement of child custody brought
under the provisions of article twenty of said
chapter;
(6) All actions for the establishment of a
parenting plan or other allocation of custodial
responsibility
or
decision-making
responsibility for a child, including actions
brought under the Uniform Child Custody
Jurisdiction and Enforcement Act, as provided
in article twenty, chapter forty-eight of this
code;
(7) All petitions for writs of habeas corpus
wherein the issue contested is custodial
responsibility for a child;
(8) All motions for temporary relief affecting
parenting plans or other allocation of custodial
responsibility
or
decision-making
responsibility for a child, child support, spousal
support or domestic violence;
(9) All motions for modification of an order
providing for a parenting plan or other
allocation of custodial responsibility or
decision-making responsibility for a child or for
child support or spousal support;
(10) All actions brought, including civil
contempt proceedings, to enforce an order of
spousal or child support or to enforce an order
for a parenting plan or other allocation of
custodial responsibility or decision-making
responsibility for a child;
(11) All actions brought by an obligor to contest
the enforcement of an order of support through
the withholding from income of amounts
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In approximately eighty percent of the cases
litigated by the CFAC, at least one family member, or
someone integrally involved in the case, suffers from
some form of opioid abuse, including prescription opioids,
heroin, fentanyl, or other opioid addiction. Also, many of
the children the CFAC has served as GAL have had a
parent or parents, family member, or immediate member
of the household incarcerated on drug-related charges.
The children in such family circumstances may bounce
from household to household because the parent is
unable to hold onto a job or to provide food and/or shelter
for them. These situations exemplify the types of adverse
childhood experiences that increase the likelihood

payable as support or to contest an affidavit of
accrued support, filed with the circuit clerk,
which seeks to collect an arrearage;
(12) All final hearings in domestic violence
proceedings;
(13) Petitions for a change of name, exercising
concurrent jurisdiction with the circuit court;
(14) All proceedings for payment of attorney
fees if the family court judge has jurisdiction of
the underlying action;
(15) All proceedings for property distribution
brought under article seven, chapter fortyeight of this code;
(16) All proceedings to obtain spousal support
brought under article eight, chapter forty-eight
of this code;
(17) All proceedings relating to the
appointment of guardians or curators of minor
children brought pursuant to sections three,
four and six, article ten, chapter forty-four of
this code, exercising concurrent jurisdiction
with the circuit court; and
(18) All proceedings relating to petitions for
sibling visitation.
Id. § 51-2A-2.
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children involved will eventually become addicts as
adults.
For example, in one case where the CFAC served
as GAL, all adult parties tested positive for drugs at some
point during a two-year period. The biological mother
tested positive for painkillers at the birth her child, and
the biological father tested positive for marijuana at the
initial court hearing. As a consequence of court-ordered
testing, the psychological father who had raised the child
and his fiancée were found to be opioid users. The family
court also was faced with allegations that the
psychological father sold and/or manufactured
methamphetamines. All parties had been arrested at
some point but were not currently incarcerated at the
time of the CFAC’s involvement. Further complicating
matters, the parties had also sought police intervention
against each other as a tactical strategy to gain
advantage as they sought custody of the child. In another
case where the CFAC served as GAL for a child, the
mother of the child died after overdosing on opioids.
Sadly, the father suffered from heroin addiction, and
there were allegations that an aunt was selling heroin.
At the time of the guardianship, the child was living with
grandparents.
As GAL in these cases, the CFAC helped provide
guidance to the family court as it attempted to decide
where the children would be safest and receive the best
care. However, resolving such issues does nothing to
resolve the underlying drug addiction issues that lie at
the root of a family crisis, nor does the determination of
legal issues like custody, divorce, or child abuse and
neglect address the threat drug addiction poses to the
children. The optimal solution is for children to have
physiologically and mentally healthy family members
who have been able to escape from opioid addiction.
In its representation of a parent in a custody case
where the other parent is struggling with drug addiction,
the CFAC has sought a family court order making drug
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treatment part of the relief granted. This request
envisioned court-imposed treatment as a condition to,
and an inducement for, the addicted parent to achieve
increased visitation with his/her children without
supervision. In this context, the CFAC clinic students
and staff attorneys considered what, if any, role lawyers
should play in addressing substance abuse when it is the
cause of the families’ problems.
In order to address opioid issues in family court
cases, clinic student attorneys and supervising lawyers
should
be
recognized
as
having
counseling
responsibilities beyond the representation of their clients
regarding only the immediate legal issues.23 Rule 2.1 of
the Model Rules of Professional Conduct mandates that
a lawyer representing a client “shall exercise
independent professional judgment and render candid
advice.”24 The rule further provides, “In rendering advice,
a lawyer may refer not only to law but to other
considerations such as moral, economic, social and
political factors, that may be relevant to the client’s
situation.”25
The comments to the model rule recognize that
“[f]amily matters can involve problems within the
professional competence of psychiatry, clinical
psychology or social work” and that we should consult
with persons in these professions when a “competent
lawyer” would do so.26 While lawyers do not have a “duty
Numerous articles have addressed a lawyer’s responsibilities
when a client suffers from addiction. See, e.g., Erin Sparks,
Comment, Attorney-Client Relationships: Ethical Dilemmas
with Clients Battling Addiction, 36 J. Legal Prof. 255 (2011);
Jean Marie Leslie, Understanding Addiction, Helping Clients
and Colleagues, 69 Ala. Law. 348 (Sept. 2008); Timothy David
Edwards, The Lawyer as Counselor Representing the Impaired
Client, GPSolo, Oct./Nov. 2004, at 34.
24 MODEL RULES OF PROF’L CONDUCT r. 2.1 (AM. BAR ASS’N
1983).
25 Id.
26 The Comment to Rule 2.1 observes:
23
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to initiate investigation of a client’s affairs or to give
advice that the client has indicated is unwanted, . . . a
lawyer may initiate advice to a client when doing so
appears to be in the client’s best interests.”27
Advising a client to seek treatment for opioid
addiction is clearly in the client’s best interests, though
it is acknowledged that the client may not be receptive to
such counseling. I contend that encouraging a client to
seek drug addiction treatment falls within an attorney’s
ethical responsibilities. Helping clients or other parties
in litigation gain access to needed treatment programs
and encouraging their completion of these programs is
also part of the attorney’s ethical responsibilities as a

Matters that go beyond strictly legal questions
may also be in the domain of another
profession. Family matters can involve
problems within the professional competence of
psychiatry, clinical psychology or social work;
. . . Where consultation with a professional in
another field is itself something a competent
lawyer would recommend, the lawyer should
make such a recommendation.
MODEL RULES OF PROF’L CONDUCT r. 2.1 cmt. (AM. BAR
ASS’N 1983).
27 The Comment to Rule 2.1 also instructs:
When a lawyer knows that a client proposes a
course of action that is likely to result in
substantial adverse legal consequences to the
client, the lawyer’s duty to the client under
Rule 1.4 may require that the lawyer offer
advice if the client’s course of action is related
to the representation . . . . A lawyer ordinarily
has no duty to initiate investigation of a client’s
affairs or to give advice that the client has
indicated is unwanted, but a lawyer may
initiate advice to a client when doing so
appears to be in the client’s best interests.
Id.
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counselor.28 Assuming that such counsel is an ethical
imperative, it must be recognized that the clinical
lawyer’s efforts can be exceptionally challenging without
the support provided by relationships with healthcare
partners who can assist in attaining treatment goals.
Lawyer-healthcare partner relationships must be
developed and nurtured to achieve the highest possible
likelihood of successful treatment.
B.
Using Medical-legal Partnerships to
Assist Clients in Seeking and Receiving
Treatment of Opioid Addiction.
Medical Legal Partnerships (“MLPs”) were first
established in Massachusetts in 1993 at Boston City
Hospital (now Boston Medical Center).29 The National
Center for Medical-Legal Partnership was founded in
2006 and is now housed in the Department of Health
Policy and Management at the Milken Institute School of

In helping clients seek and obtain the treatment they need
for addiction, attorneys also must comply with the provisions
of Rule 1.14 governing their responsibilities to clients with
diminished capacities. MODEL RULES OF PROF’L CONDUCT r.
1.14 (AM. BAR ASS’N 1983). Rule 1.14(b) provides that an
attorney may take “reasonably necessary protective action”
when “the lawyer reasonably believes the client has diminished
capacity.” MODEL RULES OF PROF’L CONDUCT r. 1.14(b).
Importantly, Rule 1.14(c) provides that “[w]hen taking
protective action pursuant to paragraph (b), the lawyer is
impliedly authorized under Rule 1.6(a) to reveal information
about the client, but only to the extent reasonably necessary to
protect the client’s interests.” MODEL RULES OF PROF’L
CONDUCT r. 1.14(c).
29 Ellen Cohen et al., Medical-Legal Partnership: Collaborating
with Lawyers to Identify and Address Health Disparities, 25 J.
GEN. INTERN. MED. 136 (2010).
28
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Public Health at the George Washington University.30
Currently, there are 155 hospitals, 139 health centers, 34
health schools, 126 legal aid agencies, and 52 law schools
and pro bono partners operating MLPs to address
patients’ health-related social needs.31
The development of MLPs was based on the
recognition that many patients suffering from illness also
face social and legal dilemmas that often impact their
recovery. In MLPs, healthcare professionals and lawyers
work together as an integrative team to treat patients
medically and to meet their legal needs.32 “Patients are
often able to receive legal assistance in areas such as
addressing personal safety from exposure to domestic
violence, gaining access to entitled benefits such as food
subsidies, disability benefits, or necessary educational
services, and repairing poor housing conditions through
MLP services.”33
As an example of such collaborations, the CFAC
has entered into a medical-legal partnership with two
healthcare providers: Chestnut Ridge Center (“Chestnut
Ridge”), a West Virginia University Medicine psychiatric
facility, and with West Virginia University Medicine

About the National Center, NAT’L CTR. FOR MEDICAL-LEGAL
P’SHIP, http://medical-legalpartnership.org/about-us/ [https://
perma.cc/ 22AF-RV5Z].
31 The Partnerships, NAT’L CTR. FOR MEDICAL-LEGAL P’SHIP,
http://medical-legalpartnership.org/partnerships/
[https://perma.cc/8UWL-LGXC].
32 Cohen et al., supra note 29, at 136 (“Medical-legal
partnerships (MLPs) bring together medical professionals and
lawyers to address social causes of health disparities, including
access to adequate food, housing and income.”).
33 TIRSHA BEESON ET AL., NAT’L CTR. FOR MEDICAL-LEGAL
P’SHIP, MAKING THE CASE FOR MEDICAL-LEGAL PARTNERSHIPS:
A REVIEW OF THE EVIDENCE (2013), http://www.medicallegalpartnership.org/wp-content/uploads/2014/03/MedicalLegal-Partnership-Literature-Review-February-2013.pdf
[https://perma.cc/42BB-EBK3].
30
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Pediatrics (“WVU Pediatrics”).34 The CFAC’s MLP with
Chestnut Ridge and WVU Pediatrics allows these
healthcare providers to refer patients to the family
advocacy clinic when the stress of legal problems poses a
threat to the patients’ healing process.
Medical-legal partnerships, like the one CFAC
has established at West Virginia University, present one
way to assist clients in seeking and obtaining needed
treatment for opioid addiction.35 This partnership allows
the CFAC to work with healthcare providers in
developing a strategy for referring family law clients to
addiction treatment programs. The goal, of course, is to
facilitate clinic clients in confronting and overcoming the
addiction issues that adversely affect their relationships
with their familial relationships and entangle them in
legal problems, like child custody and divorce.36
According to key findings set forth in the Surgeon
General’s 2016 report on addiction, only one in ten people
Partners Across the U.S.: West Virginia, NAT’L CTR. FOR
MED.-LEGAL PARTNERSHIP, http://medical-legalpartnership.
org/partnerships/?fwp_states=west-virginia [https://perma.cc/
8JC7-RBRM].
35 For more information on Medical-Legal Partnerships, see
Brief: How Medical-Legal Partnership Services Can Help
Address the Opioid Crisis, NAT’L CTR. FOR MEDICAL-LEGAL
P’SHIP,
http://medical-legalpartnership.org/mlp-resources/
opioid-crisis-brief/
[https://perma.cc/HSM2-XDQR].
The
National Center for Medical-Legal Partnership hosted a
federal round table in the fall of 2017 to discuss the opioid
epidemic and the role MLPs can play in helping those afflicted.
See National Center Convened Federal Agency Roundtable on
the Opioid Crisis, NAT’L CTR. FOR MEDICAL-LEGAL P’SHIP (Sept.
27, 2017), http://medical-legalpartnership.org/opioid-round
table/ [https://perma.cc/GZ4E-BPSN].
36 JAY CHAUDHARY ET AL., NAT’L CTR. FOR MEDICAL-LEGAL
P’SHIP, THE OPIOID CRISIS IN AMERICA & THE ROLE MEDICALLEGAL PARTNERSHIP CAN PLAY IN RECOVERY (2018),
http://medical-legalpartnership.org/wp-content/uploads/2018/
02/MLP-and-the-Opioid-Crisis.pdf
[https://perma.cc/3TVNPM3V].
34
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suffering from a drug use disorder obtain specialty
treatment.37 Moreover, a study funded by the National
Institute on Alcohol Abuse and Alcoholism (“NIAAA”), an
arm of the National Institutes of Health, reported that
seventy-five percent of adults in the United States
suffering from a drug use disorder never receive
treatment.38 The low rate of treatment is attributed to
diverse causes such as the “inability to access or afford
care, fear of shame and discrimination, and lack of
screening for substance misuse and substance use
disorders in general health care settings.”39 Moreover,
many who suffer from drug addiction are not able to
realize they need treatment or they otherwise reject
treatment.40
Simply referring clients to a treatment programs
will not solve their addiction issues— clients will have to
affirmatively desire help and be able to summon the
U.S. DEP’T OF HEALTH & HUMAN SERVS., supra note 9, at 42. Of those who did not receive treatment but needed it, “over
7 million were women and more than 1 million were
adolescents aged 12 to 17.” Id. at 4-8 (citing CTR. FOR
BEHAVIORAL HEALTH STATISTICS & QUALITY, SUBSTANCE
AUBSE & MENTAL HEALTH SERVS. ADMIN., Results from the 2015
National Survey on Drug Use and Health: Detailed Tables,
(2016), https://www.samhsa.gov/data/sites/default/files/NSD
UH-DetTabs-2015/NSDUH-DetTabs-2015/NSDUH-DetTabs2015. pdf [https://perma.cc/JH2V-U9X9]).
38 10 Percent of US Adults Have Drug Use Disorder at Some
Point in Their Lives: 75 Percent Report Not Receiving Any Form
of Treatment, NAT’L INST. OF HEALTH (Nov. 18, 2015),
https://www.nih.gov/news-events/news-releases/10-percentus-adults-have-drug-use-disorder-some-point-their-lives
[https://perma.cc/2P7V-ZHT4].
39Executive Summary of the Surgeon General’s Report on
Alcohol, Drugs and Health, SURGEON GEN., https://addiction.
surgeongeneral.gov/executive-summary
[https://perma.cc/99HC-M5D6].
40 U.S. DEP’T OF HEALTH & HUMAN SERVS., supra note 9, at 49.
37

[396]
136

DEFINING THE ROLE
13 TENN. J.L. & POL’Y 377 (2018)

willpower to endure the long process of treatment leading
to recovery. Some clients may prefer seeking medication
at Suboxone clinics where treatment drugs are provided
but counseling is not.41
In criminal drug courts, addicts charged with
crimes face jail time if they do not complete their courtmandated treatment program. In family treatment
courts, addicted parents often face termination of their
parental rights in abuse and neglect cases if they fail to
finish the treatment program.42 In family court
proceedings, jail time or termination of parental rights is
beyond the family court’s jurisdiction if an addicted party
fails to participate in a substance abuse treatment
program. Instead, the addicts face loss of their role as the
primary custodian of their children or are limited to
supervised visitation. Such sanctions may not provide a
sufficient incentive for them to persevere to completion of
the difficult process of treatment and recovery. But, in
cases where the parents have a strong desire to have
their children living with them, rather than with a
grandparent, other family member, or in foster care,
completing treatment and escaping addiction may be a
powerful incentive that will help heal the family.
Effective treatment requires an active recovery
program that includes behavioral and cognitive changes.
For example, Chestnut Ridge, the CFAC’s medical-legal
partner, has developed a program called the
Comprehensive Opioid Addiction Treatment (“COAT”)
Stand-alone Suboxone clinics have emerged as a new
business to address opioid addiction. In Ohio, where standalone Suboxone clinics are allowed to accept cash only, there is
a growing concern that these clinics will simply become the
next “pill mills.” Marty Schladen & Rita Price, Cash-Only
Suboxone Clinics Fuel Fears of New “Pill Mills”, COLUMBUS
DISPATCH (Oct. 8, 2017, 5:55 AM), http://www.dispatch.
com/news/20171008/cash-only-suboxone-clinics-fuel-fears-ofnew-pill-mills/1 [https://perma.cc/QW64-GV92].
42 See discussion of family treatment courts, supra pp. 4–6.
41
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program.43 This is not a treatment program individual
addicts can complete in a few weeks. COAT is a long-term
treatment procedure comprised of stages during which
the addicted patient is prescribed Suboxone to manage
his or her withdrawal from opioids.44 Of course, it is
important to understand that no single treatment
program will fit every person struggling with addiction.45
Treating opioid addiction should begin with a
healthcare professional’s assessment and diagnosis.46
This clinical assessment may be based on several
different models, such as the Addiction Severity Index

Behavioral Medicine and Psychiatry: Outpatient Programs,
WVU MED., http://wvumedicine.org/ruby-memorial-hospital/
services/wvu-specialty-clinics/behavioral-and-mental-health/
chestnut-ridge-center/adult-addiction-services/comprehensiveopioid-addiction-treatment-coat/ [https://perma.cc/E39P-LCH
Q].
44 Treatment professionals debate how to properly use
Suboxone as an effective treatment for opioid addiction. When
it was first introduced, Suboxone was intended to be used only
during initial detoxification. However, the more prevalent
treatment process currently followed is to use Suboxone as
long-term maintenance to suppress an addict’s opioid cravings.
NAT’L INST. ON DRUG ABUSE, SHORT-TERM OPIOID WITHDRAWAL
USING BUPRENORPHINE: FINDINGS AND STRATEGIES FROM A
NIDA CLINICAL TRIALS NETWORK (CTN) STUDY, https://www.
drugabuse.gov/sites/default/files/files/BupDetox_Factsheet.pdf
[https://perma.cc/3TF7-R2LC].
45 U.S. DEP’T OF HEALTH & HUMAN SERVS., supra note 9, at 414.
46 Id. at 4-15.
43
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(“ASI”),47 the Substance Abuse Model (“SAM”),48 the
Global Appraisal of Individual Needs (“GAIN”),49 and the
Psychiatric Research Interview for Substance and
Mental Disorders (“PRISM”).50 The Surgeon General’s
report recommends that a diagnosis of drug abuse be
based on eleven symptoms of substance abuse disorder
that are defined in the Fifth Edition of the Diagnostic and
“The Addiction Severity Index (ASI) is a structured interview
widely used by substance abuse clinicians and researchers for
client screening, determining treatment needs, and assessing
treatment outcomes.” Bertrym E. Stoffelmayr, Brian E. Mavis
& Rafa M. Kasim, The Longitudinal Stability of the Addiction
Severity Index, 11 J. SUBSTANCE ABUSE TREATMENT 373, 373
(1994). The ASI “[a]ddresses seven potential problem areas in
substance using individuals: medical status, employment and
support, drug use, alcohol use, legal status, family/social
status, and psychiatric status.” U.S. DEP’T OF HEALTH &
HUMAN SERVS., supra note 9, at 4-16.
48 SAM is “[d]esigned to assess mental disorders as defined by
the Diagnositic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV).” Id. SAM “[i]ncludes questions about
when symptoms began and how recent they are, withdrawal
symptoms, and the physical, social and psychological
consequences of each substance assessed.” Id.
49 GAIN is a “[s]eries of measures (screener, standardized
biopsychosocial intake assessment battery, follow-up
assessment battery) which integrate research and clinical
assessment.” Id. GAIN “[c]ontains 99 scales and subscales, that
are designed to measure the recency, breadth, and frequency
of problems and service utilization related to substance use
(including diagnosis and course, treatment motivation, and
relapse
potential),
physical
health,
risk/protective
involvement, mental health, environment and vocational
situation.” Id.
50PRISM
is a “[s]emi-structured, clinician-administered
interview” that “[m]easures the major DSM-IV diagnoses of
alcohol, drug, and psychiatric disorders” and “[p]rovides clear
guidelines for differentiating between the effects of
intoxication and withdrawal, substance-induced disorders, and
primary disorders.” Id.
47
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Statistical Manual of Mental Disorders (DSM-5).51
Patients may also be assessed in the context of their
“family environment.”52
Once a healthcare provider has completed an
assessment and diagnosis, an individualized treatment
plan should be developed taking into consideration the
person’s specific needs, strengths, weaknesses, financial
resources, family support, and other physical or mental
health issues.53 The individualized treatment program
should also have measures in place to engage and to
motivate the patient to remain in the program.54
Id. at 4-15.
Laura Lander, Janie Howsare & Marilyn Byrne, The Impact
of Substance Use Disorders on Families and Children: From
Theory to Practice, 28 SOC. WORK PUB. HEALTH 194, 195–205
(2013) (“Treating the individual without family involvement
may limit the effectiveness of treatment for two main reasons:
it ignores the devastating impact of [substance use disorders]
on the family system leaving family members untreated, and it
does not recognize the family as a potential system of support
for change.”).
53 U.S. DEP’T HEALTH & HUMAN SERVS., supra note 9, at 4-16.
54 The 2016 Surgeon General’s report observed:
A typical progression for someone who
has a severe substance use disorder might start
with 3 to 7 days in a medically managed
withdrawal program, followed by a 1- to 3month period of intensive rehabilitative care in
a residential treatment program, followed by
continuing care, first in an intensive outpatient
program (2 to 5 days per week for a few
months) and later in a traditional outpatient
program that meets 1 to 2 times per month. For
many patients whose current living situations
are not conducive to recovery, outpatient
services should be provided in conjunction with
recovery-supportive housing.
In general, patients with serious
substance use disorders are recommended to
stay engaged for at least 1 year in the
51
52
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Treatment may include inpatient care, residential care
outside a hospital setting, “partial hospitalization and
intensive outpatient care,” and “outpatient services.”55
Where appropriate, in order to increase the effectiveness
of treatment, the patient’s family should be involved
because it can provide “a potential system of support for
change.”56
Treatment programs may involve medication and
behavioral therapies.57 FDA approved medications might

treatment process, which may involve
participation in three to four different
programs or services at reduced levels of
intensity, all of which are ideally designed to
help the patient prepare for continued selfmanagement after treatment ends. This
expected trajectory of care explains why efforts
to
maintain
patient
motivation
and
engagement are important.
Id. at 4-18.
55 Id.
56 Laura Lander, Janie Howsare & Marilyn Byrne, The Impact
of Substance Use Disorders on Families and Children: From
Theory to Practice, 28 SOC. WORK PUB. HEALTH 194, 195 (2013)
(“Treating the individual without family involvement may
limit the effectiveness of treatment for two main reasons: it
ignores the devastating impact of [substance use disorders] on
the family system leaving family members untreated, and it
does not recognize the family as a potential system of support
for change.”).
57 U.S. DEP’T HEALTH & HUMAN SERVS., supra note 9, at 4-19 to
-31.
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include buprenorphine,58 methadone,59 or extendedrelease naltrexone60 in treatment programs.61 Suboxone
and Vivitrol are two frequently prescribed medications
for treatment of opioid addiction. Suboxone, taken daily,
contains buprenorphine hydrochloride and naloxone
hydrochloride,62 while Vivitrol is delivered by an injection
of naltrexone lasting twenty-eight days. Recent studies
have found, once started, both medications are equally
effective treatments for preventing relapse.63 Forty-three
Following the introduction of buprenorphine, the number of
opioid treatment programs “offering buprenorphine increased
from 11 percent [of OTPs] in 2003 [(121 OTPs)] to 58 percent
[of OTPs] in 2015 [(779 OTPs)].” Cathie E. Alderks, Trends in
the Use of Methadone, Buphrenorphine, and Extended-Release
Naltrexone at Substance Abuse Treatment Facilities: 2003-2015
(Update), SAMHSA: CBHSQ REP. (Substance Abuse & Mental
Health Serv. Admin., Rockville, Md.) Aug. 22, 2017,
https://www.samhsa.gov/data/sites/default/files/report_3192/
ShortReport-3192.pdf [https://perma.cc/7FD7-AN67]. Only
about five percent of non-OTP facilities offered buprenorphine
treatment in 2003; however, that number grew to twenty-one
percent (2625 facilities) by 2015. Id.
59 The Substance Abuse and Mental Health Services
Administration has found that the number of patients who
receive methadone treatment has “steadily increased from
about 227,000 in 2003 to 356,843 in 2015” and “accounted for
approximately 21 to 25 percent of all substance abuse
treatment clients each year.” Id.
60 “In 2013, 359 clients in facilities with OTPs and 3,422 clients
in facilities without OTPs received extended-release, injectable
naltrexone services, and in 2015, a total of 712 clients in
facilities with OTPs and 6,323 clients in facilities without
OTPs received these services.” Id.
61 Spencer Bujarski et al., Prevalence, Causes, and Treatment
of Substance Use Disorders, Judges J., Winter 2018, at 10, 14.
62 Buprenorphine is an opioid that treats withdrawal
symptoms, while naloxone is an opioid antagonist used to
reverse opioid overdose. Id.
63 See Joshua D. Lee et al., Comparative Effectiveness of
Extended-Release Naltrexone Versus Buprenorphine-Naloxone
58
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states limit daily total milligram dosages of
buprenorphine and buprenorphine/naloxone combination
drugs,64 while seven do not.65
Opioid treatment plans should be expected to
include behavioral therapies that may involve only the
individual; other plans may include family or group
sessions.66 Therapies such as Cognitive Behavioral

For Opioid Relapse Prevention (X:BOT): A Multicentre, OpenLabel, Randomised Controlled Trial, 391 THE LANCET 309, 317
(2018); Lars Tatum et al., Effectiveness of Injectable ExtendedRelease Naltrexone vs. Daily Buprenorphine-Naloxone for
Opioid Dependence: A Randomized Clinical Noninferiority
Trial, 74 JAMA PSYCHIATRY 1197 (2017).
64 The following states have limits in place: AK, AL, AR, CA,
CO, CT, DC, DE, FL, GA, IA, ID, IL, IN, KS, KY, LA, MA, MD,
ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NV, NY, OH,
OK, PA, TN, TX, UT, VA, VT, WA, WV, WY.CTR. FOR MEDICAID
& CHIP SERVS., MEDICAID DRUG UTILIZATION REVIEW STATE
COMPARISON/SUMMARY REPORT FFY 2016 ANNUAL REPORT:
PRESCRIPTION DRUG FEE FOR SERVICE PROGRAMS 49 (2017),
https://www.medicaid.gov/medicaid-chip-programinformation/by-topics/prescription-drugs/downloads/2016-dursummary-report.pdf [https://perma.cc/MM7V-BX2C].
65 The following seven states do not have these limits: HI, NM,
OR, RI, SC, SD, WI. Id.
66 U.S. DEP’T HEALTH & HUMAN SERVS., supra note 9, at 4-26.
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Therapy (“CBT”),67 Contingency Management (“CM”),68
Community
Reinforcement
Approach
(“CRA”),69
The Surgeon General’s 2016 report explained CBT as follows:
The theoretical foundation for CognitiveBehavioral Therapy (CBT) is that substance
use disorders develop, in part, as a result of
maladaptive
behavior
patterns
and
dysfunctional thoughts. CBT treatments thus
involve techniques to modify such behaviors
and improve coping skills by emphasizing the
identification and modification of dysfunctional
thinking. CBT is a short-term approach,
usually involving 12 to 24 weekly individual
sessions. These sessions typically explore the
positive and negative consequences of
substance use, and they use self-monitoring as
a mechanism to recognize cravings and other
situations that may lead the individual to
relapse. They also help the individual develop
coping strategies.
Id. (citing H.D. KLEBER ET AL., PRACTICE GUIDELINE FOR THE
TREATMENT OF PATIENTS WITH SUBSTANCE USE DISORDERS 42
(2006)).
68 Contingency Management involves awarding tangible items
to patients to reinforce positive behavioral changes. Id. at 4-27
(citing NAT’L INST. ON DRUG ABUSE, PRINCIPLES OF DRUG
ADDICTION TREATMENT: A RESEARCH-BASED GUIDE (3d ed.
2012)) (“In this therapy, patients receive a voucher with
monetary value that can be exchanged for food items, healthy
recreational options (e.g., movies), or other sought-after goods
or services when they exhibit desired behavior such as drugfree urine tests or participation in treatment activities.”).
69 The Surgeon General 2016 report explained CRA as follows:
Community Reinforcement Approach (CRA)
Plus Vouchers is an intensive 24-week
outpatient program that uses incentives and
reinforcers to reward individuals who reduce
their substance use. Individuals are required to
attend one to two counseling sessions each
week that emphasize improving relations,
acquiring skills to minimize substance use, and
67
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Motivational Enhancement Therapy (“MET”),70 the
Matrix Model,71 Twelve-Step Facilitation therapy
(“TSF”),72 and family therapies may be employed
reconstructing social activities and networks to
support recovery. Individuals receiving this
treatment are eligible to receive vouchers with
monetary value if they provide drug-free urine
tests several times per week.
Id. at 4-27 (endnotes omitted) (citing NAT’L INST. ON DRUG
ABUSE, supra note 68).
70 This counseling approach “uses motivational interviewing
techniques to help individuals resolve any uncertainties they
have about stopping their substance use. MET works by
promoting empathy, developing patient awareness of the
discrepancy between their goals and their unhealthy behavior,
avoiding argument and confrontation, addressing resistance,
and supporting self-efficacy to encourage motivation and
change.” Id. at 4-28 (endnote omitted) (citing CTR. FOR
SUBSTANCE ABUSE TREATMENT, TREATMENT IMPROVEMENT
PROTOCOL SER. 35, ENHANCING MOTIVATION FOR CHANGE IN
SUBSTANCE ABUSE TREATMENT, ch. 3 (1999)).
71 The surgeon general’s 2016 report explained the Matrix
Model:
The Matrix Model is a structured, multicomponent behavioral treatment that consists
of evidence-based practices, including relapse
prevention, family therapy, group therapy,
drug education, and self-help, delivered in a
sequential and clinically coordinated manner.
The model consists of 16 weeks of group
sessions held three times per week, which
combine CBT, family education, social support,
individual counseling, and urine drug testing.
Id. (endnote omitted) (citing NAT’L INST. ON DRUG ABUSE, supra
note 68).
72 TSF is “an individual therapy typically delivered in 12
weekly sessions” and “designed to prepare individuals to
understand, accept, and become engaged in . . . Narcotics
Anonymous (NA), or similar 12-step programs.” Id. (citing
Kimberly S. Walitzer et al., Facilitating Involvement in
Alcoholics Anonymous During Outpatient Treatment: A
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depending upon the individual and the severity and
duration of the addiction.73
The Substance Abuse and Mental Health Services
Administration (“SAMHSA”) is “the agency within the
U.S. Department of Health and Human Services that
leads public health efforts to advance the behavioral
health of the nation” in order “to reduce the impact of
substance abuse and mental illness on America’s
communities.”74 The number of opioid treatment
programs regulated by SAMHSA “increased from
approximately 1,100 in 2003 to almost 1,500 by the end
of 2016.”75 SAMHSA has compiled a National Directory
of Drug and Alcohol Abuse Facilities that contains
information on “federal, state, and local government
facilities and private facilities that provide substance
abuse treatment services,” including “codes that
represent the services offered” by each facility listed.76
Randomized Clinical Trial, 104 ADDICTION 391 (2009); L.A.
Kaskutas et al., Effectiveness of Making Alcoholics Anonymous
Easier: A Group Format 12-Step Facilitation Approach, 37 J.
SUBSTANCE ABUSE TREATMENT 228 (2009)).
73 Family therapies include family behavior therapy (“FBT”),
which “is a therapeutic approach used for both adolescents and
adults that addresses not only substance use but other issues
the family may also be experiencing, such as mental disorders
and family conflict. FBT includes up to 20 treatment sessions
that focus on developing skills and setting behavioral goals.”
Id. at 4-30 (endnote omitted) (citing NAT’L INST. ON DRUG
ABUSE, supra note 68).
74 About Us, SUBSTANCE ABUSE AND MENTAL HEALTH SERVICE
ADMINISTRATION, https://www.samhsa.gov/about-us [https://
perma.cc/DLG3-KUWR].
75 Alderks, supra note 58.
76 SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN.,
BEHAVIORAL HEALTH SERVICES INFORMATION SERIES:
NATIONAL DIRECTORY OF DRUG AND ALCOHOL ABUSE
TREATMENT FACILITIES 2017, at iv (2017), https://
www.samhsa.gov/data/sites/default/files/2017%20SA%20Direc
tory.pdf [https://perma.cc/2U4Y-4SLV].
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SAMHSA also tracks the number of state admissions of
patients for opioid treatment.77
For example, in 2011 in West Virginia, SAMHSA
reported that 1,294 male and female patients over the
age of twelve were admitted for treatment for opioid
abuse.78 Of those West Virginia patients admitted for
opioid abuse, ninety-nine percent were white, and eightynine percent were between the ages of twenty to fortyfour.79
Obviously, before referring their clients to any
treatment program, clinical law students and their
supervising attorneys should know the applicable law as
well as the rules, regulations, and requirements of each
program. They also should identify and be aware of the
recovery services each program provides as well as
program treatment success and failure rates. In addition
to connecting their clients with treatment programs
Treatment Episode Data Set, SUBSTANCE ABUSE AND MENTAL
HEALTH SERVICE ADMINISTRATION, CLIENT LEVEL DATA /
TREATMENT EPISODE DATA SET, https://www.samhsa.gov/data/
data-we-collect/teds-treatment-episode-data-set
[https://per
ma.cc/ASZ6-K6DB].
78 SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN.,
TREATMENT EPISODE DATA SET (TEDS) 2001–2011: STATE
ADMISSIONS TO SUBSTANCE ABUSE TREATMENT SERVICES 134
(2013), https://www.samhsa.gov/ data/sites/default/files/TE
DS2011St_Web/TEDS2011St_Web/TEDS2011St_Web.pdf
[https://perma.cc/Y6VZ-ARMX]. This number includes 158
patients admitted for treatment of heroin addiction and 1,136
for treatment for “other opiates.” Id. It is noteworthy that the
total number of admissions for treatment for opioid abuse in
Tennessee was more than triple of the admissions in West
Virginia. In Tennessee, a total of 4,121 patients over the age of
twelve were admitted for treatment of opioids in 2011, the
substantial majority of which were white. Id. at 128.
79 Id. The exclusive treatment of white people by West Virginia
is problematic. It strongly suggests a need to analyze
treatment programs to determine if barriers to access exist,
and if they exist, whether they may be rooted in racial
discrimination, poverty, racial preference or other factors.
77
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through an MLP, the clinic’s supervising attorneys, law
students, and staff also should be able to connect clients
to community recovery support services that provide
ongoing support during and after treatment. The
students and their supervisors may consider obtaining a
medical release from the client to enable them to consult
with healthcare providers and to receive treatment
updates that would allow them to support the client
through the treatment and recovery process.
Opioid treatment programs work when the
patients recognize they have a substance abuse problem
and desire to overcome their addiction. For example, one
CFAC client became addicted to prescription pain
medication after she was injured in a car accident. As
part of her treatment after the accident, the doctor
prescribed pain medication as part of her treatment. She
subsequently recognized that she had developed an
opioid dependence and sought treatment for the sake of
her children. She completed her treatment plan and
continues to attend counseling sessions. She also
continues to take Suboxone and will be medically
evaluated to determine whether and when she should
taper off of the drug.80
Thus, beyond their role of advising on legal
strategy and litigating on behalf of their clients, law
school clinics with established MLPs should work with
their healthcare partners to ensure that— if available—
their clients will have access to treatment and will have

As noted earlier, healthcare professionals debate whether
recovering opioid addicts will need to take medications like
Suboxone for life. Suboxone was originally proposed for shortterm use during the detoxification process. See NAT’L INST. ON
DRUG ABUSE, supra note 44. However, Suboxone is also
regarded as an opioid treatment with a “dark side” because of
the health complications it can cause and because it is subject
to abuse like other drugs. Deborah Sontag, Addiction
Treatment With a Dark Side, N.Y. TIMES, Nov. 17, 2013, at A1.
80
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support to complete the program and the recovery
process.
C.
Helping Clients and Other Party
Litigants Cover the Cost of Treatment
Beyond these challenges of supporting addicted
clients in seeking and obtaining treatment, the client will
need assistance in identifying sources of financing
treatment. Treatment costs vary based on a number of
factors, but likely are expensive. Law school clinics like
the CFAC represent clients who, because of their socioeconomic status, cannot afford to pay attorney fees; the
financial ability to pay for addiction treatment programs
is likely well beyond their reach.
Like the CFAC clients, the great majority of law
school clinic clients probably have no private health
insurance. Indeed, one study reported that in 2015
almost “441,000 non-elderly adults with opioid addiction
were uninsured.”81 That number likely understates the
level of non-elderly uninsured opioid addicted patients.
The medications used for treating opioid addiction
alone are costly. For example, the United States
Department of Defense estimated that a patient
receiving treatment in a certified opioid treatment

Julia Zur, 6 Things to Know About Uninsured Adults with
Opioid Addiction, KAISER FAMILY FOUND., https://www.kff.org/
uninsured/fact-sheet/6-things-to-know-about-uninsuredadults-with-opioid-addiction/ [https://perma.cc/7T6H-AXMX].
81
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program82 using buprenorphine83 and requiring twiceweekly visits could incur costs of “$115 per week or $5980
per year.”84 Patients receiving treatment in a certified
opioid treatment program using naltrexone and receiving
related services could incur costs of “$1,176.50 per month
or $14,112.00 per year.”85
State Medicaid programs have and hopefully will
continue to play a key role in supporting opioid addiction
treatment for those who cannot afford it.86 The most
recent data from the Agency for Healthcare Research and
Quality indicates that Medicaid expansion under the
Affordable Care Act (“ACA”) significantly increased

Certification of opioid treatment programs is governed by
federal regulations. 42 C.F.R. § 8.1 (2016). Certified opioid
treatment programs are overseen by SAMHSA’s Division of
Pharmacologic Therapies. See generally Certification of Opioid
Treatment Programs (OTPs), SUBSTANCE ABUSE & MENTAL
HEALTH SERVS. ADMIN., https://www.samhsa.gov/medicationassisted-treatment/opioid-treatment-programs
[https://perma.cc/TX2M-EDUX].
83 Over a billion dollars’ worth of Suboxone are sold annually.
In re Suboxone (Buprenorphine Hydrochloride and Naloxone)
Antitrust Litig., 64 F. Supp. 2d 665, 673 (E.D. Pa. 2014).
84 How Much Does Opioid Treatment Cost?, NAT’L INST. ON
DRUG
ABUSE,
https://www.drugabuse.gov/publications/
research-reports/medications-to-treat-opioid-addiction/howmuch-does-opioid-treatment-cost
[https://perma.cc/86GS6QX5] (citing TRICARE, Mental Health and Substance Use
Disorder Treatment, 81 Fed. Reg. 61,068 (Sept. 2, 2016)
(codified at 32 C.F.R. pt. 199), https://www.federalregister.gov/
documents/2016/09/02/2016-21125/tricare-mental-health-andsubstance-use-disorder-treatment
[https://perma.cc/4TQ84YDX]).
85 Id.
86 Medicaid’s Role in Addressing the Opioid Epidemic, KAISER
FAMILY FOUND., https://www.kff.org/infographic/medicaidsrole-in-addressing-opioid-epidemic/
[https://perma.cc/HZ9PFRK9].
82
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access to and coverage for opioid treatment.87 Medicaid
expansion under the ACA now provides coverage for
adults in some states who are suffering from opioid
addiction that were not eligible for treatment under the
previous state programs.88 According to data collected by
the Kaiser Family Foundation, Medicaid covers four in
ten “nonelderly adults with opioid addiction.”89
Under the expansion in West Virginia,90 Medicaid
will cover inpatient or detox treatment, partial
hospitalization, care coordination and case management,
and prescription drugs like Suboxone.91 Starting in
January of 2018, Medicaid expansion in West Virginia
included “a new screening tool to identify treatment
Matt Broaddus, Peggy Bailey, & Aviva Aron-Dine, Medicaid
Expansion Dramatically Increased Coverage for People with
Opioid-Use Disorders, Latest Data Show, CTR. ON BUDGET &
POLICY PRIORITIES, https://www.cbpp.org/research/health/
medicaid-expansion-dramatically-increased-coverage-forpeople-with-opioid-use [https://perma.cc/RG5X-BGMB].
88 Id.
89 Zur, supra note 81. The report recognizes “[t]hat number
may become substantially larger as a result of the GOP’s
efforts to restructure the Medicaid program through the
American Health Care Act, which may decrease eligibility and
coverage, setting back states’ efforts to address the epidemic.”
Id.
90 In October of 2017, the Centers for Medicare & Medicaid
Services approved a waiver for West Virginia to help the state
cover substance abuse treatment for more people. Press
Release, W. Va. Dep’t of Health & Human Res., DHHR’s
Medicaid Program to Expand Substance Use Treatment and
Services (Oct. 10, 2017), https://dhhr.wv.gov/News/2017/Pages/
DHHR’s-Medicaid-Program-to-Expand-Substance-Use-Treat
ment-and-Services.aspx [https://perma.cc/8QYR-7KTQ].
91 Press Release, W. Va. Dep’t Health & Human Res., DHHR
Receives CMS Approval for Neonatal Abstinence Syndrome
Treatment Services (Feb. 13, 2018), https://dhhr.wv.gov/News/
2018/Pages/DHHR-Receives-CMS-approval-for-NeonatalAbstinence-Syndrome-Treatment-Services.aspx
[https://per
ma.cc/5XYF-HRUW].
87
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needs and Medicaid coverage for providing methadone for
opioid addiction withdrawal.”92 The Medicaid expansion
will also “allow West Virginia to cover methadone,
naloxone,
peer
recovery
support,
withdrawal
management, and short-term residential services to all
Medicaid enrollees.”93
Significantly, West Virginia’s Medicaid will also
cover the treatment costs of infants who are born to
addicted mothers.94 The West Virginia Department of
Health and Human Resources announced on February
13, 2018, that its Bureau for Medical Services had
received “approval from the U.S. Centers for Medicare
and Medicaid Services (“CMS”) to offer Neonatal
Abstinence Syndrome (“NAS”) treatment services. West
Virginia is the first state in the nation to receive such an
approval.”95 To treat their opioid withdrawal symptoms,
the program will allow NAS babies to receive (1) a
“[c]omprehensive assessment to determine a plan of
care”; (2) “[l]ow or reduced stimulus environment, slow
introduction to sensory stimulation (both site and
sound)”; (3) “Pharmaceutical Withdrawal Management,
with tapering protocol as referenced by the American
Academy of Pediatrics”; and (4) Monitoring Withdrawal
Associated Press, West Virginia Expands Medicaid Drug
Treatment, WHSV (Harrisonburg, Va.), http://www.whsv.com/
content/news/West-Virginia-expands-Medicaid-drug-treat
ment-469605873.html [https://perma.cc/NS3U-B57Q] (“The
program waiver from the U.S. Centers for Medicare and
Medicaid Services is more than 80 percent federally funded.”)
93 W. Va. Dep’t of Health & Human Res., supra note 90.
94 Associated Press, West Virginia Medicaid Will Now Cover
Babies in Drug Rehab, MODERN HEALTHCARE (Feb. 14, 2018),
http://www.modernhealthcare.com/article/20180214/NEWS/
180219963 [https://perma.cc/4L29-M232] (“The Centers for
Disease Control and Prevention says the rate of babies born
dependent on drugs in West Virginia was 33.4 per 1,000
hospital births in 2013, the latest year available, compared
with the national average of 5.8.”)
95 W. Va. Dep’t Health & Human Res., supra note 91.
92
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Objective Assessment, at least twice, daily.”96 In
addition, the babies will receive non-pharmaceutical
interventions such as “[t]herapeutic swaddling,”
“[v]estibular stimulation/vertical rocking,” “C-position,”
“[h]ead-to-toe movements,” “[c]lapping,” “[e]xercise to
relieve gas discomfort,” and “[n]ewborn massage.”97
However, unlike West Virginia, access to
treatment in other states is not increasing. The American
Society of Addiction Medicine conducted a benefits
survey of states, receiving responses from thirty-seven
states.98 The survey revealed that “[c]overage for
[Medically-Assisted Treatment] clearly depends on which
state Medicaid agency, which medication and which
official is involved, whether or not counseling and
medical monitoring is covered and required.”99 Another
study found “several clusters of counties with higher than
average rates of opioid use disorder (OUD) and lower
than average treatment admissions among [opioid
treatment programs] that accept Medicaid . . . [in]
Arkansas, Kentucky, Louisiana, Mississippi, and
Tennessee.”100
Some states have sought and obtained grants to
increase access to treatment services.101 Three-year grant
Id.
Id.
98 AM. SOC’Y OF ADDICTION MED., ADVANCING ACCESS TO
ADDICTION MEDICATIONS: IMPLICATIONS FOR OPIOID ADDICTION
TREATMENT 21 (2013), http://www.asam.org/docs/advocacy/
implications-for-opioid-addiction-treatment [https://perma.cc/
YLR7-Y5WB].
99 Id. at 36.
100 Amanda J. Abraham et al., Geographic Disparities in
Availability of Opioid Use Disorder Treatment for Medicaid
Enrollees, 53 HEALTH SERVS. RES. 389, 389 (2017).
101 For example, Arkansas has obtained a grant from the
SAMHSA Center for Substance Abuse Treatment to fund the
Arkansas Access to Recovery Program:
The initiative provides vouchers through the
Arkansas Department of Human Services for
96
97
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programs are available to “states with high rates of
primary treatment admissions for heroin and opioids per
capita.”102 SAMHSA has compiled state-by-state
abstracts of “State Targeted Response to the Opioid
Crisis (Opioid STR) Grant Awards.”103
Types of treatment programs available vary in
each state that provides affordable or free treatment

patients to purchase treatment for substance
use disorders and for support services. The
program's goal is to `expand capacity, support
client choice, and increase the array of faithbased and community-based providers for
clinical treatment and recovery support
services.’ Currently, the program provides
vouchers that patients use to obtain treatment
and support services in thirteen counties,
including Benton, Craighead, Crawford,
Faulkner, Garland, Independence, Jefferson,
Lonoke,
Pulaski,
Saline,
Sebastian,
Washington, and White counties. A Care
Coordinator assists each patient in obtaining
the services needed. The funds support medical
care, dental care, addiction treatment, mental
health treatment, childcare, drug-free housing,
life-skills training, peer coaching, and some
other recovery services.
Frankie M. Griffen, Prescription Opioids in Arkansas: Finding
a Legislative Balance, 68 ARK. L. REV. 913, 952–53 (2016).
102 State Grant Programs, SUBSTANCE ABUSE & MENTAL
HEALTH SERVS. ADMIN., https://www.samhsa.gov/programscampaigns/medicat ion-assisted-treatment/training-materialsresources/state-grant-programs#mat-pdoa [https://perma.cc/U
B5R-TBXF].
103 State Targeted Response to the Opioid Crisis (Opioid STR)
Grant Awards, SUBSTANCE ABUSE & MENTAL HEALTH SERVS.
ADMIN., https://www.samhsa.gov/sites/default/files/grants/.../
ti-17-014-opioid-str-abstracts.pdf
[https://perma.cc/4NE7AWDC].
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services.104 Some programs provide “sliding scale
treatment” where the fees charged are based upon a
patient’s income and ability to pay. There are also nonprofit treatment centers that are able to provide free
treatment or lower cost treatment because of their nonprofit status. Faith-based treatment programs are
another alternative that may be a source of free
treatment or may offer payment assistance for those who
cannot afford treatment as part of their ministry
services.105 Treatment programs are also available to
veterans for free or at lower costs.106 Finally, most larger
treatment programs offer payment assistance based
upon need.
D. Pro bono Representation by Clinical Law
Students and Members of the Bar in Family
Court.
People affected by the opioid epidemic enter the
legal system in different ways. They may face criminal
drug charges, allegations of abuse and neglect, or the loss
of primary custody of their children by family court order.
Counsel is usually appointed in criminal cases
and in abuse and neglect cases where the party cannot

SAMHSA has a free national hotline that provides
treatment referral and information services for families facing
opioid addiction issues. The hotline refers those who have no
insurance or are underinsured to state offices “responsible for
state-funded treatment.” The hotline can also refer callers to
treatment programs that charge on a sliding scale or that
accept Medicaid and Medicare. National Helpline, SUBSTANCE
ABUSE & MENTAL HEALTH SERVS. ADMIN., https://www.
samhsa.gov/find-help/national-helpline
[https://perma.cc/F5
HH-HEUR].
105 See Griffen, supra note 101.
106 See Substance Use Disorder (SUD) Program Locator, U.S.
DEP’T OF VETERAN AFFAIRS, https://www.va.gov/directory/
guide/sud.asp [https://perma.cc/S3KM-8Q4B].
104
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afford counsel.107 Under the present system, many people
affected by the opioid epidemic cannot afford the
For example, criminal defendants in West Virginia may be
eligible for court-appointed counsel:
“A court of record may appoint counsel to assist
an accused in criminal cases at any time upon
request . . . In every case where the court
appoints counsel for the accused and the
accused presents an affidavit showing that he
cannot pay therefor, the attorney so appointed
shall be paid for his services and expenses in
accordance with the provisions of article
twenty-one, chapter twenty-nine of this Code.”
W. Va. Code Ann. § 62-3-1 (2015). In addition, respondents in
abuse and neglect cases in West Virginia have a right to
counsel if they cannot afford one:
(f) Right to counsel. –
(1) In any proceeding under this article, the
child, his or her parents and his or her legally
established custodian or other persons
standing in loco parentis to him or her has the
right to be represented by counsel at every
stage of the proceedings and shall be informed
by the court of their right to be so represented
and that if they cannot pay for the services of
counsel, that counsel will be appointed.
(2) Counsel shall be appointed in the initial
order. For parents, legal guardians, and other
persons standing in loco parentis, the
representation may only continue after the
first appearance if the parent or other persons
standing in loco parentis cannot pay for the
services of counsel.
(3) Counsel for other parties shall only be
appointed upon request for appointment of
counsel. If the requesting parties have not
retained counsel and cannot pay for the
services of counsel, the court shall, by order
entered of record, appoint an attorney or
attorneys to represent the other party or
parties and so inform the parties.
107
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assistance of legal counsel when they become involved in
family court proceedings, and there is no constitutionally
or statutorily-based right to court-appointed counsel in
family court custody cases. Therefore, if the adults in
these family court matters desire the assistance of
lawyers, they generally have no alternative but to seek
pro bono legal services from legal aid and law school
clinics.
It is axiomatic that the best interests of children
in family court cases are served when parents suffering
from addiction are connected with treatment services and
are provided legal representation in their custody
matters. Under Rule 6.1 of the Model Rules of
Professional Conduct, the family court could and should
call upon private-sector attorneys to undertake pro bono
representation of individuals struggling with opioid
addiction who face losing visitation rights or custody of
their children in family court.108 Rule 6.1 of the Model
Rules of Professional Conduct recognizes that “[e]very
lawyer has a professional responsibility to provide legal
services to those unable to pay.”109 To fulfill their ethical
responsibilities, law school clinicians, clinical law
students, and members of the bar in private practice
should be strongly encouraged to provide legal services to
persons of limited means in such family court cases
where addiction lies at the root of a family’s legal
problems.
For lawyers who are not schooled in family court
issues or otherwise unable to provide pro bono
representation to clients for practical reasons, Rule 6.1
provides that they can participate “in activities for
improving the law [or] the legal system” as it relates to

W. VA. CODE ANN. § 49-4-601(f) (2015).
108 MODEL RULES OF PROF’L CONDUCT r. 6.1 (AM. BAR ASS’N
1983).
109 Id.
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opioid addiction and treatment.110 “Because the provision
of pro bono services is a professional responsibility, it is
the individual ethical commitment of each lawyer.”111
Despite this “ethical commitment,” the provision of pro
bono services has only been mandated in one state.112
Many lawyers may be hesitant to commit to pro
bono representation in cases involving parties or clients
suffering from opioid addiction because it may prove
difficult and/or require prolonged services. A lawyer
volunteering to represent a client experiencing addiction
to opioids undertakes what is a difficult, but exceedingly
important assignment. She should be fully aware of the
potential difficulties that such representation may
present: the client may have an underlying untreated
psychiatric disorder that led to the addiction; the client
may be in denial about his addiction and the impact it is
having on the family; the client may not be able to
comprehend the severity of the situation he faces; and the
client’s addiction may impair his ability to participate
effectively in the case. Lawyering in such circumstances
can present considerable challenges not faced by many in
private civil practice, but such work is honorable and
provides a vital public service.
Legal aid lawyers and clinical law students
already provide pro bono legal services in family court
Id. One author has described this provision as a “loophole to
excuse them from doing pro bono work.” Spencer Rand, A
Poverty of Representation: The Attorney’s Role to Advocate for
the Powerless, 13 TEX. WESLEYAN L. REV. 545, 565 (2007).
111 Id. at cmt. 9.
112 Only New Jersey requires practitioners to perform some
form of pro bono work. Lydia Chan, New York’s New Rule: A
Novel Approach to Closing the Access to Justice Gap, 26 GEO.
J. LEGAL ETHICS 597, 600, 610 (2013) (citing Deborah L. Rhode,
Cultures of Commitment: Pro Bono for Lawyers and Law
Students, 67 FORDHAM L. REV. 2415, 2418 (1999)). See also
Cory H. Morris, Access to Justice, Observations and Thoughts
from the Incubator—A New York State of Mind, 83 UMKC L.
Rev. 883, 884 (2015).
110
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cases involving substance abuse issues. Moreover, many
state bars, as in West Virginia, have established pro bono
assistance projects.113 However, because the opioid
epidemic is fracturing families and increasing caseloads,
family courts should identify and compile a list of
attorneys who are willing to work pro bono specifically in
family court cases where addiction and custody are at
issue.114 Recognition is needed for a specialized bar of pro
bono attorneys who are willing to take on cases where the
need to help the addiction-afflicted family is great, the

For example, West Virginia has established the Pro Bono
Referral Project.
The State Bar approved an aspirational goal
for each active practicing lawyer in West
Virginia to provide 20 hours of legal work to
assist our low-income men, women and
children. The legal aid programs at that time—
there were four of them— agreed to work with
the State Bar in setting up the program. The
legal aid offices would determine the financial
eligibility of our citizens, ascertain if the legal
case was a priority matter and match a
volunteer lawyer with the case to handle the
legal responsibilities. The Pro Bono Referral
Project was born.
Thomas R. Tinder, The Tinder Box: A Case in Point, W. VA.
LAW., Sept./Oct. 2005, at 46, 46. The American Bar Association
has an online state-by-state directory of pro bono legal
programs:
https://www.americanbar.org/portals/public_re
sources/aba_home_front/directory_programs.html [https://per
ma.cc/YB5M-RG2L].
114 Attorneys who volunteer for such pro bono representation
would have to be those that the family court can rely upon to
provide the same quality of representation that they give their
paying clients. See Barbara Graves-Poller, Is Pro Bono Practice
in Legal “Backwaters” Beyond the Scope of the Model Rules?, 13
U.N.H. L. REV. 1, 5–6 (2015).
113
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work is challenging, and the attainability of the goals is
uncertain.115
E.
Educating Law Students About
Counseling Clients with Substance Abuse
Issues and About Educating Themselves.
Finally, as part of the seminar component of
family law clinics, students should be educated about
substance abuse and its origins so that they may counsel
their clients where such a role is appropriate. Students
can be trained by attending live or videotaped lectures
and presentations on substance abuse treatment offered
by their medical-legal partners, like Chestnut Ridge and
WVU Pediatrics referenced above. As part of such
training, clinicians should assign students research
projects on treatment options and programs, as well as
identification of funding for treatment of clients who
cannot otherwise afford it.
Typically, at the beginning of the first semester of
the clinic’s training component, students should learn the
skills necessary to effectively interview clients who are
addicts or are affected by addiction in the context of their
family. As part of this process, students should also learn
how to ask the right questions to gauge whether and to
what extent substance abuse is an issue. Further,
students should be sensitive to their potential clients’
responses, family situation, and needs.
Clinic law students should communicate with
community programs helping those with substance abuse
disorders and develop working relationships with
programs providing recovery services. Additionally,
This would not be the first occasion for a specialized pro
bono bar to be created to meet a crucial need. See, e.g., Barbara
Hart, DV and the Law: Creating a DV Bar, NAT’L BULL. ON
DOMESTIC VIOLENCE PREVENTION, Feb. 2017, at 4; Chandlee
Johnson Kuhn, Pro Bono Work in the Family Court, 23 DEL.
LAW. 28, 28 (2005).
115
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students should develop a list of local treatment facilities
and community programs, become familiar with the
services they provide, and update the list each year.
Students should also have information available to
provide to their clients regarding programs such as
Alcoholics Anonymous and Narcotics Anonymous. Of
course, it goes without saying that clinical faculty should
supervise such tasks assigned to law students.
As part of the clinical law seminar, clinicians can
invite guest speakers, including drug court and family
court judges, healthcare professionals, and community
service providers to speak with their students and engage
them in a dialogue about mutual professional
responsibilities to the families who are the focus of
clinical efforts.
Clinical law students also could organize
continuing legal education seminars for practitioners and
other law students to educate them on state-of-the-art
treatment, developing trends in the family court system
for addressing opioid addiction, as well as information
relating to clients’ access to treatment while they help
them resolve their legal issues.116
Drug courts may also have a need for pro bono
assistance by clinical law students.117 To determine
For example, clinical law students could organize a
continuing legal education seminar on representing impaired
clients. See Annemarie E. Kill, Representing Impaired Clients:
Challenge and Opportunity, THE CATALYST, Mar. 2009, at 10
https://www.isba.org/committees/women/newsletter/2009/03/
representingimpairedclientschalleng [https://perma.cc/9GLAZ7X R].
117 Law schools have externship programs where law students
are exposed to drug courts. See, e.g., Gregory Baker & Jennifer
Zawid, The Birth of a Therapeutic Courts Externship Program:
Hard Labor but Worth the Effort, 17 ST. THOMAS L. REV. 711
(2005). Some clinical law programs represent clients in drug
court. See, e.g., Tamar M. Meekins, Risky Business: Criminal
Specialty Courts and the Ethical Obligations of the Zealous
Criminal Defender, 12 BERKELEY J. CRIM. L. 75, 75 n.2 (2007).
116
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whether the need exists, clinical law supervisors could
obtain approval from judges to allow students to observe
juvenile drug and adult drug court.118 Because of their
closer proximity in age, clinical law students may be
uniquely able to help youth entangled in juvenile drug
court,119 many of whom have been subjected to adverse
childhood experiences.120 Should the court determine a
Incarceration alone is not the solution to drug-addicted
offenders. There is evidence that in-prison treatment for those
who are not diverted to drug court can decrease opioid abuse
and “reduce associated criminal behavior.” Redonna K.
Chandler, Bennett W. Fletcher & Nora D. Volkov, Treating
Drug Abuse and Addiction in the Criminal Justice System:
Improving Public Health and Safety, 301 JAMA 183 (2009),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2681083/
[https://perma.cc/BM2X-5PVG]; see also Catherine D. McKay,
Steven T. Davis & Adam Taylor, Confronting Delaware’s
Heroin
Epidemic:
In-Prison
Treatment,
Methadone
Maintenance and Providing Post-Release Support and
Counseling Can Reduce Recidivism and Discourage a Return to
Addiction, DEL. LAW., Spring2015, at 14.
119 In addition to helping resolve their legal issues, law
students could serve as positive adult role models and help
these youthful offenders recognize their potential and set goals
for the future. See generally SCOTT BERNARD PETERSON,
TEEN/YOUTH COURT PROGRAMS AND MENTORING: THE
REFERRAL
STAGE
(2018),
https://www.globalyouthjustice.org/wp-content/uploads/sites/
19/2018/01/Teen_Court_and_Mentoring_TA.pdf
[https://per
ma.cc/N3ZZ-46NP].
120 The Office of Juvenile Justice and Delinquency Prevention
conducted a study examining the prevalence of adverse
childhood experiences and their negative repercussions among
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need, clinical law students could supplement the list of
pro bono attorneys volunteering their time. This
representation should include encouraging and helping
youth obtain treatment and counseling to address their
drug abuse and the ACEs that may have led them to
experiment with opioids in the first place.
III.

Conclusion

Clearly, children’s best interests are not served
when they are in the care of parents impaired by opioid
addiction. Few would dispute that parents’ opioid
addiction can lead to custody disputes that cause scarring
adverse childhood experiences for the children in their
care. Nor would many disagree the proposition that
medication-assisted treatment, behavior counseling, and
community support for opioid-affected families can help
them ultimately remain together in a healthy home
environment. Legal and healthcare partners who
collaborate in medical-legal partnerships hopefully
would agree that combining their resources and working
together to provide access to treatment and recovery can
lead to positive, long-term outcomes for clients and
patients. Moreover, attorneys should appreciate and
embrace the ethical and moral dimensions attendant
providing wise counsel and legal assistance to opioidimpaired clients who seek treatment and long-term
recovery.
Clinical law students and pro bono family court
attorneys have the opportunity to identify resources
available to clients for treatment and counseling and to
identify programs that clients can afford that will
motivate them to engage in the long-term process of
recovery. As a practical matter, clients in family court
will have to desire treatment if they are to have a realistic
hope of recovery. While the availability of affordable
number of ACEs of youths in the juvenile justice system in
Florida is higher than the general youth population. Id.
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treatment and counseling will present serious challenges
to client and attorney alike, the greatest challenge is
likely to be the ability of the parents or other addicted
caregivers to summon their inner strength and resolve to
overcome their opioid affliction for the sake of their
children and families.
The Rules of Professional Conduct should, in my
view, be interpreted as imposing an ethical responsibility
on student attorneys and their supervisors to counsel and
assist clients who are struggling with addiction but
willing to do what is necessary to heal their children and
their families. Notwithstanding whether such a formal
ethical duty flows from the Rules of Professional
Conduct, it surely is a higher calling for clinical law
programs to explore all available options within their
charters to add their professional expertise to the
exceedingly important struggle to bring the nationwide
opioid epidemic under control. Helping to restore families
shattered by the opioid-fed crisis and protecting innocent
children ensnared as the collateral damage of addiction
can be empowering to law students and their institutions
and bring honor to our profession.
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BIG PHARMA, PRESCRIPTION
OPIOIDS, AND THE DEA
DRUG DEALING IN PLAIN VIEW
Patrick C. McGinley*
[This symposium article is forthcoming and will be published
in Volume 13 Issue 2 (Winter 2019).]

Patrick C. McGinley is a member of the West Virginia
University College of Law faculty where he serves as the Judge
Charles H. Haden II Professor of Law. A major focus of
Professor McGinley’s teaching and scholarship is access to
public information. He has represented newspapers and news
organizations in Freedom of Information and Open Records
law litigation. In 2016 he and co-counsel intervened on behalf
of the Charleston Gazette-Mail in two “pill mill” cases brought
by the West Virginia Attorney General against major U.S. drug
distributors. In those cases, the State plaintiff had sought
damages for the drug companies’ alleged complicity in the
opioid epidemic ravaging the state. Over the companies’
objections, Professor McGinley successfully advocated for
public disclosure of DEA prescription opioid distribution
information contained in sealed court records. Using this
previously secret information, reporter Eric Eyre was awarded
the 2017 Pulitzer Prize “for courageous reporting, performed in
the face of powerful opposition, to expose the flood of opioids
flowing into depressed West Virginia counties with the highest
overdose death rates in the country.”
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Abstract
The U.S. Center for Disease Control reports that
from 1999–2016 more than 350,000 people died from
overdoses involving prescription and/or illicit opioids. In
2016 alone, deaths from prescription opioids and illegal
opioids like heroin and illicitly manufactured fentanyl
totaled almost 42,000. The number of overdose deaths
involving opioids was 5 times higher in 2016 than in
1999. On average, 115 Americans die every day from an
opioid overdose. In this article, Professor McGinley
examines the evolution of the nationwide opioid epidemic
over the last two decades focusing on the role played by
drug manufacturers, drug distributors and the U.S. Drug
Enforcement Administration in the flood of literally
billions of “legal” prescription opioid pills inundating
communities across the nation.
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